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*Legislative Background 
The toxicological profiles are developed in response to the Super-fund Amendments and 
Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental 
Response, Compensation, and Liability Act of 1980 (CERCLA or Superfkd). This public law directed ATSDR 
to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA 
National Priorities List and that pose the most significant potential threat to human health, as determined by 
ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced 
in the Federal Register on April 29, 1996 (61 FR 18744). For prior versions of the list of 
substances, see Federal Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 
FR 41280); October 26, 1989 (54 FR 43619); October 17,199O (55 FR 42067); October 17, 1991 (56 FR 
52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486).  Section 104(i)(3) of CERCLA, 
as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the 
list. 
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PEER REVIEW 
A peer review panel was assembled for chlorpyrifos. The panel consisted of the following members: 
1 . Dr. William Buck, Professor of Toxicology, University of Illinois, Tolono, IL 61880; 
2 . Dr. Joel Coats, Professor, Department of Entomology, Iowa State University, Ames, IA 50011; 
and 
3 . Dr. Frederick Oehme, Professor, Comparative Toxicology Laboratories, Kansas State University, 
Manhattan, KS 66506-5606 
These experts collectively have knowledge of chlorpyrifos’ physical and chemical properties, toxicokinetics, 
key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. 
All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)( 13) of 
the Comprehensive Environmental Response, Compensation, and Liability Act, as amended. 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers’ comments and determined which comments will be addressed in the profile. A listing of the peer 
reviewers’ comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, 
exists as part of the administrative record for this compound. A list of databases reviewed and a list of 
unpublished documents cited are also included in the administrative record. 
The citation of the peer review panel should not be understood to imply its approval of the profile’s final 
content. The responsibility for the content of this profile lies with the ATSDR. 
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1. PUBLIC HEALTH STATEMENT 
This public health statement tells you about chlorpyrifos and the effects of exposure. 
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the nation. 
These sites make up the National Priorities List (NPL) and are the sites targeted for long-term federal cleanup. 
Chlorpyrifos has been found in at least 7 of the 1,428 current or former NPL sites. However, it’s unknown how 
many NPL sites have been evaluated for this substance. As more sites are evaluated, the sites with chlorpyrifos 
may increase. This information is important because exposure to this substance may harm you and because these 
sites may be sources of exposure. 
When a substance is released from a large area, such as an industrial plant, or from a container, such as a drum 
or bottle, it enters the environment. This release does not always lead to exposure. You are exposed to a 
substance only when you come in contact with it.  You may be exposed by breathing, eating, or drinking the 
substance or by skin contact. 
If you are exposed to chlorpyrifos, many factors determine whether you’ll be harmed. These factors include the 
dose (how much), the duration (how long), and how you come in contact with it. You must also consider the 
other chemicals you’re exposed to and your age, sex, diet, family traits, lifestyle, and state of health. 
1.1 WHAT IS CHLORPYRIFOS? 
Chlorpyrifos is an organophosphorus insecticide that has been widely used in the home and on the farm. In the 
home, chlorpyrifos has been used to control cockroaches, fleas, and termites; it has also been an active 
ingredient in some pet flea and tick collars. On the farm, it is used to control ticks on cattle and as a spray to 
control crop pests. In 1997, chlorpyrifos was voluntarily withdrawn from most indoor and pet uses by the 
manufacturer, DowElanco. 
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Chlorpyrifos is a white crystal-like solid with a strong odor. It does not mix well with water, so it is usually 
mixed with oily liquids before it is applied to crops or animals. It may also be applied to crops in a 
microencapsulated form. Chlorpyrifos is the active ingredient of various commercial insecticides including 
Dursban® and Lorsban®. See Chapter 3 for more information on the chemical and physical properties of 
chlorpyrifos. See Chapter 4 for more information on the production and use of chlorpyrifos. 
1.2 WHAT HAPPENS TO CHLORPYRIFOS WHEN IT ENTERS THE
 ENVIRONMENT? 
Chlorpyrifos enters the environment through direct application to crops, lawns, domesticated animals, and in the 
home and workplace. Chlorpyrifos may also enter the environment through volatilization, spills, and the 
disposal of chlorpyrifos waste. Chlorpyrifos that has been applied to the soil generally stays in the area where it 
has been applied because it sticks tightly to soil particles. Because of this, there is a low chance that chlorpyrifos 
will be washed off the soil and enter local water systems. Also, since it does not mix well with water, if it does 
get into the natural waters, it will be in small amounts and will remain on or near the surface and will evaporate. 
Volatilization is the major way in which chlorpyrifos disperses after it has been applied. Once in the 
environment (soil, air, or water), chlorpyrifos is broken down by sunlight, bacteria, or other chemical processes. 
Please refer to Chapters 4 and 5 for more information. 
1.3 HOW MIGHT I BE EXPOSED TO CHLORPYRIFOS? 
You can be exposed to chlorpyrifos in many places because of its wide range of uses. You can be exposed to it 
in your home or office if chlorpyrifos has recently been used to control household pests such as fleas or 
cockroaches. Exposure can also occur outside your home if chlorpyrifos has been applied to the ground around 
the foundation to control termites.  Chlorpyrifos degrades rapidly in the environment; however, low levels may 
persist for long 
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periods of time after it has been applied either inside or outside the home. Opening windows before and after 
chlorpyrifos spraying rapidly lowers airborne levels in a house. 
You can also be exposed to chlorpyrifos in a farm setting. The greatest risk occurs soon after a crop has been 
sprayed, because that is when its levels will be the highest. However, chlorpyrifos rapidly degrades and becomes 
bound to plants and the ground. The EPA recommends a 24-hour waiting period before entering fields where 
chlorpyrifos has been applied. In addition, there is the risk of exposure to chlorpyrifos when it is being prepared 
for use. Care should be taken to ensure that only a licensed applicator sprays chlorpyrifos, and that unnecessary 
or unprotected individuals remain away from the site of application during the spraying. 
Chlorpyrifos can also be found at some waste disposal sites, so exposure to higher levels than what is commonly 
found after home or commercial use may occur there. 
1.4 HOW CAN CHLORPYRIFOS ENTER AND LEAVE MY BODY? 
Chlorpyrifos can enter your body through your mouth, lungs, and skin. After being eaten or drunk, chlorpyrifos 
quickly passes from the intestines to the bloodstream, where it is distributed to the rest of the body. It can also 
enter the body through the lungs by breathing chlorpyrifos sprays or dust. When chlorpyrifos enters the body 
this way, it passes quickly into the blood. It may also enter your body through the skin, but the chances of being 
exposed to harmful levels of chlorpyrifos this way are not as great as with inhalation and oral exposure, because 
the amount that gets through the skin is relatively small (less than 3% of what was put on the skin). Dermal 
exposure of infants represents a greater health risk than with adults because of the texture of infant skin and 
because infants laying or crawling on an area sprayed with chlorpyrifos may have a greater amount of their skin 
exposed to chlorpyrifos. Infants crawling on areas recently sprayed with chlorpyrifos may also be exposed to 
greater amounts of chlorpyrifos through inhalation of its vapors. For more information, please refer to Chapter 
2. 
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1.5 HOW CAN CHLORPYRIFOS AFFECT MY HEALTH? 
To protect the public from the harmful effects of toxic chemicals and to find ways to treat 
people who have been harmed, scientists use many tests. 
One way to see if a chemical can harm people is to learn how the chemical is absorbed, used, and released 
by the body; for some chemicals, animal testing may be necessary. Animal testing may also be used to 
identify health effects such as cancer or birth defects. Without laboratory animals, scientists would lose a 
basic method to get information needed to make wise decisions to protect public health. Scientists have 
the responsibility to treat research animals with care and compassion. Laws today protect the welfare of 
research animals, and scientists must comply with strict animal care guidelines. 
In people, short-term oral exposure (one day) to low (milligrams) levels of chlorpyrifos can cause 
dizziness, fatigue, runny nose or eyes, salivation, nausea, intestinal discomfort, sweating, and changes in 
heart rate. Short-term oral exposure to much higher (grams) levels of chlorpyrifos may cause paralysis, 
seizures, loss of consciousness, and death. Reports in people also show that short-term exposure to 
chlorpyrifos may cause muscle weakness weeks after the original symptoms have disappeared. Other 
effects of exposure to chlorpyrifos include changes in behavior or sleeping pattern, mood changes, and 
effects on the nerves and/or muscles in the limbs (which may appear as odd sensations such as numbness 
or tingling, or as muscle weakness). The EPA has not classified chlorpyrifos for carcinogenicity (Class 
D). For more information, please refer to Chapter 2. 
1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 
CHLORPYRIFOS? 
There is a general test that can be performed to determine if you have been exposed to carbamate or 
organophosphate insecticides. Those types of pesticides inhibit the activity of acetylcholinesterase, the 
enzyme responsible for inactivating acetylcholine, the compound ultimately responsible for most of the 
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toxic symptoms seen with chlorpyrifos. The test measures the activity of the enzyme acetylcholinesterase 
in the blood or a similar enzyme, pseudocholinesterase, in the plasma, or both. If enzyme activity is 
inhibited, then exposure to an organophosphate or carbamate pesticide is suspected. There is also a 
biochemical test that can determine if you have been specifically exposed to chlorpyrifos. After 
chlorpyrifos enters the body, it is changed by the liver into other forms of the compound that may or may 
not be less toxic than the original material. The major nontoxic chlorpyrifos metabolic product formed by 
the liver is 3,5,6-trichloro-2-pyridinol, or TCP. TCP is primarily eliminated from the body in the urine 
and can be detected in the urine using readily available laboratory equipment. The extent of the exposure, 
length of time after exposure, and the amount of water in the body will affect the level of TCP in the 
urine. Typically, TCP can be found in the urine for several days after exposure to chlorpyrifos. In addition 
to chlorpyrifos, TCP is a metabolite of methyl chlorpyrifos and triclopyr. TCP may also be found in the 
environment, but it is unlikely that urinary levels of TCP result from environmental-TCP exposure. Direct 
exposure to chlorpyrifos or chlorpyrifos-like compounds is the most likely cause. For more information, 
please refer to Chapter 2. 
1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE
       TO PROTECT HUMAN HEALTH? 
The federal government develops regulations and recommendations to protect public health. Regulations 
can be enforced by law. Federal agencies that develop regulations for toxic substances include the 
Environmental Protection Agency (EPA), the Occupational Safety and Health Administration (OSHA), 
and the Food and Drug Administration (FDA).  Recommendations, on the other hand, provide valuable 
guidelines to protect public health but cannot be enforced by law.  Federal organizations that develop 
recommendations for toxic substances include the Agency for Toxic Substances and Disease Registry 
(ATSDR) and the National Institute for Occupational Safety and Health (NIOSH). 
Regulations and recommendations can be expressed in not-to-exceed levels in air, water, soil, or food
 that are usually based on levels that affect animals; then the levels are adjusted to help protect people. 
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because of different exposure times (an 8-hour workday or a 24-hour day), the use of different animal studies, or 
other factors. 
Recommendations and regulations are also periodically updated as more information becomes available. For the 
most current information, check with the federal agency or organization that provides it. Some regulations and 
recommendations for chlorpyrifos include the following: 
•	 Chlorpyrifos is one of a list of chemicals regulated under “The Emergency Planning and Community Right-
to-Know Act of 1986” (EPCRA). This requires owners and operators of certain facilities that manufacture, 
import, process, or otherwise use the chemicals on this list to report their release of those chemicals to any 
environmental media annually. 
•	 Chlorpyrifos is designated a hazardous substance and subject to regulations in the 
Federal Water Pollution Act and the Clean Water Act. 
•	 EPA has established tolerances for chlorpyrifos in raw agricultural commodities, foods, and animal feeds. 
See Chapter 7 for specific regulatory values for chlorpyrifos. 
1.8 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or environmental 
quality department or: 
Agency for Toxic Substances and Disease Registry
 
Division of Toxicology
 
1600 Clifton Road NE, Mailstop E-29
 
Atlanta, GA 30333
 
* Information line and technical assistance 
Phone: (404) 639-6000
 
Fax: (404) 639-63 15 or 6324
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ATSDR can also tell you the location of occupational and environmental health clinics. These clinics specialize 
in recognizing, evaluating, and treating illnesses resulting from exposure to hazardous substances. 
* To order toxicological profiles. contact 
National Technical Information Service
 
5285 Port Royal Road
 
Springfield, VA 22 161
 
Phone: (800) 553-6847 or (703) 487-4650
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2.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective of the toxicology of chlorpyrifos. It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health 
guidance. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposureinhalation, 
oral, and dermal; and then by health effect-death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects. These data are discussed in terms of three exposure 
periods-acute (14 days or less), intermediate (15-364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or 
lowestobserved-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the 
studies. LOAELS have been classified into “less serious” or “serious” effects. “Serious” effects are 
those that evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute 
respiratory distress or death). “Less serious” effects are those that are not expected to cause significant 
dysfunction or death, or those whose significance to the organism is not entirely clear. ATSDR 
acknowledges that a considerable amount of judgment may be required in establishing whether an end 
point should be classified as a NOAEL, “less serious” LOAEL, or “serious” LOAEL, and that in some 
cases, there will be insufficient data to decide whether the effect is indicative of significant dys-function. 
However, the Agency has established guidelines and policies that are used to classify these end 
points. ATSDR believes that there is sufficient merit in this approach to warrant an attempt 
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at distinguishing between “less serious” and “serious” effects. The distinction between “less serious”effects and 
“serious” effects is considered to be important because it helps the users of the profiles to identify levels of 
exposure at which major health effects start to appear. LOAELs or NOAELs should also help in determining 
whether or not the effects vary with dose and/or duration, and place into perspective the possible significance of 
these effects to human health. 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and figures 
may differ depending on the user’s perspective. Public health officials and others concerned with appropriate 
actions to take at hazardous waste sites may want information on levels of exposure associated with more subtle 
effects in humans or animals (LOAEL) or exposure levels below which no adverse effects (NOAELs) have been 
observed. Estimates of levels posing minimal risk to humans (Minimal Risk Levels or MRLs) may be of interest 
to health professionals and citizens alike. 
Estimates of exposure levels posing minimal risk to humans (Minimal Risk Levels or MRLs) have been made 
for chlorpyrifos. An MRL is defined as an estimate of daily human exposure to a substance that is likely to be 
without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs 
are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure. MRLs are based on noncancerous health 
effects only and do not consider carcinogenic effects. MRLs can be derived for acute-, intermediate-, and 
chronic-duration exposures for inhalation and oral routes. Appropriate methodology does not exist to develop 
MRLs for dermal exposure. 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques. Furthermore, ATSDR acknowledges additional uncertainties 
inherent in the application of the procedures to derive less than lifetime MRLs. As an example, acute-duration 
inhalation MRLs may not be protective for health effects that are delayed in development or are acquired 
following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic bronchitis. As these kinds 
of health effects data become available and methods to assess levels of significant human exposure improve, 
these MRLs will be revised. 
A User’s Guide has been provided at the end of this profile (see Appendix B). This guide should aid in the 
interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
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Chlorpyrifos (O,O-diethyl O-[3,5,6-trichloro-2-pyridyl] phosphorothioate) is a clear to white crystalline 
solid pesticide (EPA 1988b) with a strong mercaptan odor (Worthing 1987). Chlorpyrifos is widely used 
to control insects in the home, workplace, and in agriculture; it has also been found in at least 7 current 
and former EPA National Priorities List (NPL) hazardous waste sites (HazDat 1996). Thus, the potential 
for chlorpyrifos exposure is significant. 
2.2.1 Inhalation Exposure 
2.2.1.1 Death 
No information was found concerning the potential for death in humans following acute-, 
intermediate-, or chronic-duration inhalation exposure. For animals, no data were located for death 
following intermediate- or chronic-exposure to chlorpyrifos, but limited LD50 (lethal dose, 50% kill) 
studies were available. 
The LD50 for acute-duration inhalation exposure to chlorpyrifos aerosol has been determined for mice and 
female rats (Berteau and Deen 1978). In mice, an LD50 of 94 mg/kg (milligrams per killogram of body 
weight) was determined after whole-body inhalation exposure to 6,700-7,900 mg/m3 chlorpyrifos in 65% 
xylene. In that study, the dose range was achieved by varying the length of exposure from 27 to 50 
minutes. Virgin female Sprague-Dawley rats were similarly exposed to 5,900-7,500 mg/m3 chlorpyrifos 
in 65% xylene, and an acute-exposure inhalation LD50 of 78 mg/kg was determined by varying the 
exposure duration from 60 to 180 minutes. Numerous assumptions about minute ventilation and 
pulmonary absorption were made in this study, and no correction was made for the large amount of 
xylene in the formulation or for the percutaneous and oral absorption of chlorpyrifos entrapped in the fur. 
Thus, the LD50 values are crude estimates. 
Mortality was also observed in 5 male and 5 female Sprague-Dawley rats acutely exposed to a lower 
concentration of chlorpyrifos but for a longer duration (Dow 1983a). In males, 80% mortality was 
observed following a single 4-hour, whole-body exposure to an atmosphere containing 5,300 mg/m3 of 
the commercial chlorpyrifos preparation Pyrenone-Dursban®. In similarly exposed females, 20% 
mortality was observed. However, no mortality was observed in 5 male or 5 female Sprague-Dawley rats 
exposed to 2,500 mg/m3 of Pyrenone-Dursban® W.B. Pressurized Spray for 4 hours (Dow 1984). 
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It should be noted that in these and other animal whole-body inhalation studies, exposure may include 
ingestion as a route of exposure because the compound gets on the fur of the animals and may then be 
ingested during grooming. 
The LOAEL values for lethality in each reliable study for each species and duration category are shown 
in Table 2-l and Figure 2-l. 
2.2.1.2 Systemic Effects 
No studies were located concerning endocrine or metabolic effects of chlorpyrifos in humans or animals 
following acute-, intermediate-, or chronic-duration inhalation exposure to chlorpyrifos. The highest 
NOAEL value and all LOAEL values for systemic effects in each reliable study for each species and 
duration category are shown in Table 2-l and Figure 2- 1. 
Respiratory Effects.  No information was located concerning the potential respiratory effects of 
inhaled chlorpyrifos in humans following acute- or intermediate-duration exposure. In a chronicduration 
exposure study by Brenner et al. (1984), the prevalence of selected illnesses and symptoms in 175 
employees involved in the production of chlorpyrifos and 335 matched controls with no history of 
exposure to organophosphorus chemicals were compared. Employees were further subdivided for dose-
response testing into three exposure intensity groups on the basis of job title and air-monitoring data. The 
prevalence of respiratory illness or other respiratory symptoms were compared. There  were no 
statistically significant differences in the number of subjects with respiratory illness or other respiratory 
symptoms between the exposed and control groups. Exposure was assumed to be via inhalation and 
dermal routes. 
The respiratory effects of acute-duration exposure to the commercial chlorpyrifos preparation, 
Pyrenone-Dursban®, were investigated in 5 male and 5 female Sprague-Dawley rats (Dow 1983a). 
One male  rat was observed gasping the day after a single 4-hour whole-body exposure to 5,300 
mg/m3. The animal was found dead later that day. Two additional males were found dead 2 days 
post-exposure and one male was found dead three days post-exposure. Scattered dark red areas 
ranging from 2 mm to extensive hepatization involving up to 75% of lung tissue were observed in 
these rats. Fibrinous pleurisy was observed in 1 female rat that died 14 days post-exposure (Dow 
1983a). No respiratory effects were observed, however, in male or female Sprague-Dawley rats 
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exposed to an atmosphere containing 2,500 mg/m3 Pyrenone-Dursban® Pressurized Spray for 4 hours 
(Dow 1984). 
The effects of intermediate-duration exposure to chlorpyrifos on lung histology were assessed in male and 
female Fischer 344 rats (Corley et al. 1989). The rats were exposed nose-only to 0, 0.075, 0.148, or 0.295 
mg/m3 chlorpyrifos for 6 hours a day, 5 days a week for 13 weeks. Histopathological evaluation of lungs 
from the control and 0.295 mg/m3 groups revealed normal lung histology. The exposure levels in this 
study did not inhibit erythrocyte or plasma cholinesterase activity. 
No data were located for respiratory effects in animals following chronic-exposure to chlorpyrifos. 
Cardiovascular Effects. No information was located concerning the cardiovascular effects of inhaled 
chlorpyrifos in humans following intermediate- or chronic-duration exposure. Unstable blood pressure 
and pulse were noted in a 33-year-old male acutely exposed to an unspecified concentration of Dursban® 
that was accidentally sprayed into the ventilating system at his place of work. The symptoms began 
approximately 6 weeks after exposure and slowly resolved over 8-10 weeks (Kaplan et al. 1993). 
Exposure was assumed to be via inhalation and dermal routes. While cardiovascular effects are possible 
after acute-duration exposure to chlorpyrifos because of cholinergic overstimulation, the 6-week interval 
between a single exposure and onset of symptoms raises doubts as to whether chlorpyrifos was the 
causative agent in this case. 
The cardiovascular effects of acute-duration exposure to the commercial chlorpyrifos preparation 
Pyrenone-Dursban® were investigated in 5 male and 5 female Sprague-Dawley rats (Dow 1983a). 
Pericarditis was observed in one female rat that died 14 days after a single 4-hour whole-body 
exposure to 5,300 mg/m3. No cardiovascular effects were noted in the male rats. Intermediate-
duration exposure caused cardiovascular effects in a female domestic short-hair cat (Jaggy and Oliver 
1992). The cat was exposed to an unspecified amount of chlorpyrifos used to spray the apartment for 
fleas. The apartment was sprayed 6 times (every 3 days) during an 1%day period. The-cat was kept in 
another apartment during the first 2-3 hours after the spraying on each day. The cat became anorexic 
and lethargic, and was taken for treatment. The cat was found to have elevated levels of creatine kinase, 
but the lectrocardio gram was negative. It is assumed that exposure was via inhalation, although oral 
exposure from grooming may also have occurred. No data were located for cardiovascular effects in 
animals following chronic-exposure to chlorpyrifos. 
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Gastrointestinal Effects. Gastrointestinal effects following acute-duration exposure to chlorpyrifos 
have been observed in humans (Kaplan et al. 1993). A family became ill and complained of feeling 
nauseated after their house was sprayed with Dursban® (Kaplan et al. 1993). The time from exposure to 
the onset of symptoms and exposure-level data were not reported. Exposure was assumed to be via 
inhalation and dermal routes. Intermediate-duration exposure to chlorpyrifos may be associated with 
diarrhea in humans. Diarrhea developed in a 40-year-old male exterminator who was repeatedly exposed 
to an unknown concentration of Dursban® in a closed environment over a 6-month period (Kaplan et al. 
1993). Exposure was assumed to be via inhalation and dermal routes.  Erythrocyte cholinesterase levels 
determined at the onset of symptoms were initially low (value not given). The diarrhea probably resulted 
from stimulation of the parasympathetic nervous system as a consequence of cholinesterase inhibition. 
Stimulation of the parasympathetic nervous system increases gastrointestinal motility, thereby decreasing 
food transit times. The net result is that there is less time for water to be absorbed by the gastrointestinal 
tract and diarrhea results. In a chronic-duration exposure study by Brenner et al. (1984), the prevalence of 
selected illnesses and symptoms in 175 employees involved in the production of chlorpyrifos were 
compared with 335 matched controls with no history of exposure to organophosphorus chemicals. 
Employees were further subdivided for dose-response testing into three exposure intensity groups on the 
basis of job title and air-monitoring data. No statistically significant differences in the prevalence of 
illnesses of the gastrointestinal tract were found in the exposed groups compared to matched controls. 
Exposure was assumed to be via inhalation and dermal routes. 
No data were located for gastrointestinal effects for animals following acute-, intermediate-, or 
chronic-duration inhalation exposure to chlorpyrifos. 
Hematological Effects. A 33-year-old man acutely exposed to an undetermined amount of 
chlorpyrifos after it was sprayed into the ventilation system of his place of work was examined 
2 weeks later because of neurological problems (Kaplan et al. 1993). Routine blood chemistry and 
hematological evaluations were performed and found to be within normal limits. Similar tests 
performed on a 40-year-old male exterminator repeatedly exposed to Dursban® in a closed 
environment over a 6-month interval were also negative. In both cases, exposure was assumed to 
be via inhalation and dermal routes. No information was located concerning the hematological 
effects of chronic-duration exposure to inhaled chlorpyrifos in humans. 
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No information was located concerning the hematological effects of inhaled chlorpyrifos after acute- or 
chronic-duration exposure in animals. No effects on hematological parameters were seen in Fischer 344 
rats exposed to up to 0.295 mg/m3 chlorpyrifos 6 hours a day, 5 days a week for 13 weeks (Corley et al. 
1989). 
Musculoskeletal Effects. In humans, acute- and intermediate-duration exposures have been associated 
with musculoskeletal effects. A family became ill, and family members complained of muscle cramps, 
after their house was sprayed with Dursban® (Kaplan et al. 1993). Exposure-level data and the time from 
exposure to the onset of symptoms were not reported. Muscle twitching developed in a 40-year-old male 
exterminator who was repeatedly exposed to an unknown concentration of Dursban® in a closed 
environment over a 6-month interval (Kaplan et al. 1993). In both cases, exposure was assumed to be via 
inhalation and dermal routes. In a chronic-duration exposure study by Brenner et al. (1984), the 
prevalence of selected illnesses and symptoms in 175 employees involved in the production of 
chlorpyrifos was compared with 335 matched controls with no history of exposure to organophosphorus 
chemicals. Employees were further subdivided for dose-response testing into three exposure intensity 
groups on the basis of job title and air-monitoring data. No statistically significant differences in the 
prevalence of illnesses or symptoms involving the musculoskeletal system were found in the exposed 
groups compared to matched controls. Exposure was assumed to be via inhalation and dermal routes. 
For animals, no data were located for musculoskeletal effects following acute- or chronic-duration 
exposure to chlorpyrifos. Musculoskeletal effects have been observed following intermediate-duration 
oral exposure in cats. Creatine kinase activity increased an undetermined amount in a female cat exposed 
to an unspecified amount of chlorpyrifos every third day for 18 days via inhalation (Jaggy and Oliver 
1992). It is assumed that all exposure was via inhalation, although oral exposure may also 
have occurred through grooming. 
Hepatic Effects. No information was located concerning hepatic effects of inhaled chlorpyrifos in 
humans following acute- or intermediate-duration exposure. In a chronic-duration exposure study 
(Brenner et al. 1984), the prevalence of selected illnesses and symptoms in 175 employees involved in the 
production of chlorpyrifos was compared with 335 matched controls with no history of exposure to 
organophosphorns chemicals. Employees were further subdivided for dose-response testing into three 
exposure intensity groups on the basis of job title and air-monitoring data. No statistically significant 
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differences in the prevalence of liver illnesses were found in the exposed groups compared to matched 
controls or among the three exposure subgroups. Exposure was assumed to be via inhalation and dermal 
routes. 
The effect of intermediate-duration exposure to chlorpyrifos on liver histology was assessed in male and 
female Fischer 344 rats (Corley et al. 1989). The rats were exposed nose-only to 0, 0.075, 0.148, or 0.295 
mg/m3 chlorpyrifos for 6 hours a day, 5 days a week for 13 weeks. Histopathological evaluation of livers 
from the control and 0.295 mg/m3 groups revealed normal liver histology in the chlorpyrifos-treated rats. 
The exposure levels in this study were not sufficient to inhibit erythrocyte or plasma cholinesterase. No 
data were located for hepatic effects in animals following acute- or chronicduration exposure to 
chlorpyrifos. 
Renal Effects. The acute-duration exposure of a 33-year-old male to an unspecified amount of 
chlorpyrifos that was sprayed into a workplace ventilation system caused an increase in urinary frequency 
(Kaplan et al. 1993). Exposure was assumed to be via inhalation and dermal routes.  Intermediate-
duration inhalation exposure (data collected over a 3-month period) to undetermined amounts of 
chlorpyrifos in humans was assessed in a survey of pesticide applicators working in a variety of settings 
(Ames et al. 1989). Exposure was assumed to be via inhalation and dermal routes. The applicators in this 
study reported an unspecified decrease in urinary frequency. In a chronic-duration exposure study by 
Brenner et al. (1984), the prevalence of selected illnesses and symptoms in 175 employees involved in the 
production of chlorpyrifos was compared with 335 matched controls with no history of exposure to 
organophosphorus chemicals. Illnesses and symptoms included those of the kidney. Employees were 
further subdivided for dose-response testing into three exposure intensity groups on the basis of job title 
and air-monitoring data. No statistically significant differences in the prevalence of renal illnesses were 
found in the exposed groups compared to matched controls.  Exposure was assumed to be via inhalation 
and dermal routes. 
The effects of intermediate-duration exposure to chlorpyrifos on urine chemistry have also been assessed 
in male and female Fischer 344 rats (Corley et al. 1989). The rats were exposed nose-only to 0, 0.075, 
0.148, or 0.295 mg/m3 chlorpyrifos for 6 hours a day, 5 days a week for 13 weeks. Urinary chemistry in 
the treated groups was comparable to controls. The exposure levels in this study were not sufficient to 
inhibit erythrocyte or plasma cholinesterase. No effects on kidney weight or histopathology were seen in 
the rats exposed to up to 0.295 mg/m3 chlorpyrifos for 13 weeks. 
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No data were located in for renal effects in animals following acute- or chronic-duration exposure to 
chlorpyrifos. 
Dermal Effects. No information was located concerning dermal effects of inhaled chlorpyrifos in 
humans following acute-duration exposure. The intermediate-duration inhalation exposure to 
undetermined amounts of chlorpyrifos in humans was assessed in a survey of pesticide applicators 
working in a variety of settings (Ames et al. 1989). Exposure was assumed to be via inhalation and 
dermal routes. The applicators in this study reported an unspecified increase in skin flushing. This effect 
may be related to a disruption of autonomic function. In a chronic-duration exposure study by Brenner et 
al. (1984) the prevalence of selected illnesses and symptoms in 175 employees involved in the production 
of chlorpyrifos was compared with 335 matched controls with no history of exposure to 
organophosphorus chemicals. Employees were further subdivided for dose-response testing into three 
exposure intensity groups on the basis of job title and air-monitoring data. No statistically significant 
differences in the prevalence of illnesses of the skin or other integumentary tissue were found in the 
exposed groups compared to matched controls. Exposure was assumed to be via inhalation and dermal 
routes. 
For other animals, no data were located for dermal effects following acute-, intermediate- or 
chronicduration inhalation exposure to chlorpyrifos. 
Ocular Effects. Intermediate-duration exposure to an undetermined amount of chlorpyrifos caused an 
unspecified increase in tearing in a 40-year-old male exterminator repeatedly exposed to Dursban® over a 
6-month period (Kaplan et al. 1993). Exposure was assumed to be via inhalation and dermal routes. 
Additionally, intermediate-duration inhalation exposure to undetermined amounts of chlorpyrifos in 
humans was assessed in a survey of pesticide applicators working in a variety of settings (Ames et al. 
1989). Exposure was assumed to be via inhalation and dermal routes. The applicators reported an 
unspecified increase in blurred vision. It should be noted that in the Kaplan et al. (1993) and Ames et al. 
(1989) studies, exposure concentration data were not available. Additionally, because these incidences 
occurred in pesticide applicators, the possibility of exposure to other compounds must be considered; 
blurred vision is a common symptom after high exposure to organophosphate insecticides. 
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No information was located concerning ocular effects of inhaled chlorpyrifos in humans following acute-
or chronic-duration exposure. 
For other animals, no data were located for ocular effects following acute-, intermediate-, or 
chronicduration exposure to chlorpyrifos. 
Body Weight Effects. No information was located concerning the effects on body weight of inhaled 
chlorpyrifos in humans following acute-, intermediate-, or chronic-duration exposure. 
The effects on body weight of acute-duration exposure to the commercial chlorpyrifos preparation 
Pyrenone-Dursban® weight were investigated in male and female Sprague-Dawley rats exposed for 4 
hours to an atmosphere containing 5,300 mg/m3 (Dow 1983a). Male rats that survived 2 days 
postexposure lost 9-l1% of their body weight. Exposed females also lost weight during the first two days 
post-exposure. Weight loss ranged from 1 to 33% with a mean of 10%. Surviving male and female rats 
subsequently gained weight within normal ranges (Dow 1983a). No body weight effects were observed, 
however, in male or female Sprague-Dawley rats exposed to an atmosphere containing 2,500 mg/m3 
Pyrenone-Dursban® Pressurized Spray (Dow 1984). The effects of intermediate-duration exposure to 
chlorpyrifos on body weight were assessed in male and female Fischer 344 rats (Corley et al. 1989). The 
rats were exposed nose-only to 0, 0.075, 0.148, or 0.295 mg/m3 chlorpyrifos for 6 hours a day, 5 days a 
week for 13 weeks. Body weight was not affected by any concentration of chlorpyrifos. The exposure 
levels in this study were not sufficient to inhibit erythrocyte or plasma cholinesterase. No data were 
located for body weight effects following chronic-duration exposure to chlorpyrifos. 
2.2.1.3 Immunological and Lymphoreticular Effects 
No data were located for immunological and lymphoreticular effects in humans or animals following 
acute-, intermediate-, or chronic-duration inhalation exposure to chlorpyrifos. 
2.2.1.4 Neurological Effects 
The majority of the neurological symptoms associated with chlorpyrifos exposure result from its 
inhibition of acetylcholinesterase and the subsequent cholinergic overstimulation. Common symptoms 
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related to excessive cholinergic activity include headache, diaphoresis, nausea, vomiting, diarrhea, epigastric 
cramping, bradycardia, blurred vision, miosis, bronchoconstriction and excess mucous secretions, pulmonary 
edema, dyspnea, muscle fasciculations, salivation, lacrimation, and urination (Ballantyne and Marts 1992). In 
adults and children, acute-duration inhalation exposure to unspecified concentrations of chlorpyrifos is 
associated with paresthesia and lightheadedness (Kaplan et al. 1993;Sherman 1995). Headache is also a 
common occurrence (Kaplan et al. 1993; Sherman 1995). Additionally, in the Sherman (1995) report, acute-
duration chlorpyrifos exposure may produce signs of neurological toxicity weeks or months after the initial 
symptoms have resolved. For example, a family which became ill after an unspecified concentration of 
chlorpyrifos was applied in their home initially presented with headaches, nausea, and muscle cramps (Kaplan 
et al. 1993). However, numbness, paresthesia (most prominent in the legs), and memory impairment were 
reported by the family 1 month later. The children also showed a decline in scholastic performance that lasted 
for approximately 6 months. Neurological exams conducted 6 months post-exposure revealed mild shortterm 
memory loss on all routine mental status testing of recall of multiple objects.  Neuropsychological testing was 
declined by the subjects, all other neurological exams were normal. Nerve conduction studies revealed low-
amplitude sural nerve action potentials in all family members. Motor and upper-extremity sensory nerve action 
potentials were normal. Sural nerve amplitudes in all but one family member had returned to normal 6 months 
later. Although inhalation was the most likely route of exposure, the family could also have been exposed 
dermally. 
Other patients in the compilation of case reports by Kaplan et al. (1993) presented with similar deferred 
neurotoxicity that resolved after a period of weeks or months. In a review of the physical, neurotoxic, and 
respiratory problems suffered by people exposed to organophosphate pesticidal products, similar 
symptoms of severe organophosphate poisoning were reported in men and women exposed to unspecified 
amounts of chlorpyrifos at home or at work (Sherman 1995). However, in the Kaplan et al. (1993) and 
Sherman (1995) reports, no exposure-level data were presented, and the cognitive complaints were 
nonspecific, nonquantitative, and possibly attributable to a wide variety of possible causes. Additionally, 
measurements of erythrocyte acetylcholinesterase, a biomarker for chlorpyrifos exposure, were not taken. 
Intermediate-duration inhalation exposure to unspecified concentrations of chlorpyrifos in humans have 
been associated with deferred neurotoxicity similar to that observed after acute-duration exposure (Kaplan 
et al. 1993). For example, sensory loss, mild distal weakness, and are flexia in the lower 
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extremities were revealed in a neurological evaluation of a man 6 weeks after being exposed to Dursban® 
in a closed environment for over a 6-month interval. Nerve conduction studies and quantitative sensory 
threshold studies revealed changes consistent with peripheral neuropathy of the distal axonopathy type. 
However, follow-up one year later revealed normalization of the results of the neurological examination, 
nerve conduction studies, and quantitative sensory threshold studies, and remission of all symptoms 
(Kaplan et al. 1993). 
In a chronic-duration exposure study by Brenner et al. (1984), the prevalence of selected illnesses and 
symptoms in 175 employees involved in the production of chlorpyrifos was compared with 335 matched 
controls with no history of exposure to organophosphorus chemicals. Employees were further subdivided for 
dose-response testing into three exposure intensity groups on the basis of job title and air-monitoring data. No 
statistically significant differences in the prevalence of central and peripheral nervous system symptom were 
found in the exposed groups compared to matched controls. Exposure was assumed to be via inhalation and 
dermal routes. 
In female mice, acute-duration inhalation exposure to 95.6 mg/kg chlorpyrifos (total dose received during 
5 hours of exposure) caused an approximate 90% decrease in plasma cholinesterase, a marker for 
exposure, 3 days after exposure (Berteau and Deen 1978). Fourteen days after exposure, plasma 
cholinesterase had returned to within 20% of predosing levels. The effects of acute-duration inhalation 
exposure to the commercial chlorpyrifos Pyrenone-Dursban® on behavior were investigated in male and 
female Sprague-Dawley rats exposed for 4 hours to an atmosphere containing 5,300 mg/m3 (Dow 1983a). 
Locomotor activity was reduced for up to 2 days post-exposure (Dow 1983a). No behavioral effects were 
observed, however, in male or female Sprague-Dawley rats exposed to an atmosphere containing 2,500 
mg/m3 Pyrenone-Dursban® Pressurized Spray (Dow 1984). The effects of intermediate-duration exposure 
to chlorpyrifos on brain weight and brain cholinesterase were assessed in male and female Fischer 344 
rats (Corley et al. 1989). The rats were exposed nose-only to 0, 0.075, 0.148, or 0.295 mg/m3 chlorpyrifos 
for 6 hours a day, 5 days a week for 13 weeks. Brain weight and brain acetylcholinesterase activity were 
not affected by any concentration of chlorpyrifos.  The concentrations of chlorpyrifos used in this study 
were not sufficient to inhibit erythrocyte or plasma cholinesterase activity. No data were located for 
neurological effects in animals following chronic-duration exposure to chlorpyrifos. 
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All LOAEL values for neurological effects in each reliable study for each species and duration category 
are shown in Table 2-l and Figure 2-l. 
2.2.1.5 Reproductive Effects 
No information was located concerning reproductive effects of inhaled chlorpyrifos in humans following 
acute-, intermediate-, or chronic-duration exposure. 
The effect of intermediate-duration exposure to chlorpyrifos on testicular weight and histology was 
assessed in male Fischer 344 rats (Corley et al. 1989). The rats were exposed nose-only to 0, 0.075, 0.148, 
or 0.295 mg/m3 chlorpyrifos for 6 hours a day, 5 days a week for 13 weeks. No effects of treatment on 
testes weight or histology were detected. The air concentrations of chlorpyrifos used in this study were 
not sufficient to inhibit erythrocyte or plasma cholinesterase activity. No data were located for 
reproductive effects in animals following acute- or chronic-duration exposure to chlorpyrifos. 
2.2.1.6 Developmental Effects 
No information was located concerning developmental effects of inhaled chlorpyrifos in humans or other 
animals following acute-, intermediate-, or chronic-duration exposure. 
2.2.1.7 Genotoxic Effects 
No information was located concerning genotoxic effects of inhaled chlorpyrifos in humans following 
acute-, intermediate-, or chronic-duration exposure. 
Chlorpyrifos was tested for its ability to induce complete and partial chromosome losses in Drosophila 
melunogaster males (Woodruff et al. 1983). Initial attempts were made to identify an approximate 
LD50 (lethal dose, 30% kill) dose prior to treatment, with toxicity defined as the number of dead 
flies out of the total number treated over a 3-day period. Mortality was recorded at 24, 48, and 72 
hours. At 72 hours, males were removed and mated with mus-302 repair-defective females, and F1 
male progeny were screened for complete and partial chromosome loss. Treated and control males 
that had a ring-X chromosome and a doubly-marked Y chromosome were used in a screen for ring 
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chromosome loss and for loss of Y-chromosome markers. A significant increase in complete chromosome 
loss was induced by 0.717 mg/m3 chlorpyrifos, but no effect on partial chromosome loss was observed. No 
information was located concerning genotoxic effects of inhaled chlorpyrifos in animals following 
intermediate- or chronic-duration exposure. Genotoxicity studies are also discussed in Section 2.5. 
2.2.1.8 Cancer 
No information was located concerning the cancer risk of inhaled chlorpyrifos in humans or other animals 
following acute-, intermediate-, or chronic-duration exposure. 
2.2.2 Oral Exposure 
2.2.2.1 Death 
No information was found concerning death in humans following acute-, intermediate-, or chronicduration 
oral exposure. 
Acute oral LD50 has been assessed in rodents (El-Sebae et al. 1978; Gaines 1969; McCollister et al.1974). In 
rats, chlorpyrifos appears to be more toxic to females than males. Gaines (1969) reported an LD50 of 82 
mg/kg for female Sherman rats and an LD50 of 155 mg/kg for males. Similarly, McCollister et al. (1974) 
reported an LD50 of 135 mg/kg for female Dow-Wistar rats and an LD50 of 163 mg/kg for males. However, 
in contrast to this apparent sex effect suggested by Gaines’ (1969) data, an LD50 of 155 mg/kg was reported 
for female Sherman rats while the male LD50 was 118 mg/kg (McCollister et al. 1974). An LD50 of 60 mg/kg 
has been determined for mice (unspecified gender) (El-Sebae et al. 1978). In male guinea pigs, an oral LD50 
of 504 mg/kg has been reported (McCollister et al. 1974). In chickens, a single oral dose of 75 mg/kg 
chlorpyrifos caused death in 1 of 3 animals following regurgitation and aspiration within 8 hours of dosing 
(Richardson et al. 1983a). However, no hens exposed to 150 or 300 mg/kg died in that study, although at the 
time of sacrifice, 1 of 3 in the 150 mg/kg group and all in the 300 mg/kg group appeared moribund. In other 
chicken studies, LD50 values of 32 mg/kg (McCollister et al. 1974) and 34.8 mg/kg (Miyazaki and Hodgson 
1972) were reported in male Leghorns. In adult hens, acute-duration oral administration of “pure” 
chlorpyrifos resulted in deaths within 48 hours in all dose groups (20-60%). In hens dosed 
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with 4, 6, 16, or 32 mg/kg chlorpyrifos, 1 of 5, 1 of 5, 3 of 5, and 3 of 5, respectively, died (Capodicasa et al. 
1991). In pregnant CF-1 mice, 25 mg/kg/day Dursban F® (96.8% chlorpyrifos) as a solution in cottonseed oil 
administered via gavage from gestation day (Gd) 6-15 caused death in 4 of 47 of the treated. mice (Deacon et 
al. 1980); one death was observed at each 1 mg/kg/day and 10 mg/kg/day chlorpyrifos dose. 
Intermediate-duration oral exposure to chlorpyrifos has also been shown to cause death in rodents (Chiappa et al. 
1995). Death was observed in 6 of 10 male Long-Evans rats exposed to 100 mg/kg/day chlorpyrifos in corn oil via 
gavage for 3 days, followed by 75 mg/kg/day chlorpyrifos for 2-4 weeks (Chiappa et al. 1995), time to death was 
not specifically reported. No treatment-related deaths were observed in a multigeneration study where rats (30 
males and 30 females per dose group) received 0, 0.1, 1, or 5 mg/kg/day chlorpyrifos in feed (Breslin et al. 1996). 
In another multigeneration study, no deaths were observed in male and female Sprague-Dawley rats 
(30/sex/group) exposed to 0.5, 0.8, or 1.2 mg/kg/day Dursban ® in feed for 120-135 days (Dow 1983b). 
Similarly, exposure to up to 15 mg/kg/day Dursban® in feed for 13 weeks caused no deaths in Fischer 344 rats 
(Dow 1993). Intermediate-duration (90 days) oral exposure did not cause deaths in two Leghorn hens exposed to 
10 mg/kg/day chlorpyrifos in capsules. In chronic-duration oral exposure studies, no deaths were observed in 
Sherman rats or Beagle dogs exposed to up to 3 mg/kg/day chlorpyrifos in feed for up to 2 years (McCollister et 
al. 1974). 
The LOAEL and LD50 values for lethality in each reliable study for each species and duration category are 
shown in Table 2-2 and Figure 2-2. 
2.2.2.2 Systemic Effects 
The highest NOAEL value and all LOAEL values for systemic effects in each reliable study for each species 
and duration category are shown in Table 2-2 and Figure 2-2. 
Respiratory Effects. In humans, acute-duration oral exposure to chlorpyrifos has been shown to 
cause respiratory distress resulting from cholinesterase inhibition. A 3-year-old boy was taken to the 
hospital in respiratory distress following the ingestion of an unknown amount of chlorpyrifos (Aiuto 
et al. 1993). He lapsed into a coma and was placed on a respirator. After 3 days, the endotracheal tube 
was removed, but the boy soon developed severe stridor and respiratory distress. Upper-airway edema 
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was also evident. It should be noted that stridor often develops in children after they are removed from artificial 
respirators. Stridor recurred, but the boy responded well to aerosolized racemic epinephrine and cool mist. An 
acute episode of stridor that did not respond to the aforementioned treatment occurred on day 11 of 
hospitalization. The airway appeared normal after direct laryngoscopy and bronchoscopy. Bilateral vocal cord 
paralysis was noted. However, this may have been caused or exacerbated by the intubation. All respiratory 
symptoms had resolved by day 52 of hospitalization. Similar symptoms were reported in a 5-year-old girl who 
drank an undetermined amount of Rid-A-Bug®, a pesticide preparation containing chlorpyrifos. When she arrived 
at the hospital, she presented with rapid and labored breathing, wheezing, and copious secretions in the nose and 
mouth that required frequent suctioning (Selden and Curry 1987). The symptoms resolved by day 6 of 
hospitalization. Respiratory distress was also observed in an adult following acute-duration oral exposure to 
approximately 300 mg/kg chlorpyrifos (Lotti et al. 1986). No information was found concerning respiratory 
effects in humans following intermediate- or chronic-duration oral exposure. 
No histopathological lesions of the lungs were noted following acute-duration exposure to 40 mg/kg 
chlorpyrifos dissolved in methylene chloride and administered via gavage in olive oil to male domestic 
short-hair cats (Hooser et al. 1988) or chronic-duration exposure of Sherman rats and Beagle dogs to as 
much as 3 mg/kg/day chlorpyrifos in feed (McCollister et al. 1974). No data were located for respiratory 
effects in animals following intermediate-duration oral exposure to chlorpyrifos. 
Cardiovascular Effects. Acute-duration oral exposure to undetermined amounts of chlorpyrifos in 
humans has been shown to cause tachycardia (Aiuto et al. 1993; Selden and Curry 1987). Although these 
studies only found tachycardia, the initial response after exposure to an acetylcholinesterase inhibitor is 
likely to be bradycardia because of stimulation of muscarinic receptors in the heart. No information was 
found concerning cardiovascular effects in humans following intermediate- or chronicduration oral exposure 
to chlorpyrifos. 
No histopathological lesions of the heart were noted following acute-duration exposure to 40 mg/kg 
chlorpyrifos dissolved in methylene chloride and administered in olive oil to cats (Hooser et al. 1988). 
Similarly, no heart weight changes or histopathological lesions were observed following chronic-
duration exposure of Sherman rats and Beagle dogs to as much as 3 mg/kg/day chlorpyrifos in feed 
(McCollister et al. 1974). Intermediate-duration exposure of a female domestic short-hair cat to an 
unspecified concentration of chlorpyrifos 2-3 hours after an apartment was sprayed for fleas did result 
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in increased creatine kinase levels in the cat. No effect was seen on an electrocardiogram, however (Jaggy 
and Oliver 1992). It is assumed that at least some of the exposure to this animal was oral through grooming. 
Gastrointestinal Effects. No information was found concerning gastrointestinal effects in humans 
following acute-, intermediate-, or chronic-duration oral exposure to chlorpyrifos. 
Limited gastrointestinal effects have been noted in rats following intermediate-duration oral exposure to 
chlorpyrifos. In female Fischer 344 rats, perineal soiling was observed in animals exposed to 5 mg/kg/day 
chlorpyrifos in feed for 13 weeks and may have been related to cholinesterase inhibition (Dow 1993). This 
effect was not seen in male rats exposed to as much as 15 mg/kg/day in feed for the same duration. This 
effect may be part of the spectrum of cholinergic effects. No histopathological lesions of the stomach were 
noted following either acute-duration exposure to 40 mg/kg chlorpyrifos in male domestic short-hair cats 
(Hooser et al. 1988) or chronic-duration exposure of Sherman rats and Beagle dogs to as much as 3 
mg/kg/day chlorpyrifos in feed (McCollister et al. 1974). 
Hematological Effects. Acute-duration oral exposure to an undetermined amount of 
chlorpyrifos by ingestion caused elevated serum glucose and creatinine kinase levels and low lactate 
dehydrogenase levels in a 3-year-old boy who ingested an unknown amount of Dursban® (Aiuto et al. 
1993). No effect on hematological or serum chemistry parameters were seen, however, in adult male 
volunteers treated with up to 0.1 mg/kg/day chlorpyrifos by capsule for 9 days or up to 0.03 mg/kg/day 
chlorpyrifos for 20 days (Coulston et al. 1972). No information was found concerning hematological effects 
in humans following chronic-duration oral exposure to chlorpyrifos.  No information was found concerning 
hematological effects in other animals following acute- or intermediate-duration oral exposure to 
chlorpyrifos. No effect was seen on hematological parameters monitored in Sherman rats and Beagle dogs 
exposed to up to 3 mg/kg/day chlorpyrifos in the feed for l-2 years (McCollister et al. 1974). 
Musculoskeletal Effects. Acute-duration oral exposure to an undetermined amount of 
chlorpyrifos caused increased muscle tone in a 23-year-old woman (Joubert et al. 1984), and 
fasciculations in a 42-year-old male (Lotti et al. 1986). Bilateral vocal cord paralysis was also 
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observed in a 3-year-old boy who swallowed an undetermined amount of chlorpyrifos (Aiuto et al.1993); the 
vocal cord paralysis, however, may have been caused or exacerbated by the intubation of this patient. No 
information was found concerning musculoskeletal effects in humans following intermediate- or chronic-
duration oral exposure to chlorpyrifos. 
No histopathological lesions of the skeletal muscle were noted following acute-, intermediate-, or chronic-
duration exposure to chlorpyrifos. Exposure to 40 mg/kg chlorpyrifos dissolved in methylene chloride and 
administered in olive oil to male domestic short-hair cats (Hooser et al. 1988), to 15 mg/kg/day Dursban ® in feed 
administered to male and female Fischer 344 rats (Dow 1993), or chronic-duration exposure of Sherman rats and 
Beagle dogs to as much as 3 mg/kg/day chlorpyrifos in feed (McCollister et al. 1974) caused no histopathology of 
the skeletal muscles. No data were located for musculoskeletal effects in animals following acute- or chronic-
duration oral exposure to chlorpyrifos. 
Hepatic Effects. No information was found concerning hepatic effects in humans following acute-, 
intermediate-, or chronic-duration oral exposure to chlorpyrifos. 
The effects on liver weight and relative liver weight (liver weight/body weight) were assessed in pregnant CF-1 
mice following acute-duration oral exposure to doses as high as 25 mg/kg/day chlorpyrifos from Gd 6 to 15 
(Deacon et al. 1980). Liver weight and relative liver weight determined on Gd 18 were comparable to controls in 
all treatment groups. Hepatic effects were also noted in pregnant female Fischer 344 rats dosed by gavage with 0, 
0.1, 3, or 15 mg/kg/day of the technicalgrade chlorpyrifos Dursban F® in corn oil on Gd 6-15. Porphyrin deposits 
about the eyes were observed during the dosing period in maternal animals exposed to 15 mg/kg/day chlorpyrifos. 
This effect was not seen at doses of 3 mg/kg/day or below (Breslin et al. 1996). Increased serum total protein and 
albumin levels were observed in a female domestic short-hair cat exposed to an unspecified amount of 
chlorpyrifos in an apartment that was sprayed with chlorpyrifos every third day for 18 days (Jaggy and Oliver 
1992). It is assumed that some of the exposure was via the oral route as a result of grooming. No histopathological 
lesions or organ weight changes were observed in livers of Sherman rats or Beagle dogs chronically exposed to as 
much as 3 mg/kg/day chlorpyrifos in feed (McCollister et al. 1974). 
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Renal Effects. No chlorpyrifos-induced renal effects have been observed in humans. Urinalyses conducted 
for adult male volunteers treated with up to 0.1 mg/kg/day chlorpyrifos by capsule for 9 days or up to 0.03 
mg/kg/day chlorpyrifos for 20 days were normal (Coulston et al. 1972). No information was found 
concerning renal effects in humans following chronic-duration oral exposure to chlorpyrifos. 
In laboratory animals, chlorpyrifos-induced renal effects were few. No renal lesions were noted following a single 
oral exposure to 40 mg/kg chlorpyrifos dissolved in methylene chloride and administered in olive oil to adult male 
domestic short-hair cats (Hooser et al. 1988). Urine staining of the perineal region was observed in pregnant Fischer 
344 rats exposed via gavage on Gd 6-15 to 15 mg/kg/day of the technical-grade chlorpyrifos, Dursban F®, in corn 
oil (Breslin et al. 1996). In the same study, no renal effects were noted in rats exposed to 0.1 or 3 mg/kg/day 
chlorpyrifos. Renal effects have been observed following intermediate-duration oral exposure. Unspecified 
increases in urea nitrogen, alkaline phosphatase, and alanine aminotransferase were observed in a female domestic 
short-hair cat orally exposed to an unspecified amount of chlorpyrifos every third day for 18 days (Jaggy and Oliver 
1992). It is assumed that some of the exposure was oral through grooming. No renal effects were seen in the 
parental generation of Sprague-Dawley rats exposed to 0, 0.5, 0.8, or 1.2 mg/kg/day chlorpyrifos in feed for 135 
days (Dow 1983b). Chronic-duration oral exposure to up to 3 mg/kg/day chlorpyrifos in feed also caused no organ 
weight changes or histopathological lesions of the kidneys in either male or female Sherman rats or Beagle dogs 
exposed to chlorpyrifos in feed for l-2 years (McCollister et al. 1974). 
Endocrine Effects. No information was found concerning endocrine effects in humans following acute-, 
intermediate-, or chronic-duration oral exposure to chlorpyrifos. 
Acute-duration oral exposure to 40 mg/kg chlorpyrifos dissolved in methylene chloride and administered in olive 
oil to male domestic short-hair cats caused no microscopic lesions of the thyroid or adrenal glands (Hooser et al. 
1988). Mild endocrine effects were, however, observed-following intermediate-duration oral exposure (Breslin et 
al. 1996). In a multigeneration study, rats (30 males and females per dose group) received chlorpyrifos dosages 
equivalent to 0, 0.1, 1, or 5 mg/kg/day/day in feed. Very slight to slight vacuolation of the adrenal gland fasiculata 
was observed at 5 mg/kg/day in both males and females in the parental generation. These alterations were 
characterized by very slight to slight vacuolation in males and very slight vacuolation and altered tinctorial 
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properties in females. The toxicological significance of these effects is unclear. No endocrine effects were 
observed at the 0.1 or 1 mg/kg/day doses (Breslin et al. 1996). No information was found concerning 
endocrine effects in animals following chronic-duration oral exposure to chlorpyrifos. 
Ocular Effects. No information was found concerning ocular effects in humans following intermediate- or 
chronic-duration oral exposure to chlorpyrifos. 
Miosis was observed in a man after a single oral exposure to 300 mg/kg chlorpyrifos (Lotti et al.1986). No 
data were located for ocular effects in other animals following acute-duration oral exposure to chlorpyrifos. 
No ocular histopathology was found in male and female Fisher 344 rats exposed for 13 weeks to 0, 0.1, 1, 5, 
or 15 mg/kg/day chlorpyrifos in feed (Dow 1993). Chronic-duration oral exposure in feed to as high as 3 
mgikg/day chlorpyrifos caused no ocular effects in either male or female Sherman (30-32/sex/group) rats 
dosed for 2 years or Beagle dogs (3/sex/group) exposed for 1-2 years (McCollister et al. 1974). 
Body Weight Effects. No information was found concerning effects on body weight in humans following 
acute-, intermediate-, or chronic-duration oral exposure to chlorpyrifos. 
The effects on body weight and body weight gain were assessed in pregnant CF-1 mice following acute-
duration oral exposure to doses as high as 25 mg/kg/day chlorpyrifos in cottonseed oil on Gd 615 
(Deacon et al. 1980). A statistically significant decrease in mean body weight gain for Gd lo-15 (33.3%) 
and overall (Gd 6-17, 14%) was observed in animals exposed to 25 mg/kg/day chlorpyrifos. Food 
consumption was unaffected. The body weight gain and food consumption of dams exposed to 1 or 10 
mg/kg/day chlorpyrifos were comparable to controls. Additionally, body weights determined on 
Gd 18 for all the treatment groups were similar to control values. Similar effects have been observed 
in rats (Breslin et al. 1996; Moser 1995). A single dose of 100 mg/kg technical-grade chlorpyrifos 
(99%) administered via gavage in corn oil caused a 13.3% decrease in the body weight of male Long-
Evans rats by 24 hours post-dosing. Recovery was seen at one week postdosing.  Decreased body 
weight was not seen at doses of 50 mg/kg or less (Moser 1995). Similarly, pregnant Fischer 344 rats 
exposed via gavage to 15 mg/kg/day Dursban F® (technical-grade chlorpyrifos) in corn oil on Gd 6-15 
experienced a statistically significant decrease in mean body weight gain for Gd 9-12 (44%). The body weight 
gain of dams exposed to 0.1 or 3 mg/kg/day chlorpyrifos was comparable to controls (Breslin et al. 1996). 
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Body weight effects have not been seen following intermediate-duration oral exposure of rodents (Breslin et al. 
1996; Dow 1983b, 1993). No body weight changes were observed in male and female Fischer 344 rats exposed to 
up to 15 mg/kg/day Dursban  in feed for 13 weeks (Dow 1993).  Similarly, in a rat multigeneration study, no body 
weight or feed intake changes were observed in male and female Sprague-Dawley rats exposed to 0, 0.1, 1, or 5 
mg/kg/day chlorpyrifos in feed (Breslin et al. 1996). I n another rat multigeneration study, no body weight or feed 
intake changes were observed in male and female Sprague-Dawley parental animals or first generation offspring 
exposed to 0, 0.5, 0.8, or 1.2 mg/kg/day Dursban for 135 or 120 days, respectively (Dow 1983b). However, body 
weight decreases following intermediate-duration chlorpyrifos exposure have been observed in chickens. A dose of 
10 mgtkglday chlorpyrifos for 20 days caused a 25% decrease in body weight in hens by the end of the dosing 
period (Richardson et al. 1993b). Chronic-duration oral exposure to ≤3 mg/kg/day chlorpyrifos in feed also caused 
no body weight effects in either male or female Sherman rats or Beagle dogs exposed for l-2 years (McCollister et 
al. 1974). 
Metabolic Effects. No information was found concerning the metabolic effects in humans following acute-, 
intermediate-, or chronic-duration oral exposure to chlorpyrifos. 
Hypothermia was observed in male Long-Evans rats 3.5 hours after acute-duration exposure to 50 or 100 
mg/kg technical-grade (99%) chlorpyrifos in corn oil via gavage (Moser 1995). Hypothermia was present at 
24 hours post-dosing only in the 100 mg/kg group and was no longer detectable at 72 hours post-dosing. 
Hypothermia was not observed in animals exposed to 20 mg/kg. No information was found concerning the 
potential metabolic effects in animals following intermediate- or chronic-duration exposure to chlorpyrifos. 
2.2.2.3 Immunological and Lymphoreticular Effects. 
No information was found concerning immunological or lymphoreticular effects in humans following 
acute-, intermediate-, or chronic-duration oral exposure to chlorpyrifos.  No immunological or 
lymphoreticular effects were observed microscopically in the spleen or mesenteric lymph nodes of 
2 male domestic short-hair cats acutely exposed to 40 mg/kg chlorpyrifos (Hooser et al. 1988). 
Similarly, chickens exposed orally to 10 mg/kg/day chlorpyrifos for 20 days also exhibited no 
immunological or lymphoreticular effects (Richardson et al. 1993b). Breslin et al. (1996) 
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investigated the reproductive and developmental effects of chlorpyrifos at 0.1, 1, and 5 mg/kg/day/day in a 2-
generation reproductive study in Sprague-Dawley rats. Their results indicated no treatmentrelated histopathological 
changes in thymus, spleen, mesenteric lymph node, or bone marrow in any of the F0 or F1 adults. Chronic-duration 
oral exposure to up to 3 mg/kg/day chlorpyrifos in feed also caused no histopathology of the spleen or organ 
weight change in either male or female Sherman rats or Beagle dogs orally exposed for l-2 years (McCollister et al. 
1974). Taken together, the available evidence indicates that exposure to chlorpyrifos produces little or no structural 
changes in the immune system, even when administered chronically at doses causing statistically significant 
decreases in acetylcholinesterase activity. 
2.2.2.4 Neurological Effects 
In humans, acute-duration oral exposure to 0.1 mg/kg/day/day of chlorpyrifos for 9 days has been reported to 
inhibit plasma cholinesterase activity 66% (Coulston et al. 1972). Additionally, acuteduration oral exposure to 
undetermined amounts of chlorpyrifos has been reported to inhibit both erythrocyte and plasma cholinester 
ase activity 78-95% (Joubert et al. 1984; Selden and Curry 1987).  These latter levels of inhibition were 
associated with life-threatening cholinergic symptoms requiring hospitalization. Acute-duration oral exposure 
to undetermined amounts of chlorpyrifos caused stupor in a 23-year-old woman (Joubert et al. 1984), seizure-
like motor activity in a 5-year-old girl (Selden and Curry 1987), and coma in a 42-year-old man (Lotti et al. 
1986) and a 3-year-old boy (Aiuto et al. 1993). A variety of other symptoms have also been associated with 
exposure to unspecified amounts of chlorpyrifos: miosis, muscle twitching and fasciculations, hyper- or 
hyporeflexia, lacrimation, salivation, sweating, bronchorrhea, diaphoresis, and coreo-athetotic motions (Aiuto 
et al. 1993; Joubert et al. 1984; Selden and Curry 1987). Similar chlorpyrifos-related effects have been 
observed for CF-1 mice at 25 mg/kg/day, but not at 10 mg/kg/day chlorpyrifos (Deacon et al. 1980); in 
domestic shorthair cats at 40 mg/kg (Hooser et al. 1988); and in hens at 90 mg/kg (Capodicasa et al. 1991). 
Plasma and erythrocyte cholinesterase activity in adult humans volunteers following intermediate-duration 
oral exposure to doses up to 0.03 mg/kg/day chlorpyrifos for 20 days were unaffected (Coulston et al. 1972). 
No information was found concerning neurological effects in humans following chronicduration oral 
exposure to chlorpyrifos. 
In male domestic short-hair cats, acute-duration oral exposure to 40 mg/kg chlorpyrifos caused a 43-57% 
decrease in whole blood acetylcholinesterase activity and a 71% decrease in plasma 
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cholinesterase activity (Hooser et al. 1988). Similar effects were observed in pregnant Fischer 344 rats 
exposed to technical-grade chlorpyrifos Dursban F® administered via gavage on Gd 6-15. Erythrocyte 
acetylcholinesterase activity decreased 74 and 85% compared to control values at the 3 and 15 mg/kg/day 
body weight doses, respectively (Breslin et al. 1996). The dams exposed to 15 mg/kg/day chlorpyrifos also 
exhibited classic signs of organophosphate poisoning during the dosing period, including excessive salivation, 
tremors, and decreased plasma cholinesterase activity. In the same study, no neurological effects were seen at 
0.1 mg/kg/day. Female CF-1 mice (40-51 per group) were exposed by gavage to 1, 10, or 25 mg/kg/day/day 
Dursban F (96.8% chlorpyrifos) as a solution in cottonseed oil on day 6, days 6-10, or Gd 6-15 (Deacon et 
al. 1980). Plasma and erythrocyte cholinesterase levels were significantly decreased from control values 
among mice given 10 or 25 mg/kg/day chlorpyrifos on day 6 (plasma, 95 and 97% decrease, respectively; 
erythrocyte, 20 and 40%, respectively) and, days 6-10 (plasma, 97 and 99%, respectively; erythrocyte, 43 and 
71%, respectively), or days 6-15 (plasma, 96 and 98%, respectively; erythrocyte, 43 and 57%, respectively). 
Plasma cholinesterase levels were significantly reduced among mice given 1 mg/kg/day chlorpyrifos during 
the same time intervals (69, 78, and 85%, respectively). Erythrocyte cholinesterase levels were also reduced 
(43%) after 1 mg/kg/day chlorpyrifos, but only after exposure on Gd 6-10 (Deacon et al.1980). In a 
concurrent study of cholinesterase inhibition using dosages of 0.1, 1, and 10 mg/kg/day, Deacon et al. (1980) 
determined a no-effect level of 0.1 mg/kg/day for erythrocyte and plasma cholinesterase inhibition. Similar 
effects on erythrocyte and plasma cholinesterase activities were noted in a multigeneration study in rats 
(Breslin et al. 1996). Significantly decreased erythrocyte and plasma cholinesterase levels were seen in first 
and second generation male and female Sprague-Dawley rats exposed to 1 mg/kg/day Dursban F® in feed. In 
males, erythrocyte cholinesterase was decreased 65-69%, while plasma cholinesterase was decreased 4344%. 
In females, erythrocyte cholinesterase was decreased 67%, while plasma cholinesterase was decreased 49­
55%. These effects were not observed in rats fed diets containing 0.1 mg/kg/day Dursban F® (Breslin et al. 
1996). 
In one human suicide attempt, acute-duration oral exposure to approximately 300 mg/kg of a 
commercial formulation of chlorpyrifos caused transient distal polyneuropathy that resolved 
approximately 90 days after exposure (Lotti et al. 1986). Acute-duration oral exposure to un­
determined amounts of chlorpyrifos produced clinical findings in a 3-year-old boy that were 
consistent with proximal polyneuropathy (Aiuto et al. 1993). Eleven days following exposure, the
 boy was areflexic, and electromyography demonstrated the absence of voluntary motor units on the 18th 
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day of hospitalization. Nerve conduction studies revealed a lack of F latencies. The patient was fully recovered 
by day 52 of his hospital stay. 
In the chicken, the species of choice for the evaluation of the OPIDN (Johnson 1982), a single oral exposure to 150 or 
300 mg/kg chlorpyrifos (with atropine prophylaxis to prevent death from acute cholinergic effects) caused a 3880% 
inhibition of neurotoxic esterase (NTE) 4 days after exposure (Capodicasa et al. 1991; Richardson et al. 1993a). NTE 
inhibition is believed by some to be directly related to the onset of OPIDN (Johnson 1982). Mild ataxia (indicating 
OPIDN) was observed in 4 of 7 chickens receiving 5 daily doses of 90 mg/kg/day chlorpyrifos (with atropine 
prophylaxis) and observed for a further 2 weeks (Capodicasa et al. 1991). A repeated-dose study showed that 20 daily 
doses of 10 mg/kg/day/day chlorpyrifos in corn oil (the maximally tolerated dose that did not require atropine 
prophylaxis) followed by a 4-week recovery produced signs of toxicity, including a significant decrease in body 
weight and brain and blood AChE (Richardson et al. 1993a). It also produced a maximum 18% inhibition of brain 
NTE, with no significant inhibition of lymphocyte NTE or clinical signs of OPIDN. 
In the chicken, brain AChE has also been shown to be inhibited by acute-duration oral exposure to chlorpyrifos. 
Exposure to 150 or 300 mg/kg caused brain AChE inhibition of >80% 4 days after exposure (Richardson et al. 
1993a). Intermediate-duration exposure to 10 mg/kg/day chlorpyrifos inhibited brain AChE 58-70% during days 4-20 
of exposure (Richardson et al. 1993b). Similar effects on brain AChE were observed in male Long-Evans rats 
exposed to 75 mg/kg/day chlorpyrifos in corn oil via gavage for 24 weeks. Brain AChE was decreased 85, 91, 86, and 
73% in the whole brain, forebrain, hippocampus, and cerebellum, respectively. Additionally, brain immunoreactive 
AChE was increased 56, 29, 26, and 26% in the whole brain, forebrain, hippocampus, and cerebellum, indicating 
increased synthesis of AChE or inhibited degradation to compensate for the effects of chlorpyrifos (Chiappa et al. 
1995). In a study to examine the potential for intermediate-duration chlorpyrifos exposure to produce OPIDN 
(Francis et al. 1985), 2 hens were exposed to 10 mg/kg/day chlorpyrifos for 90 days. Physical deterioration began 30 
days after exposure, and extreme debilitation, weakness, and lethargy occurred between 35 and 60 days of dosing. 
The report indicates that both hens recovered from the chlorpyrifos-induced neurotoxicity after the cessation of 
dosing, but the time to recovery was not given. The time-course of toxicity and the eventual resolution of 
neurological symptoms following the exposure indicate that chlorpyrifos did not cause the classic OPIDN, from 
which recovery would not be expected, in this study. In fact, work by Richardson et al. 
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(1993a) indicates that chlorpyrifos-related OPIDN would only be expected at doses that would cause death 
without aggressive therapy. 
Other neurological effects were also noted in acute- and intermediate-duration studies of humans and animals 
(Aiuto et al. 1993; Dow 1993; Joubert et al. 1984; Lotti et al. 1986; Moser 1995; Selden and Curry 1987). Acute-
duration exposure to unspecified amounts of chlorpyrifos in children (a 3-year-old boy [Aiuto et al. 19931 and a 5­
year-old girl [Selden and Curry 19871) and a 23-year-old woman (Joubert et al. 1984) caused miosis. Miosis was 
also observed in a man who ingested an estimated 300 mg/kg chlorpyrifos in a suicide attempt (Lotti et al. 1986). 
Decreased motor activity was noted in male Long-Evans rats 3.5 hours after a single gavage exposure to 20, 50, or 
100 mg/kg technical-grade chlorpyrifos (99%) in corn oil. At 24 hours post-dosing, decreased motor activity was 
still present in the 100 mg/kg group, but these effects were no longer evident at 72 hours post-dosing (Moser 
1995).  Male and female Sprague-Dawley rats exposed to 1.5 mg/kg/day Dursban F® in feed for 13 weeks 
displayed a transient decrease in motor activity at the fourth week of dosing (Dow 1993). Chronicduration oral 
exposure to chlorpyrifos in feed also caused neurological effects in rats and dogs (McCollister et al. 1974). Brain 
acetylcholinesterase AChE activity was depressed at all sampling times in rats fed 3 mg/kg/day chlorpyrifos for up 
to 2 years, with overall means averaging 56% of control value for males and 57% for females. There was no 
overall reduction in brain AChE activity at study termination in rats dosed with 1 mg/kg/day, although there were 
individually significant differences at some of the sampling times. Rat plasma cholinesterase (ChE) and red blood 
cell (RBC) AChE activities were significantly depressed for both male and female rats dosed with 1 and 3 
mgfkglday chlorpyrifos. For example, at 1 mg/kg/day, plasma ChE activity was decreased 20-53% while RBC 
AChE activity was decreased 65-70%. At 0.1 mg/kg/day, the AChE activity of the RBCs for females was 
significantly different from controls at 2 of the 6 sampling periods only. Otherwise, doses of 0.1 mg/kg/day and 
below had no effect on either plasma or RBC activity. Cholinesterase activities in plasma, RBC, and brain returned 
to normal levels in males and females in all dose groups maintained on control diets for 7-8 weeks (McCollister et 
al. 1974). In Beagle dogs, similar effects were observed in males exposed to 1 mg/kg/day chlorpyrifos in feed for 1 
or 2 years or-females receiving that same daily dose for 2 years. However, this effect was not seen in females 
exposed to as much as 3 mg/kg/day chlorpyrifos in feed for 1 year (McCollister et al. 1974), suggesting that there 
may be a cumulative effect of chlorpyrifos exposure. 
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Any sex-dependent toxicity of chlorpyrifos may be due to an increased rate of extrahepatic detoxification of 
the pesticide in males. A complete discussion of this phenomenon may be found in Section 2.3, 
Toxicokinetics, of this profile. 
The highest NOAEL value and all LOAEL values for neurological effects in each reliable study for each 
species and duration category are shown in Table 2-2 and Figure 2-2. 
2.2.2.5 Reproductive Effects 
No information was found concerning reproductive effects in humans following oral acute-, intermediate-, or 
chronic-duration exposure to chlorpyrifos. 
Pregnant CF-1 mice were exposed on Gd 6, Gd 6-10 or Gd 6-15, to 0, 1, 10, or 25 mg/kg/day chlorpyrifos (Deacon 
et al. 1980). Four of 47 dams exposed to 25 mg/kg/day chlorpyrifos died. That dose also caused a significant 
decrease in body weight gain during Gd lo-15 (33%) and Gd 6-17 (14%). Despite the deficits in weight gain, 
overall body weight at study termination was not affected at that dose. Thirty-two of 47 mice exposed to 25 
mg/kg/day chlorpyrifos exhibited symptoms (excessive salivation, tremors, urine-soaked coat, ataxia, and lethargy) 
of cholinergic  overstimulation; similar clinical signs were seen in 5 of 44 dams dosed with 10 mg/kg/day/day 
chlorpyrifos. Food and water intake were also significantly decreased at that dose. Despite the maternal toxicity, 
chlorpyrifos did not affect the ability of the surviving dams to maintain pregnancy. No overt neurological 
symptoms were observed at the lower chlorpyrifos doses (1 or 10 mg/kg/day). In a concurrent study, pregnant mice 
were orally administered 0, 0.1, 1, or 10 mg/kg/day chlorpyrifos. No significant clinical signs of maternal toxicity 
were noted at any dose of chlorpyrifos. In pregnant Fischer 344 rats exposed by gavage to 0, 0.1, 3, or 15 
mg/kg/day technical-grade chlorpyrifos as Dursban F®, on Gd 6-15, vaginal bleeding was observed in dams 
exposed to 15 mg/kg/day chlorpyrifos, but no other reproductive organ effects were noted (Breslin et al. 1996). No 
reproductive effects were seen in rats exposed to 0.1 or 3 mg/kg/day. No adverse effects on fertility, mating, or 
gestation indices were observed in multigeneration studies conducted using Sprague-Dawley rats (30/sex/group) 
dosed with 0.1-5 mg/kg/day Dursban®  feed (Breslin et al. 1996; Dow 1983b). No effects on testes weight or 
reproductive organ histology were observed in male and female Sherman rats or Beagle dogs exposed to as 
high as 3 mg/kg/day chlorpyrifos in feed for l-2 years (McCollister et al. 1974). 
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The highest NOAEL values for reproductive effects in each reliable study for each species and duration 
category are shown in Table 2-2 and Figure 2-2. 
2.2.2.6 Developmental Effects 
No information was found concerning developmental effects in humans following oral acute-, intermediate-, 
or chronic-duration exposure to chlorpyrifos. 
The potential for chlorpyrifos to cause developmental toxicity was assessed in CF-1 mice exposed to 0, 1, 10, or 25 
mg/kg/day chlorpyrifos on Gd 6-15 (Deacon et al. 1980). On Gd 18, all fetuses were weighed, sexed, examined for 
external malformations and cleft palate, and had their crown-rump length determined. One-third of the fetuses of 
each litter were also examined for evidence of softtissue alterations. There was no biologically significant effect of 
treatment on the number of live fetuses per litter, the number of dead fetuses per litter, the number of resorptions 
per litter, the average fetal body weight, or average crown-rump length. However, significant increases in skeletal 
variations were observed in litters exposed to 25 mg/kg/day chlorpyrifos. Increases were seen for the number of 
fetuses with delayed ossification of the skull bones (6.8-fold increase), delayed ossification of the stemebrae (2.1­
fold increase), and unfused stemebrae (4-fold increase). These effects, however, may have been due, in part, to 
maternal toxicity as opposed to a direct effect of chlorpyrifos on the developing offspring. In the same study, 10 
and 25 mg/kg/day significantly decreased whole fetal homogenate cholinesterase activity by 35 and 65%, 
respectively. Similar exposure in rats, however, caused no developmental effects (Breslin et al. 1996). Pregnant 
Fischer 344 rats exposed to 0.1, 3, or 15 mg/kg/day technical-grade chlorpyrifos Dursban F® in corn oil 
administered via gavage on Gd 6-15 showed no effect on pregnancy rate, number of implantations, preimplantation 
loss, resorption, number of dead fetuses, litter size, fetal body weight, crown-rump length, or sex ratio in any 
treatment group. Increased fetal body weight was observed in the 3 and 15 mg/kg groups, but was not considered 
treatment-related. There were no treatment-related effects on fetal malformations or variations at any exposure 
level (Breslin et al. 1996). 
Few developmental effects have been seen following intermediate-duration oral exposure to 
chlorpyrifos. No adverse effects on gestation indices; gestation survival indices; total number of live 
pups per litter on day 1 of lactation; pup survival indices on days 1, 4, 7, 14, and 21 of lactation; sex 
ratio of pups at day 21; or incidence of external alterations in first and second generation offspring 
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between birth and 21 days of age were observed in a multigeneration study conducted using Sprague-Dawley 
rats (30/sex/dose group) fed the equivalent of 0.5, 0.8, or 1.2 mg/kg/day Dursban® (Dow 1983b). However, a 
10-l1% decrease in pup body weight was observed in first generation pups in a multigeneration study of male 
and female Sprague-Dawley rats fed diets containing 5 mg/kg/day Dursban F® (Breslin et al. 1996). Using a 
similar study design and numbers of animals, Breslin et al.(1996) did not report offspring body weight deficits 
in animals fed 1 mg/kg/day or less chlorpyrifos.  No data were located for developmental effects in animals 
following chronic-duration oral exposure to chlorpyrifos. 
The LOAEL values for developmental effects in each reliable study for each species and duration category 
are shown in Table 2-2 and Figure 2-2. 
2.2.2.7 Genotoxic Effects 
No information was found concerning the potential genotoxic effects in humans following oral acute-, 
intermediate-, or chronic-duration exposure to chlorpyrifos. 
Chlorpyrifos was tested for its ability to induce complete and partial chromosome losses in D. melanogaster 
males (Woodruff et al. 1983). Initial attempts were made to identify an approximate LD30 dose prior to 
treatment, with toxicity defined as the number of dead flies out of the total number treated over a 3-day 
period. Mortality was recorded at 24, 48, and 72 hours. At 72 hours, males were removed and mated with 
mus-302 repair-defective females, and F1 male progeny were screened for complete and partial chromosome 
loss. Treated and control males that had a ring-X chromosome and a doubly-marked Y chromosome were 
used in a screen for ring-chromosome loss and for loss of Y-chromosome markers. A significant increase in 
complete chromosome loss was induced by 0.05 mg/kg chlorpyrifos, but no effect on partial chromosome loss 
was observed. 
The mutagenic potential of an unspecified dose of Durmet® (20% chlorpyrifos) was assessed using the 
Drosophila wing mosaic and sex-linked recessive lethal tests (Patnaik and Tripathy 1992). In the wing 
mosaic test, second- and third-instar larvae that were trans-heterozygous for the recessive marker 
mutations multiple wing hair (mwh) and flare-3 (flr3) were obtained from a cross of mwh females and 
flr3/TM3 Ser males. They were exposed to various concentrations of Durmet®, and the frequency of the 
mutant mosaic spot induction on the wings noted. The Basc technique was used to evaluate the 
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induction of sex-linked lethals. Because of an increase in the frequency of induction of mosaic wing spots and 
sex-linked recessive lethals, Durmet® was considered to be genotoxic to Drosophila somatic and germ cells. 
Intermediate-duration oral exposure to chlorpyrifos (as Dursban®) has been shown to increase the incidence of 
erythroblast chromosomal aberrations (Amer and Fahmy 1982). In that study, mice received rat chow containing 
either 0, 80, or 240 ppm Dursban® for 24 hours, 7 days, 14 days, or 14 days with a 7-day recovery period. Doses of 
1.39 or 4.18 mg/kg/day Dursban® were estimated from those concentrations. Dursban® at 4.18 mg/kg/day caused a 
statistically significant increase in the percentage of polychromatic erythrocytes (PE) and PE with micronuclei after 
24 hours (70 and 176% increases, respectively) and 7 days (25 and 257% increases, respectively) of exposure. PE 
with micronuclei were also significantly increased at 14 days of treatment with 4.18 mg/kg/day (458% increase). 
These increases were transient, and percentages of PE and PE with micronuclei were normal seven days after the 
end of the dosing period. These results indicate that during exposure, chlorpyrifos increased the incidence of 
erythroblast chromosomal aberrations. Similar transient increases in PE and PE with micronuclei were found after 
mice were dose-fed 2.09 mg/kg/day Dursban® for 10 weeks (Amer and Fahmy 1982). No data were located for 
genotoxic effects in animals following chronic-duration oral exposure to chlorpyrifos. Genotoxicity studies are also 
discussed in Section 2.5. 
2.2.2.8 Cancer 
No information was located concerning carcinogenic effects of chlorpyrifos in humans following oral acute-, 
intermediate-, or chronic-duration exposures. 
No studies were located concerning carcinogenic effects of chlorpyrifos in animals following acute- or 
intermediate-duration exposure. Chronic-duration exposure studies have shown no carcinogenicity.  Male and 
female Sherman rats and Beagle dogs exposed to up to 3 mg/kg/day chlorpyrifos in feed for l-2 years had no 
increased incidence of tumors compared to controls (McCollister et al. 1974). 
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2.2.3 Dermal Exposure 
2.2.3.1 Death 
No information was found concerning death in humans following acute-, intermediate-, or chronicduration 
dermal exposure to chlorpyrifos. 
Acute-duration dermal exposure LD50 for chlorpyrifos was determined to be 202 mg/kg in Sherman  rats (Gaines 
1969). Survival times of 46 hours to 13 days were reported. Acute-duration dermal exposure of 185 young (9-52 
months of age) bulls to an undetermined dose of Dursban 44® to control lice killed 7 of the animals (Everett 1982). 
Additionally, age-related death was observed in newborn piglets sprayed with an undetermined amount of 
chlorpyrifos at various times after birth (Long et al.1986). Mortality was 4 of 4 in piglets treated 0-3 hours after 
birth, 3 of 3 in piglets treated l-3 hours after birth, 3 of 5 in piglets treated 24-30 hours after birth, and 0 of 3 in 
piglets treated 30-36 hours after birth. The results indicate that newborn piglets are more susceptible to the 
chlorpyrifos toxicity.  In hens, intermediate-duration dermal exposure to 20 mg/kg/day killed 2 of 3 hens after 30 
and 38 days of exposure, respectively (Francis et al. 1985). No data were located concerning death in animals 
following chronic-duration dermal exposure to chlorpyrifos. 
The LD50 value for mortality in rats in shown in Table 2-3. 
2.2.3.2 Systemic Effects 
No studies were located concerning the potential cardiovascular, endocrine, body weight, or metabolic effects 
of chlorpyrifos in humans or animals following acute-, intermediate-, or chronic-duration dermal exposure to 
chlorpyrifos. 
Respiratory Effects. No information was found concerning respiratory effects in humans following 
intermediate-duration dermal exposure to chlorpyrifos. 
The effects of presumed acute-duration dermal exposure to chlorpyrifos were reported for 12 persons exposed 
to chlorpyrifos primarily in the home or workplace following professional application of the pesticide 
(Thrasher et al. 1993). The route of exposure was not reported; however, dermal in addition 
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to inhalation exposure was likely. The approximate dose received and the length of time between exposure and the 
onset of symptoms was not known for any of the patients. The pesticide-exposed persons reported an increase in 
flu-like symptoms and upper and lower respiratory problems when compared to 60 (28 male and 32 female) 
control subjects. In a chronic-duration exposure study by Brenner et al. (1984) the prevalence of selected illnesses 
and symptoms in 175 employees involved in the production of chlorpyrifos was compared with 335 matched 
controls with no history of exposure to organophosphorus chemicals. Employees were further subdivided for dose-
response testing into three exposure intensity groups on the basis of job title and air-monitoring data. There were 
no statistically significant differences in the prevalence of respiratory illness or other respiratory symptoms in the 
exposed groups compared to matched controls. Exposure was assumed to be via both inhalation and dermal routes. 
Piglets acutely exposed (by spraying) to an undetermined amount of chlorpyrifos at 0-3, 1-3, 24-30, or 30-36 hours 
after birth were observed for clinical signs of toxicity, and various tissues were taken for histopathological 
evaluations (Long et al. 1986). Mortality was 4 of 4, 3 of 3, 3 of 5, and 0 of 3 in piglets treated 0-3, 1-3, 24-30, and 
30-36 hours after birth, respectively. Dyspnea, resulting from cholinergic over-stimulation, was observed in the 
pigs that eventually died. However, microscopic evaluation of the lung tissues from the treated piglets did not 
reveal any abnormalities. No data were located for respiratory effects in animals following intermediate- or 
chronic-duration dermal exposure to chlorpyrifos. 
Gastrointestinal Effects. Gastrointestinal effects have been observed in humans following acute-, 
intermediate-, and chronic-duration exposures (Kaplan et al. 1993; Thrasher et al. 1993). Nonspecific 
gastrointestinal disturbances were reported by individuals acutely exposed to unknown quantities of 
chlorpyrifos. The exact number of individuals experiencing gastrointestinal disturbances, however, 
was not reported. Additionally, the approximate dose received and the length of time between exposure 
and the onset of symptoms was not known for any of the patients (Thrasher et al. 1993). Intermediate-
duration exposure to chlorpyrifos also causes gastrointestinal distress in humans.  Diarrhea developed 
in a 40-year-old male exterminator who was repeatedly exposed to an unknown concentration of 
Dursban® in a closed environment over a 6-month interval (Kaplan et al. 1993).  Exposure -was 
assumed to be via both inhalation and dermal routes. Erythrocyte cholinesterase levels determined 
at the onset of symptoms were reported to be initially low (value not given). The diarrhea probably
 resulted from stimulation of parasympathetic nervous system-dependent physiological 
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processes as a consequence of cholinesterase inhibition. Stimulation of the parasympathetic nervous system 
increases gastrointestinal motility, thereby decreasing food transit times. The net result is that there is less 
time for water to be absorbed by the intestinal system and diarrhea results. In a chronicduration exposure 
study by Brenner et al. (1984), the prevalence of selected illnesses and symptoms in 175 employees involved 
in the production of chlorpyrifos was compared with 335 matched controls with no history of exposure to 
organophosphorus chemicals. Employees were further subdivided for dose-response testing into three 
exposure intensity groups on the basis of job title and air-monitoring data. There were no statistically 
significant differences in the prevalence of digestive system illnesses or symptoms between the exposed 
groups and matched controls. Exposure was assumed to be via both inhalation and dermal routes. 
Piglets acutely exposed by spraying an undetermined amount of chlorpyrifos at 0-3, 1-3, 24-30, or 30-36 hours 
after birth were observed for clinical signs of toxicosis, and various tissues were taken for histopathological 
evaluations (Long et al. 1986). Mortality was 4 of 4, 3 of 3, 3 of 5, and 0 of 3 in piglets treated 0-3, 1-3, 24-30, and 
30-36 hours after birth. Diarrhea resulting from cholinergic overstimulation was observed in the pigs that 
eventually died. Necropsy of the piglets revealed increased fluid in the intestines of some, but only in those piglets 
exposed l-3 hours after birth. Two of 4 bulls treated with 1 g testosterone for 86 days, then dermally exposed to 
0.33 mL/kg of a chlorpyrifos solution (equivalent to approximately 0.04 mg/kg) 28 and 58 days after the start of 
the testosterone treatment, had to be killed because of severe diarrhea (Haas et al. 1983). No data were located for 
gastrointestinal effects in animals following intermediate- or chronic-duration dermal exposure to chlorpyrifos. 
Hematological Effects. No hematological effects were observed in a 40-year-old male 
exterminator who was repeatedly exposed to an unknown concentration of Dursban ® in a closed environment 
over a 6-month interval (Kaplan et al. 1993). Exposure was assumed to be via inhalation and dermal routes. 
No information was found concerning hematological effects in humans following acute- or intermediate-
duration dermal exposure to chlorpyrifos. 
Acute-duration dermal exposure to 0.33 mL/kg of a chlorpyrifos solution (equivalent to approximately 0.04 
mg/kg) caused no hematological effects in groups of 4 Holstein bulls and steers (Haas et al. 1983). No 
information was found concerning hematological effects in animals following intermediateor chronic-duration 
dermal exposure to chlorpyrifos. 
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Musculoskeletal Effects. Musculoskeletal effects have been observed in humans following acuteand 
intermediate-duration exposure to chlorpyrifos (Brenner et al. 1984; Kaplan et al. 1993; Thrasher et al. 1993). 
In humans, acute-duration exposure to undetermined amounts of chlorpyrifos was reported to produce 
unspecified muscle pain (Thrasher et al. 1993) and muscle cramps (Kaplan et al. 1993). A family became ill 
and complained of muscle cramps after their house was sprayed with Dursban (Kaplan et al. 1993). The time 
from exposure to the onset of symptoms and exposure-level data were not reported. Intermediate-duration 
exposure to chlorpyrifos also causes musculoskeletal effects in humans. Muscle twitching was reported by a 
40-year-old exterminator exposed to unspecified amounts of chlorpyrifos over a 6-month period (Kaplan et al. 
1993). In the Kaplan et al. (1993) case reports, exposure was assumed to be via inhalation and dermal routes. 
It should be noted that in the Kaplan et al. (1993) and Thrasher et al. (1993) studies, chlorpyrifos exposure 
could not be conclusively determined for each case report. Also, in the Thrasher et al. (1993) study, the 
approximate dose received and the length of time between exposure and the onset of symptoms was not 
known for any of the patients. 
In a chronic-duration exposure study by Brenner et al. (1984), the prevalence of selected illnesses and 
symptoms in 175 employees involved in the production of chlorpyrifos was compared with 335 matched 
controls with no history of exposure to organophosphorus chemicals. Employees were further subdivided for 
dose-response testing into three exposure intensity groups on the basis of job title and air-monitoring data. 
There were no statistically significant differences in the prevalence of musculoskeletal illnesses or symptoms 
between the exposed groups and matched controls. Exposure was assumed to be via both inhalation and 
dermal routes. 
In animals, musculoskeletal effects have been observed following intermediate-duration exposure (Jaggy and 
Oliver 1992). Creatine kinase activity increased an undetermined amount in a female cat exposed to an 
unspecified amount of chlorpyrifos during apartment spraying every third day for 18 days (Jaggy and Oliver 
1992). It was assumed that some of the exposure was dermal. No information was found concerning 
musculoskeletal effects in animals following acute- or chronicduration dermal exposure to chlorpyrifos. 
Hepatic Effects. In a chronic-duration exposure study by Brenner et al. (1984), the prevalence of selected 
illnesses and symptoms in 175 employees involved in the production of chlorpyrifos was compared with 335 
matched controls with no history of exposure to organophosphorus chemicals. 
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Employees were further subdivided for dose-response testing into three exposure intensity groups on the basis of 
job title and air-monitoring data. There were no statistically significant differences in the prevalence of hepatic 
illnesses or symptoms between the exposed groups and matched controls.  Exposure was assumed to be via both 
inhalation and dermal routes. No information was found concerning hepatic effects in humans following acute- or 
intermediate-duration dermal exposure to chlorpyrifos. 
In animals, hepatic effects have been observed following intermediate-duration exposure (Jaggy and Oliver 
1992). Increased serum total protein and albumin levels were observed in a female domestic short-hair cat 
exposed to an unspecified amount of chlorpyrifos in an apartment that was sprayed with chlorpyrifos every 
third day for 18 days (Jaggy and Oliver 1992). It is assumed that some of the exposure was via the oral route 
as a result of grooming. No information was found concerning hepatic effects in animals following acute- or 
chronic-duration dermal exposure to chlorpyrifos. 
Renal Effects. No information was found concerning renal effects in humans following acute duration 
dermal exposure to chlorpyrifos. 
The effects of intermediate-duration exposure to undetermined amounts of chlorpyrifos in humans were assessed in 
a survey of pesticide applicators working in a variety of settings (Ames et al. 1989).  Exposure was assumed to be 
via inhalation and dermal routes. Those applicators reported an unspecified decrease in urinary frequency. This 
information is also presented in Section 2.2.1 of this profile because the route of exposure is not specified in the 
Ames et al. (1989) report, and it is probable that exposure occurred by multiple routes. In a chronic-duration 
exposure study by Brenner et al. (1984) the prevalence of selected illnesses and symptoms in 175 employees 
involved in the production of chlorpyrifos was compared with 335 matched controls with no history of exposure to 
organophosphorus chemicals. Employees were further subdivided for dose-response testing into three exposure 
intensity groups on the basis of job title and air-monitoring data. There were no statistically significant differences 
in the prevalence of renal illnesses or symptoms between the exposed groups and matched controls. Exposure was 
assumed to be via both inhalation and dermal routes. No information was found concerning renal effects in humans 
following acute- or intermediate-duration dermal exposure to chlorpyrifos. Exposure was assumed to be via 
inhalation and dermal routes. 
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In animals, renal effects have been observed following intermediate-duration exposure (Jaggy and Oliver 1992). Urea 
nitrogen, alkaline phosphatase, and alanine aminotransferase levels increased in a female cat exposed to an 
unspecified amount of chlorpyrifos during apartment spraying every third day for 18 days (Jaggy and Oliver 1992). It 
was assumed that at least some of the exposure was dermal.  No information was found concerning hepatic effects in 
animals following acute- or chronic-duration dermal exposure to chlorpyrifos. No data were located for renal effects 
in animals following acute- or chronic-duration dermal exposure to chlorpyrifos. 
Dermal Effects. No information was found concerning dermal effects in humans following acuteduration 
dermal exposure to chlorpyrifos. 
The effects of intermediate-duration exposure to undetermined amounts of chlorpyrifos in humans were assessed in a 
survey of pesticide applicators working in a variety of settings (Ames et al. 1989).  Exposure was assumed to be via 
inhalation and dermal routes. Those applicators reported an unspecified increase in skin flushing. This effect may be 
related to a disruption of autonomic function. This information is also presented in Section 2.2.1 of this profile, 
because the route of exposure is not specified in the Ames et al. (1989) report, and it is probable that exposure 
occurred by multiple routes. Additionally, prolonged dermal contact with chlorpyrifos may produce irritation; dermal 
sensitization may also occur (HSDB 1995). In a chronic-duration exposure study by Brenner et al. (1984), the 
prevalence of selected illnesses and symptoms in 175 employees involved in the production of chlorpyrifos was 
compared with 335 matched controls with no history of exposure to organophosphorus chemicals. Employees were 
further subdivided for dose-response testing into three exposure intensity groups on the basis of job title and air-
monitoring data. There were no statistically significant differences in the prevalence of dermal illnesses or symptoms 
between the exposed groups and matched controls. Exposure was assumed to be via both inhalation and dermal 
routes. No information was found concerning dermal effects in humans following acute- or intermediate-duration 
dermal exposure to chlorpyrifos. Exposure was assumed to be via inhalation and dermal routes. 
No data were located for dermal effects in animals following acute-, intermediate-, or chronic-duration dermal 
exposure to chlorpyrifos. 
Ocular Effects. No information was found concerning ocular effects in humans following acuteor chronic-
duration dermal exposure to chlorpyrifos. 
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Intermediate-duration exposure to an undetermined amount of chlorpyrifos caused an unspecified increase in 
tearing in a 40-year-old male exterminator repeatedly exposed to Dursban® over a 6-month period (Kaplan et 
al. 1993). Exposure was assumed to be via inhalation and dermal routes. Additionally, the effects of 
intermediate-duration exposure to undetermined amounts of chlorpyrifos in humans were assessed in a survey 
of pesticide applicators working in a variety of settings (Ames et al. 1989). Exposure was assumed to be via 
inhalation and dermal routes. Those applicators reported an unspecified increase in blurred vision. This 
information is also presented in Section 2.2.1 of this profile, because the route of exposure is not specified in 
the Ames et al. (1989) report, and it is probable that exposure occurred by multiple routes. 
No data were located for ocular effects in other animals following acute-, intermediate-, or chronic-duration 
dermal exposure to chlorpyrifos. 
2.2.3.3 Immunological and Lymphoreticular Effects 
No information was located concerning the potential immunological and lymphoreticular effects of 
chlorpyrifos in humans following intermediate- or chronic-duration dermal exposure, or in other animals 
following acute-, intermediate-, or chronic-duration dermal exposure. 
The effects of acute-duration dermal exposure to chlorpyrifos were reported for 12 persons exposed to 
chlorpyrifos primarily in the home or work place following professional application of the pesticide (Thrasher 
et al. 1993). The route of exposure for any of the exposed persons was not given. The approximate dose 
received and the length of time following exposure were not known for any of the patients. It is assumed 
that exposure occurred primarily by inhalation, but dermal exposure was also possible. Examination of blood 
taken from the chlorpyrifos-exposed persons indicated that there were changes in some lymphocyte subtypes
 when compared to 60 (28 male and 32 female) control subjects.  The presence of autoantibodies to smooth 
muscle, parietal cells, intestinal brush border, mitochondria, or nuclei was also determined. Analysis of the blood 
revealed a 300% increase in the mean absolute counts of CD26 cells and a decrease in the relative percentages of 
CD5 (11%) and CD4 (7%) lymphocytes. Additionally, 83% of the chlorpyrifos-exposed individuals had increased 
levels (300-1,200%) of circulating autoantibodies to at least one of the cell types or organelles (except 
mitochondria) listed above, and 25% of the chlorpyrifos-exposed patients had elevated autoantibodies to three 
or more of the cell types or organelles, compared to 0-3.7% in the control group. The authors 
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suggested that the increase in autoantibodies was due to chlorpyrifos-induced tissue damage (Thrasher et al. 1993). 
However, the causality of these effects must be interpreted with caution. This study was a retrospective case study 
where the symptoms arose 14.5 years post-exposure to chlorpyrifos. No exposure data were presented and there 
were no objective data or methods for ruling out confounding chemical exposures. Ten of the patients had a history 
of some type of atopy or drug sensitivity, while one patient had been diagnosed with systemic lupus erythematous 
and another had a lupus-like syndrome. From the results of this study, it may be concluded that the patients had 
some immunological abnormalities, but it is difficult to attribute the effects to chlorpyrifos exposure (Richardson 
1995). Additionally, although CD26 is a surface marker whose expression is increased on the surface of activated 
T cells, it has not been validated as a diagnostic indicator of immunotoxicity in either animal or human studies. Of 
primary importance is the fact that the following are not known: how the expression of the CD26 marker varies in a 
normal human population; what kinds of conditions can cause changes in the expression of CD26, especially 
regarding studies of potential drug/chemical-induced changes in its expression; the functional significance of 
changes in CD26 expression; and how much the expression of CD26 must change to be causally associated with 
changes in immune function. Finally, although it is true that elevations in autoantibodies to a number of self-
antigens can be caused by exposure to a variety of drugs and chemicals, the presence of autoantibodies can also be 
measured in normal healthy human populations. Thus, the biological significance of these findings is unclear. 
In spite of the widespread use of insecticides containing chlorpyrifos, there are no definitive reports that it 
sensitizes human skin. A study, which assessed a number of pesticides via patch tests in California nursery 
workers, reported no positive responses with chlorpyrifos in 38 out of the 39 exposed workers who were 
tested (O’Malley et al. 1995). The duration of exposure to any of the 6 pesticide formulations to which 
exposure occurred was not specified in this paper. Although none of the 21 control subjects were positive for 
chlorpyrifos, there were positive responses to other pesticides noted in the controls. Therefore, the biological 
significance of the positive response to chlorpyrifos in the single exposed worker could not be determined 
2.2.3.4 Neurological Effects 
The accidental application of an unspecified amount chlorpyrifos into the eye of a 42-year-old woman caused 
unilateral miosis presenting as anisocoria (Flach and Donahue 1994). Unilateral effects were 
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probably due to the unilateral application of the pesticide. In a review of the physical, neurotoxic, and respiratory 
problems suffered by 41 people exposed to organophosphate pesticidal products, symptoms of moderate to severe 
organophosphate poisoning were reported. In men and women exposed to unspecified amounts of only 
chlorpyrifos at home or at work, these symptoms included: seizures; peripheral and central nervous system 
disturbances; headaches; dizziness; nausea/vomiting; chest problems; heart problems; ear, nose, and throat 
problems; eye problems; skin problems; diarrhea; incoordination of the bowel/bladder; multiple chemical 
sensitivity; arthritis; fatigue; bladder symptoms; nightmares; sleep disturbances; joint problems; abnormal limbic 
system responses; thyroid problems; and weakness (Sherman 1995). However, in the Sherman (1995) report, no 
exposure-level data were presented. Additionally, the effects were reported by patients in uncontrolled studies. The 
cognitive complaints were nonspecific, nonquantitative, and could be attributable to a wide variety of possible 
causes. 
Intermediate-duration dermal exposure to chlorpyrifos has been associated with neurological effects (Kaplan et al. 
1993). Memory impairment and sensory loss were observed in a 42-year-old female exposed to Dursban ®that had 
been applied in her basement 8 times over 3 weeks (Kaplan et al. 1993). Muscle twitching, paresthesia, numbness, 
sensory loss, mild distal weakness, areflexia of lower extremities, and nerve conduction and quantitative sensory 
threshold abnormalities were observed in a 40-year-old male exterminator repeatedly exposed to Dursban®over a 
6-month period (Kaplan et al. 1993). Exposure in this study was assumed to be via inhalation and dermal routes. In 
a chronicduration exposure study by Brenner et al. (1984), the prevalence of selected illnesses and symptoms in 
175 employees involved in the production of chlorpyrifos was compared with 335 matched controls with no history 
of exposure to organophosphorus chemicals were. Employees were further subdivided for dose-response testing 
into three exposure intensity groups on the basis of job title and airmonitoring data. There were no statistically 
significant differences in the prevalence of central and peripheral nervous system illnesses or symptoms between 
the exposed groups and matched controls.  Exposure was assumed to be via both inhalation and dermal routes. 
Piglets acutely exposed by spraying an undetermined amount of chlorpyrifos at 0-3, 1-3, 24-30, or 30-36 
hours after birth were observed for clinical signs of toxicity (Long et al. 1986). Mortality was 4 of 4, 3 
of 3, 3 of 5, and 0 of 3 in piglets treated 0-3, 1-3, 24-30, and 30-36 hours, respectively, after birth. 
Weakness, trembling, ataxia, miosis, and lateral recumbency were observed in the piglets that eventually 
died. Additionally, determinations of brain cholinesterase activity in piglets exposed 
  
   
  
 
CHLORPYRIFOS 62 
2. HEALTH EFFECTS 
l-3 hours after births showed a 55--67% inhibition in activity. Blood acetylcholinesterase activity determined 
in piglets 12-17 hours after exposure displayed 8l-99% decreases in activity in piglets exposed up to 30 hours 
after birth. Intermediate-duration dermal exposure to 20 mg/kg/day chlorpyrifos applied to the ventral wing 
surface at the humerus for at least 28 days produced debilitation and paralysis in 2 of 3 exposed hens after 20­
28 days of dosing (Francis et al. 1985). No data were located for neurological effects in animals following 
chronic-duration dermal exposure to chlorpyrifos. 
2.2.3.5 Reproductive Effects 
No information was found concerning reproductive effects in humans following acute-, intermediate-, or 
chronic-duration dermal exposure to chlorpyrifos. 
An unspecified amount of Dursban 44® was applied once to 185 young bulls (9-52 months of age) for lice control. 
Semen output was analyzed from historical samples collected from 583 control animals to establish normal 
production (Everett 1982). Following exposure, semen production and sperm viability were determined in frozen 
samples. The bulls were divided into 2 post-exposure groups (6-month and 7-12-month) in order to assess the 
short- and long-term effects of the treatment, respectively. Six months post-exposure, the treated bulls were 
reported to have an unspecified increase in nonmotile sperm upon thawing of samples. Sperm motility and 
ejaculate volume were decreased, and the number of post-thaw nonmotile sperm increased in those bulls that 
became ill after treatment and required veterinary interventions. No adverse effects on bull sperm were observed 7­
12 months postexposure. No data were located for reproductive effects in animals following intermediate- or 
chronic-duration dermal exposure to chlorpyrifos. 
2.2.3.6 Developmental Effects 
No information was located concerning the potential developmental effects of chlorpyrifes in humans or 
animals following acute-, intermediate-, or chronic-duration dermal exposure. 
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2.2.3.7 Genotoxic Effects 
No information was located concerning the potential genotoxic effects of chlorpyrifos in humans following 
acute-, intermediate-, or chronic-duration dermal exposure. 
The effect of intermediate-duration dermal exposure to chlorpyrifos was assessed in Swiss mice (Amer and Fahmy 
1982). Dursban (99 mg/kg) was applied as a solution in 0.1 mL dimethyl sulfoxide (DMSO) to the backs of mice 
for 24 hours, 7 days, or 14 days, and the percentage of polychromatic erythrocytes (PE) determined. The 
applications were performed twice weekly for the 7- and 14-day exposures. Additionally, some animals exposed 
for 14 days were allowed to recover 1 or 2 weeks before having the percentage of PE determined. Controls 
received DMSO only. After 1 and 14 days of exposure, the percentage of PE increased 17 and 82%, respectively. 
However, no effect on PE was observed for the 7-day-exposure group. As a result, the authors concluded that the 
effect seen after one day of exposure was probably spurious. The percentage of PE was still elevated in the 14-day 
exposure group 7 days after termination of exposure. However, normal percentages of PE were found in the 14-
day-exposure group after 14 days of recovery. Additionally, there was no induction of micronuclei in any of the 
treatment groups. The results indicate that chlorpyrifos has the potential to cause transient increases in the 
incidence of erythroblast chromosomal aberrations. No data were located for genotoxic effects in animals 
following acute- or chronic-duration dermal exposure to chlorpyrifos. 
Other genotoxicity studies are discussed in Section 2.5. 
2.2.3.8 Cancer 
No information was located concerning the potential carcinogenic effects of chlorpyrifos in humans or other 
animals following acute-, intermediate-, or chronic-duration dermal exposure. 
2 . 3 TOXICOKINETICS 
Most of the toxicokinetic data on chlorpyrifos were collected following oral or dermal administration. 
Limited inhalation exposure data are available. Studies in humans and other animals indicate that 
orally administered chlorpyrifos is well absorbed, with 70-90% of the administered dose being 
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absorbed within 48 hours after exposure. In humans, only 3% of a the dermally applied dose is absorbed. In animals, 
the skin did not appear to provide an effective barrier to absorption. This seems unexpected based on the human data. 
However, those animal studies are confounded by the fact that dermal irritation, which may have decreased skin 
integrity, accompanied the dermal dosing, thereby increasing absorption. Animal studies indicate that orally and 
dermally administered chlorpyrifos rapidly distributes to all the major organs. Chlorpyrifos metabolism is similar in 
both humans and other animals. Chlorpyrifos is bioactivated to chlorpyrifos oxon in the liver via cytochrome P-450­
dependent desulfuration. The oxon is hydrolyzed by A-esterase to diethylphosphate and 3,5,6-trichloro-2-pyridinol 
(TCP), the major metabolite detected in humans and other animals.  The tissue elimination of chlorpyrifos is organ-
dependent, with the slowest elimination occurring from fat (half-life 62 hours). Chlorpyrifos is primarily excreted in 
the urine in the form of TCP conjugates. 
2.3.1 Absorption 
2.3.1.1 Inhalation Exposure 
The absorption of chlorpyrifos following acute-duration inhalation exposure has been demonstrated in humans (Aprea 
et al. 1994). Determination of chlorpyrifos metabolites in the urine from 1 man and 11 women exposed to 
chlorpyrifos in an orchard previously sprayed with chlorpyrifos indicated that significantly higher levels of urinary 
excretion of alkylphosphates were found in all exposure groups than in unexposed controls. There was a high 
correlation between quantities of the active ingredients on the hands and urinary excretion of total dimethylated 
alkylphosphates and of dimethylthiophosphates and dimethylphosphate. Respiratory absorption appears to have been 
significant in view of the difference in urinary excretion of dimethylated alkylphosphates found between subjects 
with and without face masks. No toxicokinetic information was located concerning the absorption of chlorpyrifos 
following inhalation exposure in other animals. 
2.3.1.2 Oral Exposure 
The absorption of chlorpyrifos following acute-duration oral exposure has been investigated in humans and 
other animals. In humans, determination of chlorpyrifos metabolites in the urine from 6 adult males orally 
exposed to chlorpyrifos administered orally in dipropylene glycol methyl ether indicated an average of 70% of 
the administered dose was absorbed within 48 hours (Nolan et al. 1984). In rats 
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(Bakke et al. 1976; Smith et al. 1967) and mice (Ahdaya et al. 19Sl), nearly 90% of the administered dose of 
14C-labeled chlorpyrifos in an acute-duration oral exposure was absorbed 48-60 hours after dosing, as assessed 
by the amount of radioactivity recovered in the feces and urine. 
2.3.1.3 Dermal Exposure 
The absorption of chlorpyrifos following dermal exposure has been investigated in humans and other animals. In 
humans, determination of chlorpyrifos metabolites in the urine from 6 adult males dermally exposed to chlorpyrifos 
indicated that an average of 3% of a dose administered in dipropylene glycol methyl ether was absorbed within 48 
hours, compared to 70% of an oral dose (Nolan et al. 1984). In goats, 80-96% of a 22 mg/kg dermal dose (vehicle not 
specified) was absorbed 12-16 hours after dosing (Cheng et al. 1989). In female Fischer 344 rats, the percentage of 
chlorpyrifos dissolved in acetone absorbed through the skin during a 72-hour period was dosedependent, with 
relatively more absorption occurring at higher doses (Shah et al. 1987). In that study, approximately 99% of a 21.03 
mg/kg dose was absorbed, compared with 46% of a 4.21 mg/kg dose.  However, considerably more irritation and 
blistering accompanied the high dose, compromising the integrity of the skin and increasing the possibility of 
absorption. Thus, the dose-dependent absorption of chlorpyrifos may have been enhanced by the destruction of the 
epidermis. In that same study, Shah et al. (1987) also assessed the effect of age on dermal penetration of chlorpyrifos. 
On average, 23% more chlorpyrifos was absorbed by young (33-day-old) than by adult (82-day-old) rats. The 
possible age-dependence of the dermal absorption of chlorpyrifos was also investigated in a study in which piglets of 
varying ages were sprayed with a solution containing an unspecified concentration of chlorpyrifos (Long et al. 1986). 
In that study, the toxicity of chlorpyrifos decreased with increasing time following birth. 
2.3.2 Distribution 
2.3.2.1 Inhalation Exposure 
No toxicokinetic information was located concerning the distribution of chlorpyrifos following inhalation 
exposure in humans or other animals. 
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2.3.2.2 Oral Exposure 
The distribution of 14C-labeled chlorpyrifos following oral exposure has been investigated using male Wistar 
rats (Smith et al. 1967) and Hereford crossbred heifers (Dishburger et al. 1977). The results of the Smith et al. 
(1967) study indicate that a single dose of 50 mg/kg chlorpyrifos administered via gavage readily distributes 
to all organs of the body, but that it accumulates in the fat and is liberated slowly (t1/2, 62 hours) compared to 
elimination from other tissues (t1/2, for elimination from liver, kidney, and heart is about l0-16 hours). Similar 
distribution was seen in Hereford crossbred heifers exposed to 0, 3, 10, 30, or 100 ppm chlorpyrifos for 30 
days (Dishburger et al. 1977). In keeping with the results of the Smith et al. (1967) study, chlorpyrifos 
residues were found predominantly in fatty tissues and averaged 0.02 (<0.0l-0.05 ppm) and 3.28 ppm (2.28­
4.7 ppm) in the fat of cattle fed 3 and 100 ppm chlorpyrifos, respectively, for 30 days with no withdrawal. 
2.3.2.3 Dermal Exposure 
The distribution of dermally applied 14C-labeled chlorpyrifos has been investigated using goats (Cheng et al. 
1989), mice (Shah et al. 1981), and bovines (Claborn et al. 1968; Ivey et al. 1972). The results from those 
studies indicate that chlorpyrifos readily distributes to all organs of the body, with relatively higher 
concentrations being found in the blood, liver, and fat than in other organs (e.g., heart, gastrointestinal tract, 
skeletal muscle). Radioanalysis of the blood and selected tissues (liver, kidney, heart, fat and muscle) of 2 
male weanling goats receiving a single dose of 22 mg/kg radiolabeled chlorpyrifos indicated very low tissue 
radioactivity levels equivalent to 0.04 ppm (chlorpyrifos equivalents) in muscle to 0.90 ppm in omental fat 
(Cheng et al. 1989). Eight hours after a single dermal application of 1 mg/kg radiolabeled chlorpyrifos to 
female ICR mice, the amount of radioactivity recovered was highest in the excretory products (38.4%) 
followed by the carcass (24.1%); blood (2.7%); intestine (1.9%); liver (1.8%); kidney (0.8%); stomach 
and ear (0.5% each); lungs, brain, bladder, and fat (0.2% each); heart, bone marrow, and muscle (0.1% 
each); and spleen (<0.1%). In 11 Hereford cattle dipped once in a 0.05% emulsion of Dursban® and in 1 
Holstein-cross calf sprayed with 8.75 mL/kg of a 25% emulsion of Dursban®, chlorpyrifos residues were 
highest in fat (Clabom et al. 1968). Similarly, in 57 beef cattle dipped up to 6 times in a 0.023-0.027% 
solution of chlorpyrifos, the residues of chlorpyrifos were found mostly in the fatty tissues. The low 
residues found in other tissues (muscle, kidneys, and liver) could be attributed to the small amount 
of fat present in those tissues. The highest residues in fat occurred 1 week after the second and third 
  
  
  
 
   
   
  
CHLORPYRIFOS 67 
2. HEALTH EFFECTS 
dippings (0.726-1.24 and 0.937-2.01 ppm, respectively), and were eliminated at 10 weeks or reduced to an 
insignificant level (Ivey et al. 1972). 
2.3.3 Metabolism 
An adaptation of the scheme for the metabolism of organophosphate compounds analyzed in serum and urine of 
persons poisoned by chlorpyrifos (Drevenkar et al. 1993) is presented in Figure 2-3. 
In the rat and mouse, chlorpyrifos is bioactivated in the liver to chlorpyrifos oxon via cytochrome P-450-dependent 
desulfuration (Ma and Chambers 1994; Sultatos and Murphy 1983a). The oxon is rapidly hydrolyzed to TCP, 
probably by A-esterase (Sultatos and Murphy 1983a, 1983b). Studies using liver perfusion have shown that both 
bioactivation and detoxification of chlorpyrifos occur very rapidly, since only TCP can be detected in the hepatic 
effluent once steady-state conditions are reached (Sultatos and Murphy 1983a, 1983b). Hydrolysis of the chlorpyrifos 
oxon by A-esterase is probably the more common route of detoxification, since TCP or a conjugate of TCP is the 
major metabolite of chlorpyrifos in humans (Nolan et al. 1984) and rodents (Bakke et al. 1976; Smith et al. 1967; 
Sultatos and Murphy 1983a, 1983b; Sultatos et al. 1985). 
The relative rates of desulfuration and detoxification are gender-dependent and may account for the increased toxicity 
of chlorpyrifos in female rats (Chambers and Chambers 1989; Sultatos 1991). The results of the above studies 
indicate that although the rates of bioactivation (desulfuration) and detoxification (dearylation) are higher in males 
than females, the ratio of the rates of bioactivation to detoxification is 2-3-fold higher for females. Those studies 
suggest that females may be at increased risk to chlorpyrifos-induced toxicity. However, bulls with high levels of 
testosterone were more sensitive than steers (castrated bulls) to the toxic effects of chlorpyrifos (Haas et al. 1983). 
Although no metabolism data were present in that study, it suggests that for bovines, the male may be more 
susceptible than the female. 
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2.3.4 Elimination and Excretion 
2.3.4.1 Inhalation Exposure 
Examination of urine samples from pesticide applicators presumably exposed to chlorpyrifos by inhalation 
revealed the presence of TCP (Jitsunari et al. 1989). Examination of urine samples from 1 man and 11 women 
exposed to chlorpyrifos in an orchard previously sprayed with chlorpyrifos indicated that significantly higher 
levels of urinary excretion of alkylphosphates were found in all exposure groups than in unexposed controls. 
There was a high correlation between quantities of the active ingredients on the hands and urinary excretion 
of total dimethylated alkylphosphates and of dimethylthiophosphates and dimethylphosphate. Respiratory 
absorption appears significant in view of the difference in urinary excretion of dimethylated alkylphosphates 
found between subjects with and without face masks (Aprea et al. 1994). 
2.3.4.2 Oral Exposure 
Male rats exposed to 14C-labeled chlorpyrifos had their urine and feces collected every 12 hours for 48 hours 
(Bakke et al. 1976). The combined urine from all 4 samples contained approximately 88% of the administered 
radiolabel, and it separated into at least 6 chlorpyrifos metabolites. Three of these metabolites were identified as 
the glucuronide of TCP, a glycoside of TCP, and TCP, comprising 80, 4, and 12% of the total metabolites, 
respectively. In a similar study, 90% of the radiolabel was found in the urine, and 10% was recovered in the feces 
(Smith et al. 1967). Additionally, the elimination half-life was estimated for several compartments. Chlorpyrifos 
was eliminated slowly from fat (halflife 62 hours) and relatively rapidly from liver, heart, and kidney (half-life 10-
16 hours) (Smith et al. 1967). In humans, an elimination half-life of 27 hours has been estimated following oral or 
dermal exposure (Nolan et al. 1984). 
2.3.4.3 Dermal Exposure 
A half-life of 21 hours has been estimated for the urinary elimination and fecal excretion of 
chlorpyrifos following dermal exposure in mice (Shah et al. 1981). For humans, an elimination half-life 
of 27 hours has been estimated following oral or dermal exposure (Nolan et al. 1984). As with 
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oral exposure, the majority of dermally absorbed chlorpyrifos is eliminated in the urine, based upon the 
quantity of radioactivity in the urine (Shah et al. 1981). 
2.3.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry models. 
PBPK models are increasingly used in risk assessments, primarily to predict the concentration of potentially 
toxic moieties of a chemical that will be delivered to any given target tissue following various combinations 
of route, dose level, and test species (Clewell and Andersen 1985). Physiologically based pharmacodynamic 
(PBPD) models use mathematical descriptions of the dose-response function to quantitatively describe the 
relationship between target tissue dose and toxic end points. 
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to delineate 
and characterize the relationships between: (1) the external/exposure concentration and target tissue dose of 
the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and Krishnan 1994; 
Andersen et al. 1987). These models are biologically and mechanistically based and can be used to 
extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from route to route, 
between species, and between subpopulations within a species. The biological basis of PBPK models results 
in more meaningful extrapolations than those generated with the more conventional use of uncertainty factors. 
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan 
and Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and 
Andersen 1994; Leung 1993). PBPK models for a particular substance require estimates of t 
he chemical substance-specific physicochemical parameters, and species-specific physiological and 
biological parameters. The numerical estimates of these model parameters are incorporated within a 
set of differential and algebraic equations that describe the pharmacokinetic processes. Solving these 
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differential and algebraic equations provides the predictions of tissue dose. Computers then provide process 
simulations based on these solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true complexities 
of biological systems. If the uptake and disposition of the chemical substance(s) is adequately described, 
however, this simplification is desirable because data are often unavailable for many biological processes. A 
simplified scheme reduces the magnitude of cumulative uncertainty. The adequacy of the model is, therefore, 
of great importance, and model validation is essential to the use of PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the maximal 
(i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). PBPK 
models provide a scientifically sound means to predict the target tissue dose of chemicals in humans who are 
exposed to environmental levels (for example, levels that might occur at hazardous waste sites) based on the 
results of studies where doses were higher or were administered in different species. Figure 2-4 shows a 
conceptualized representation of a PBPK model. 
If PBPK models for chlorpyrifos exist, the overall results and individual models are discussed in this section 
in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations. 
No PBPK information was found for chlorpyrifos. 
2.4 MECHANISMS OF ACTION 
2.4.1 Pharmacokinetic Mechanisms 
Chlorpyrifos is well absorbed through the gut and lungs, but dermal absorption is considerably less 
effective. The skin presents a reasonably effective barrier to penetration, unless the pesticide is mixed 
with a carrier or the skin is compromised. However, since all commercial chlorpyrifos products, with 
the exception of granular forms, contain solvents or emulsifiers, human exposure to chlorpyrifos that 
is not mixed with a carrier is unlikely. Oral and dermal absorption of chlorpyrifos was assessed in six 
adult male humans (Nolan et al. 1984). On average, 70% of the oral dose was absorbed, compared to 
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only 3% of the dermal dose. Once chlorpyrifos has been absorbed, it rapidly distributes to all organs (Shah et al. 
1981; Smith et al. 1967). The half-life for elimination of chlorpyrifos from the various organs in rats is 
comparable (10-16 hours), except for elimination from fat, which was estimated to be 62 hours (Smith et al. 
1967). The elimination half-life in humans has been estimated to be 27 hours (Nolan et al. 1984). 
The major site of chlorpyrifos metabolism is the liver, where it is rapidly bioactivated (desulfurated) by a P-450­
dependent monooxygenase to chlorpyrifos oxon (Ma and Chambers 1994; Sultatos and Murphy 1983a). The oxon is 
300-400 times more potent at inhibiting rat brain acetylcholinesterase than the parent compound (Huff et al. 1994). 
The rate of detoxification of the oxon is also rapid (Sultatos and Murphy 1983a, 1983b). Thus, it is rare to find either 
the parent compound or the oxon in body fluid samples (Nolan et al. 1984; Sultatos and Murphy 1983a), except in 
very high exposures. What is found in the general circulation is the major oxon metabolite TCP (Bakke et al. 1976; 
Nolan et al. 1984; Smith et al. 1967). TCP is a relatively unique metabolite of chlorpyrifos, and it (or one of its 
conjugates) is almost exclusively (90%) excreted in the urine (Bakke et al. 1976; Smith et al. 1967). Kinetic studies 
using rats indicate that following a single-dose exposure, most (>90%) of the chlorpyrifos is eliminated within 48 
hours (Bakke et al. 1976; Smith et al. 1967). Thus, urine TCP can be used as a qualitative biomarker for chlorpyrifos 
exposure, provided the testing is performed within 48 hours after exposure. It should be noted that the relative rate of 
detoxification of chlorpyrifos is lower in female rats (i.e., ratio of bioactivation to detoxification), and it is postulated 
that this may account for the increased toxicity of chlorpyrifos in those animals (Chambers and Chambers 1989; 
Chambers et al. 1994; Sultatos 1991). 
The dose of chlorpyrifos is important in predicting the potential toxicity. Further, factors such as age, health, and 
possibly gender may significantly lower the threshold for toxic effects. While acuteduration, high-dose intoxication 
has been demonstrated in a variety of species, including humans, the effects of longer-term, low-level exposure are 
less clear. Small-scale attempts to quantify chlorpyrifos related toxicity in pesticide applicators suggest that 
intermediate-duration exposure to low levels of chlorpyrifos may adversely affect health (Ames et al. 1989); but 
whether the effects may be related to cumulative direct target insult or simply to cholinesterase inhibition is less clear. 
Low levels of exposure are assumed for that study, because pesticide applicators are usually presumed to wear 
protective clothing and respirators when spraying the pesticide. However, neither the dose nor the length of exposure 
could be estimated. 
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2.4.2 Mechanisms of Toxicity 
Chlorpyrifos-induced toxicity results almost entirely from inhibition of neural acetylcholinesterase by chlorpyrifos 
and its bioactivation product, chlorpyrifos oxon (Namba et al. 1971). Acetylcholinesterase (true cholinesterase) 
belongs to a class of choline ester hydrolases which includes butyrylcholinesterase, or pseudocholinesterase 
(Ballantyne and Marts 1992). Acetylcholinesterase is found postsynaptically in central and peripheral cholinergic 
synapses, including the preganglionic autonomic synapses and postganglionic parasympathetic synapses (Palmer 
1980). It is also found at the motor end plate in the neuromuscular junction and is further associated with erythrocytes 
(red blood cells) (Ballantyne and Marrs 1992). Butyrylcholinesterase can be found in the plasma, and also in 
nonneuronal tissues such as the liver and fat (Ballantyne and Marrs 1992). Butyrylcholinesterase levels can be 
affected by health, age, genetic factors, and gender, with or without exposure to cholinesterase inhibiting substance 
(Ballantyne and Marts 1992). Inhibition of butyrylcholinesterase can be used as an indicator of exposure to 
cholinesterase-inhibiting substances, but is not, in and of itself, considered to constitute an adverse health effect. 
Organophosphorus insecticides, such as chlorpyrifos and its oxon, may cause irreversible cholinesterase inhibition by 
forming a stable covalent bond at the active site (Goodman et al. 1990). Stability of the bond is further enhanced by a 
process called aging, which occurs when one of the alkyl groups of the diethylester is lost (Goodman et al. 1990). 
Aging of the cholinesterase enzyme is an important factor in determining the effectiveness of oximes, such as 
pyridine-2-aldoxime methyl chloride (2-PAM or pralidoxime), to reactivate the enzyme through nucleophilic attack 
on the phosphorus. Once aging has occurred, 2-PAM can no longer reactivate the enzyme. Thus, in the absence of 
oximes, recovery of enzyme activity often depends heavily on the synthesis of new cholinesterase enzyme. The result 
of cholinesterase inhibition is cholinergic overstimulation. The resulting effects can be reversed by administration of 
the cholinergic blocking agent, atropine. 
2.4.3 Animal-to-Human Extrapolations 
Extrapolating from laboratory animals to humans may be done in the case of chlorpyrifos because the 
mechanism of action of the pesticide is the same in all species examined, and the metabolism and excretion of 
the pesticide are similar, if not identical, in humans and common laboratory animals. 
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2.5 RELEVANCE TO PUBLIC HEALTH 
Overview 
The most likely mode of exposure to chlorpyrifos at a hazardous waste site is through the skin. The most significant 
effect of acute-duration exposure to chlorpyrifos is cholinergic over-stimulation resulting from cholinesterase 
inhibition. Clinical signs associated with parasympathetic stimulation include headache, diaphoresis, nausea, 
vomiting, diarrhea, epigastric cramping, bradycardia, blurred vision, miosis, bronchoconstriction and excess mucous 
secretions, pulmonary edema, dyspnea, muscle fasciculations, salivation, lacrimation, and urination (Ballantyne and 
Marrs 1992). Exposure to high doses can also produce a profound tachycardia, pulmonary edema, loss of bowel 
control, convulsions, coma. and death. 
The actual symptoms seen in patients poisoned with cholinesterase-inhibiting pesticides result from actions at 
both nerve synapses and neuromuscular junctions. Cholinesterase inhibition in skeletal muscle can cause muscle 
weakness, fasciculations, and tremors. Central nervous system effects may include anxiety, headaches, 
drowsiness, confusion, tremor, ataxia, abnormal gait, hypotension, respiratory depression, convulsions, and 
coma (Ballantyne and Marrs 1992). Reversible peripheral neuropathies and polyneuritis have also been observed 
in humans and other animals following acuteduration, high-dose exposures. 
Transient memory impairment following acute-duration exposure to chlorpyrifos has been observed in humans. 
Acute-duration exposure to high levels of chlorpyrifos in laboratory animals has been shown to cause long-term 
down-regulation of central muscarinic receptors (Bushnell et al. 1993).  Chlorpyrifos has not been shown to affect 
reproduction in laboratory animals, but sperm production was decreased in bulls dermally exposed to chlorpyrifos. 
Limited information for rodents suggests that in utero exposure to chlorpyrifos may increase the incidence of skeletal 
variations and be developmentally neurotoxic to offspring. Additionally, data collected from mice and Drosophila 
indicate that chlorpyrifos may be genotoxic. 
Following acute-duration exposure in humans or animals, chlorpyrifos is rapidly eliminated from the body; only 
trace amounts of chlorpyrifos metabolites can usually be found in the blood or urine 48 hours after a single 
exposure. However, in humans (Lotti et al. 1986), bulls (Haas et al. 1983), and 
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cats (Jaggy and Oliver 1992), clinical signs of toxicity may be evident for weeks following exposure, long after 
the chlorpyrifos should have been eliminated. There is no evidence to suggest that chlorpyrifos is 
bioaccumulated. Little information is available concerning the effects of intermediateduration exposure of 
humans or animals to chlorpyrifos, and no information was located regarding the effects of chronic-duration 
exposure. 
Measurement of erythrocyte and plasma cholinesterase activity is usually performed if 
organophosphate poisoning is suspected. However, erythrocyte cholinesterase inhibition by itself is not always 
associated with the presence of cholinergic symptoms, and plasma (pseudo-) cholinesterase inhibition is generally 
considered only an index of exposure. Brain acetylcholinesterase inhibition, where available, and erythrocyte 
acetylcholinesterase inhibition are commonly used to correlate cholinesterase inhibition with a threshold for toxic 
manifestations associated with inhibition of the cholinesterase enzyme. In the case of chlorpyrifos, this particular 
insecticide is considered a selective pseudocholinesterase inhibitor (HSDB 1995). The course of inhibition of the 
respective acetyl- and butyrylcholinesterase enzymes have different times of onset after a single exposure, with 
acetylcholinesterase inhibition following the drop in butyrylcholinesterase activity (Ballantyne and Marrs 1992). 
Thus, both plasma and erythrocyte cholinesterase activities should be measured if chlorpyrifos exposure is suspected. 
It should be noted that the degree of erythrocyte cholinesterase inhibition does not always correlate with toxicity; this 
is especially true in children. In some cases, children have been highly symptomatic after chlorpyrifos exposure at a 
time when only plasma cholinesterase levels have been reduced, or when all cholinesterase levels were within normal 
ranges. Thus, measuring cholinesterase activity in children may have little practical value except to confirm exposure 
to chlorpyrifos. 
There are many populations at potentially greater risk to chlorpyrifos-induced toxicity. Populations at risk include the 
elderly, persons with pre-existing medical conditions, infants and children, and women (especially pregnant women). 
The elderly are considered at risk for increased toxicity because of the general decline in health that accompanies 
aging. Persons with chronic respiratory ailments such as asthma, emphysema, and bronchitis would be at greater risk 
for respiratory distress following chlorpyrifos exposure. Additionally, approximately 5% of the population are 
succinylcholine (diacetylcholine) sensitive and would be at greater risk following chlorpyrifos exposure because they 
have a genetically based deficiency in pseudocholinesterase. Research using rats indicates that females are more 
susceptible to the toxic effects of chlorpyrifos, possibly because they detoxify chlorpyrifos at 
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a slower rate than males. However, in bovines, bulls have been shown to be at increased risk to some aspects of 
chlorpyrifos toxicosis. It is not known if gender differences in chlorpyrifos metabolism or susceptibility exist in 
humans. Additionally, the doses of chlorpyrifos needed to cause death in pregnant mice are approximately six 
times lower than those need to cause death in nonpregnant mice, suggesting that pregnancy may increase the 
risk of chlorpyrifos-induced toxicity. 
It is difficult to determine whether the increased susceptibility of children to chlorpyrifos toxicity is due to 
physiological or behavioral characteristics. Results from an animal study conducted in piglets suggest that 
chlorpyrifos more easily penetrates the skin of young animals, compared to adults. Very young children and infants 
also have a decreased metabolic capacity to eliminate toxicants and are more susceptible to central nervous system 
toxicants, thus lowering the exposure levels needed to cause chlorpyrifos toxicity in that population. Chlorpyrifos 
may also affect neurological development after birth. Studies in rat neonates indicate that 2 mg/kg chlorpyrifos 
inhibits brain DNA synthesis (Whitney et al. 1995). However, studies in pregnant rats suggest that high levels of 
chlorpyrifos exposure during gestation are needed to adversely affect offspring mortality, reduce birth weight, and 
alter offspring behavior (Breslin et al. 1996; Deacon et al. 1980), and studies in preweanling rats found that the 
neurobehavioral toxicity of chlorpyrifos was less severe and of shorter duration than in adult rats (Stanton et al. 
1994). 
Minimal Risk Levels for Chlorpyrifos 
Inhalation MRLs 
No MRLs have been derived for this route of exposure because of the lack of suitable information for any 
exposure durations. 
Oral MRLs 
•	 An MRL of 0.003 mg/kg/day has been derived for both acute (14 days or less) and intermediate (15-364 
days) oral exposure to chlorpyrifos. The combination of the length of exposure period and the critical effect 
in this study enable it to be used for the derivation of both acute- and intermediate-duration oral exposure 
MRLs. 
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These MRLs are based upon a study by Coulston et al. (1972) in which 16 human adult male volunteers (4 per dose 
group) were administered chlorpyrifos in doses of 0, 0.014, 0.03, or 0.1 mg/kg once daily in a tablet with breakfast 
for up to 28 days. The low- and mid-dose groups were dosed for 28 and 21 days, respectively, but the high-dose 
treatment was discontinued after 9 days due to one individual in this group experiencing a runny nose, blurred vision, 
and a feeling of faintness. Twice each week, blood samples were obtained from each volunteer for determination of 
cholinesterase activity. Mean plasma and RBC cholinesterase levels were ascertained for all groups and compared 
with pretreatment values, and comparison was also made between treated and control groups. At weekly intervals, 
additional blood samples were obtained for hematology and routine serum chemistry determinations. Urinalyses were 
also performed on a weekly basis. Throughout the course of the experiment, no treatment-related effects were found 
among any of the parameters examined in the urinalyses, hematological, or serum chemistry tests. In the high-dose 
group, mean plasma cholinesterase (ChE) was depressed by 66% of average baseline levels after 9 days of treatment. 
In the group receiving 0.03 mg/kg/day, plasma ChE levels were reduced by an average of 30% from baseline levels; 
however, when compared with control group levels on a day-to-day basis, plasma ChE was reduced by only 13% of 
concurrent control values. Statistical analysis of this treatment group revealed the decrease was not different from 
controls. There was no statistically significant effect on plasma ChE activity during the four-week experiment in the 
low-dose group. No effect on RBC ChE activity was apparent at any dose, and the plasma ChE levels in all high-dose 
volunteers had returned to baseline levels within four weeks. 
Although the authors of the Coulston et al. (1972) study indicated that the individual with the runny nose, blurred 
vision, and faint feeling was treated for a cold and was asymptomatic by the end of the day (day 9), they neither 
provided further comment indicating that the symptoms were unrelated to treatment nor explained why the high-dose 
treatments were discontinued after 9 days. Therefore, the highest dose that can be unequivocally stated to be a 
NOAEL in this study is the 0.03 mg/kg/day dosage. While plasma cholinesterase activity was depressed by 
approximately 65% in the high-dose group, plasma (pseudo-) cholinesterase activity is considered by ATSDR to be 
only an indicator of exposure to a cholinesterase-inhibiting substance or substances, and does not, in and of itself, 
constitute an adverse health effect. 
The MRLs derived from the Coulston et al. (1972) study are closely supported by the Deacon et al.(1980) study, 
in which pregnant adult CF-1 mice (40-47 per group) were bred and administered daily 
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gavage chlorpyrifos dosages of 1, 10, or 25 mg/kg/day in cottonseed oil on Gd 6-15. A group of 51 female control 
animals was given an equivalent volume of cottonseed oil without the test material.  Since the high dose resulted in 
severe maternal toxicity, additional mice (35-41 per dosage group) were bred and administered chlorpyrifos at doses 
of 0.1, 1, or 10 mg/kg/day on Gd 6-15, inclusively, to further evaluate the teratogenic potential of chlorpyrifos. 
Animals were observed daily (from day 6 on) for signs of toxicity. Maternal body weights were recorded for Gd 6-15. 
Maternal body weight, liver weight, and weight of the gravid uterus (including ovaries) were recorded at the time of 
cesarean section on Gd 18. After sacrifice (with CO2), the number and position of live, dead, and resorbed fetuses 
were noted. Fetuses were weighed, their crown-rump length measured, and then examined for external alterations and 
cleft palate. In addition, 1 in 3 of the fetuses from each litter were examined for evidence of soft-tissue alterations by 
dissections under a stereomicroscope. To determine the degree of plasma and erythrocyte cholinesterase depression, 
groups of 4-10 bred mice were given 0, 1, 10, or 25 mg/kg/day on Gd 6, Gd 6-10, or Gd 6-15. Subsequently, groups 
of 5-15 mice were given 0.1, 1, or 10 mg/kg/day of chlorpyrifos concurrently with the animals for the teratologic 
study on Gd 6, Gd 6-10, or Gd 6-15. Five hours after the final dosing for each period, blood was obtained by cardiac 
puncture. A homogenate of fetuses from the litters of mice sacrificed on Gd 15 was prepared to measure total fetal 
cholinesterase levels. 
In the 25 mg/kg/day group, severe maternal toxicity (4 deaths; clinical symptoms indicating “severe cholinesterase 
inhibition”) was observed in 32 of 47 mice. Cholinergic symptoms included excessive salivation, tremors, urine-
soaked coat, ataxia, and lethargy. Mean body weight was significantly decreased in this group on day 16, and the 
mean value for total body weight gain was also significantly decreased, as were food and water consumption at this 
dosage. Plasma and RBC ChE levels were significantly decreased from controls at Gd 6, Gd 6-10, and Gd 6-15, and 
fetal homogenate ChE levels were also significantly decreased. While there was no significant effect on the incidence 
of pregnancy, average number of implantations, live fetuses, or resorptions (at this or any experimental dosage), there 
was a significant decrease in fetal body weight and crown-rump length at the high dose. There were also significant 
increases in the occurrence of several minor skeletal variants, including delayed ossification of the skull bones, 
delayed ossification of the stemebrae, and unfused stemebrae at 25 mg/kg/day. By contrast, the 10 mg/kg/day groups 
showed only occasional mild to moderate symptoms of ChE inhibition in 9 of 44 treated animals, with both plasma 
and RBC ChE levels significantly decreased from controls at Gd 6, Gd 6-10, and Gd 6-15; fetal ChE levels 
significantly decreased in this group as well. In the 1 mg/kg/day groups, only a single animal showed 
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any cholinergic symptom (excess salivation on day 7). In the two 1 mg/kg/day treatment groups, plasma (but not 
RBC) levels were significantly reduced from controls at Gd 6 and Gd 6-15; both plasma and RBC levels were 
significantly reduced in mice treated from Gd 6 through 10 in the primary study; and both plasma and RBC ChE 
levels were significantly decreased on days 6-10 and 6-15 in the second (concurrent) phase of this study. There was 
also a significantly increased incidence of exencephaly at this dosage, but this effect was not seen at either of the 
higher dosages, making this finding questionable and of indeterminable significance. An increase in the incidence of 
unfused stemebrae and an decreased incidence of fused stemebrae were also observed at this treatment level. The 0.1 
mg/kg/day dosage is considered to be the NOAEL for both fetotoxicity and acetylcholinesterase inhibition for this 
study. 
With the application of appropriate uncertainty factors to account for extrapolation of animal experimental data 
to humans and for intraspecies variability (100 total uncertainty factor), an acute MRL of 0.001 mg/kg/day could 
be calculated from this study alone. However, the human data from the Coulston et al. (1972) study is 
considered to be more appropriate for use in MRL derivation, and the calculated MRL of 0.003 mg/kg/day is 
considered adequate to afford protection from all adverse health effects that have been associated experimentally 
as well as clinically with acute- and intermediate-duration exposure to chlorpyrifos. 
•	     An MRL of 0.001 mg/kg/day has been derived for chronic (365 days or more) oral
       exposure to chlorpyrifos. 
The chronic-duration exposure MRL was derived from a study by McCollister et al. (1974). In that study, Sherman 
rats were fed chlorpyrifos at levels corresponding to 0, 0.01, 0.03, 0.1, 1, or 3 mg/kg/day for 2 years, beginning at 7 
weeks of age. Additional groups of 5-7 rats of each sex at each dose level were set up to provide interim pathological 
examination and acetylcholinesterase (AChE) determinations. Red blood cell AChE activity was depressed in both 
male and female rats dosed with diets containing 1 and 3 mg/kg/day chlorpyrifos. Doses of 0.1 mg/kg/day and below 
had no effect on RBC ChE. Based on the NOAEL of 0.1 mg/kg/day for cholinesterase inhibition, an MRL of 0.001 
mg/kg/day was calculated, using uncertainty factors of 10 for interspecies extrapolation and 10 for intraspecies 
variability in susceptibility. 
Death. The LD50 for acute-duration inhalation exposure to chlorpyrifos was determined for mice and female 
rats (Berteau and Deen 1978). In mice, an LD50 of 94 mg/kg was determined after whole­
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body inhalation exposure to 6,700-7,900 mg/m3 chlorpyrifos in 65% xylene. In that study, the dose range was 
achieved by varying the length of exposure from 27 to 50 minutes. Virgin female Sprague-Dawley rats were 
similarly exposed to 5,900-7,500 mg/m3 chlorpyrifos in 65% xylene, and an acuteduration exposure 
inhalation LD50 of 78 mg/kg was determined by varying the exposure duration from 48 to 61 minutes. The 
acute-duration oral exposure LD50 in female rats ranges between 82 mg/kg (Gaines 1969) to 135 mg/kg 
(McCollister et al. 1974) and 122 mg/kg (Gaines 1969) to 163 mg/kg (McCollister) for male rats. 
Approximately 9% mortality was seen in pregnant mice orally dosed with 25 mg/kg/day chlorpyrifos on Gd 
6-15 (Deacon et al. 1980). The LD50 for male Leghorn chicken has been reported by Miyazaki and Hodgson 
(1972) and McCollister et al. (1974) to be 34.8 and 32 mg/kg chlorpyrifos, respectively. 
Systemic Effects 
Respiratory Effects. Acute-duration exposure to chlorpyrifos in humans has been shown to cause respiratory 
distress, probably due to acetylcholinesterase inhibition (Aiuto et al. 1993; Lotti et al. 1986; Selden and Curry 
1987). In piglets, acute-duration dermal exposure to chlorpyrifos causes dyspnea, also a result of 
acetylcholinesterase inhibition (Long et al. 1986). 
Cardiovascular Effects. In humans, acute-duration oral exposure to chlorpyrifos initially causes bradycardia, 
then tachycardia (Aiuto et al. 1993; Selden and Curry 1987). However, the progression to tachycardia is a 
dose-dependent effect. 
Gastrointestinal Effects. Gastrointestinal distress, including nausea and diarrhea, has been observed in 
humans following acute- (Kaplan et al. 1993) or intermediate-duration (Kaplan et al. 1993) inhalation 
exposure or acute-duration dermal exposure (Thrasher et al. 1993) to chlorpyrifos. In bulls, acuteduration 
dermal exposure caused severe diarrhea and rumen atony (Haas et al. 1983). 
Hematological Effects. Acute-duration inhalation exposure to chlorpyrifos in humans has not been shown to 
affect blood chemistry (Kaplan et al. 1993). 
Musculoskeletal Effects. In humans, muscle pain (Thrasher et al. 1993) and muscle cramps (Kaplan et al. 
1993) have been reported following acute-duration dermal and inhalation exposure, respectively, to 
chlorpyrifos. Increased muscle tone (Joubert et al. 1984) and vocal cord paralysis (Aiuto et al. 
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1993) were observed in humans following acute-duration oral exposure. Muscle twitching and fasciculations, 
hyper- or hyporeflexia, and coreo-athetotic motions have also been observed following acute-duration 
chlorpyrifos exposure (Aiuto et al. 1993; Joubert et al. 1984; Lotti et al. 1986; Selden and Curry 1987). 
Hepatic Effects. In pregnant mice, acute-duration oral exposure to 25 mg/kg/day chlorpyrifos did not affect 
absolute or relative liver weight (Deacon et al. 1980). 
Endocrine Effects. No information was found associating endocrine effects with chlorpyrifos exposure in 
humans or animals. 
Renal Effects. An increase in urinary frequency was observed in adult male humans acutely exposed by 
inhalation to chlorpyrifos (Kaplan et al. 1993). However, unspecified decreases in urinary frequency were 
observed in humans following intermediate-duration inhalation or dermal exposure to undetermined amounts 
of chlorpyrifos (Ames et al. 1989). 
Dermal Effects. In humans, intermediate-duration (3 months) inhalation or dermal exposure to undetermined 
amounts of chlorpyrifos resulted in an unspecified increase in skin flushing (Ames et al. 1989). 
Ocular Effects. Acute-duration exposure in children (Aiuto et al. 1993; Selden and Curry 1987) and adults 
(Joubert et al. 1984) can cause miosis. In humans, intermediate-duration (3 months) inhalation or dermal 
exposure to undetermined amounts of chlorpyrifos resulted in an unspecified increase in blurred vision (Ames 
et al. 1989). 
Body Weight Effects. The effects of Dursban® on body weight and body weight gain were assessed in 
pregnant mice following acute-duration oral exposure to doses as high as 25 mg/kg/day chlorpyrifos from Gd 
6-15 (Deacon et al. 1980). A statistically significant decrease in mean body weight gain for Gd lo-15 (33.3%) 
and overall (Gd 6-17, 14%) was observed in animals exposed to 25 mg/kg/day chlorpyrifos. In the same 
study, the body weight gains of dams exposed to 1 or 10 mg/kg/day chlorpyrifos were comparable to controls. 
Additionally, body weights determined on Gd 18 for all the treatment groups were similar to control values. 
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Immunological and Lymphoreticular Effects. A study by Brenner et al. (1984) compared the 
prevalence of selected illnesses and symptoms in 175 employees involved in the production of chlorpyrifos 
and 335 matched controls with no history of exposure to organophosphorus chemicals. The employees were 
further subdivided for dose-response testing into three exposure intensity groups on the basis of job title and 
air-monitoring data. There were no statistically significant differences in illness or prevalence of symptoms 
between the exposed and unexposed groups, or among the three exposure subgroups. Exposure was assumed 
to be via inhalation and dermal routes. Although the objective of this study was not to specifically address 
whether exposure to chlorpyrifos causes any changes in immune function in humans, the results offered no 
evidence to suggest that chlorpyrifos suppresses human immunocompetence. 
In spite of the widespread use of insecticides containing chlorpyrifos, there are no definitive reports that it 
sensitizes human skin. A study, which assessed a number of pesticides via patch tests in California nursery 
workers, observed no positive responses to chlorpyrifos in 38 out of the 39 exposed workers who were tested 
(O’Malley et al. 1995). The duration of exposure to any of the pesticides was not specified in this paper. 
Although none of the 21 control subjects were positive for chlorpyrifos, positive responses to other pesticides 
were noted in the controls. 
The effects of acute-duration dermal exposure to chlorpyrifos were reported for 12 persons exposed to chlorpyrifos 
primarily in the home or workplace following professional application of the pesticide (Thrasher et al. 1993). The 
approximate dose received and the length of time following exposure were not known for any of the patients. 
Examination of blood taken from the chlorpyrifos-exposed persons indicated that there were changes in some 
lymphocyte subtypes when compared to 60 (28 male and 32 female) control subjects. 
Analysis of the blood revealed a 300% increase in the mean absolute counts of CD26 cells and a decrease 
in the relative percentages of CD5 (11%) and CD4 (7%) lymphocytes. Additionally, 83% of the 
chlorpyrifos-exposed individuals had increased levels (300-l ,200%) of circulating autoantibodies to at 
least one of the following cell types or organelles: smooth muscle, parietal cells, brush boarder, and 
nuclei. Twenty-five percent of the chlorpyrifos-exposed patients had elevated autoantibodies to 3 or 
more of the cell types or organelles compared to 0-3.7% in the control group. The authors suggested 
that the increase in auto antibodies was due to chlorpyrifos-induced tissue damage. However, the 
causality of these effects must be interpreted with caution. This study was a retrospective case study 
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in which the symptoms arose l-4.5 years post-exposure to chlorpyrifos. No exposure data were presented and 
there were no objective data or methods for ruling out confounding chemical exposures.  Ten of the patients had 
a history of some type of atopy or drug sensitivity while one patient had been diagnosed with systemic lupus 
erythematous and another had a lupus-like syndrome. From the results of this study, it may be concluded that the 
patients had some immunological abnormalities, but it is difficult to attribute the effects to chlorpyrifos exposure 
(Richardson 1995). 
Neurological Effects. The most common effect in humans and other animals following acuteduration 
chlorpyrifos exposure is inhibition of cholinesterase activity (Berteau and Deen 1978; Deacon et al. 1980; 
Hooser et al. 1988; Joubert et al. 1984; Kaplan et al. 1993; Long et al. 1986; Selden and Curry 1987). In 
humans, acute-duration exposure to unspecified amounts of chlorpyrifos is associated with a variety of 
symptoms, including headache, excessive salivation, lacrimation, diaphoresis, bradycardia, tachycardia, 
excessive respiratory tract secretions, bronchoconstriction, paresthesia, lightheadedness, memory impairment, 
stupor (Joubert et al. 1984), seizure-like motor activity, and coma (Aiuto et al. 1993; Kaplan et al. 1993; Lotti et 
al. 1986; Selden and Curry 1987). Motor symptoms such as muscle twitching, fasciculations, and coreo-athetotic 
movements have also been observed following acute-duration oral exposure to chlorpyrifos (Aiuto et al. 1993; 
Joubert et al. 1984; Lotti et al. 1986; Selden and Curry 1987). Transient, delayed polyneuropathy has been noted 
in humans following acute- (Aiuto et al. 1993; Lotti et al. 1986) or intermediate-duration (Kaplan et al.1993) 
exposure to chlorpyrifos. 
Neurotoxic effects similar to the ones described above have also been observed in laboratory animals following 
acute-duration exposure (Capodicasa et al. 1991; Deacon et al. 1980; Hooser et al. 1988). In the Deacon et al. (1980) 
study, erythrocyte acetylcholinesterase activity was significantly inhibited at dosages of 10 and 1 mg/kg/day, but not 
at 0.1 mg/kg/day. Muscle weakness and abnormal gait were observed in hens orally dosed with 10 mg/kg/day 
chlorpyrifos for 90 days. The symptoms subsided by 60 days after the end of the dosing period. These symptoms 
differed from the classical OPIDN in the apparent reversibility of ataxia in the hens which survived (Francis et al. 
1985). No-symptoms of classical OPIDN were observed in hens exposed to 10 mg/kg/day chlorpyrifos for 20 days 
(Richardson et al. 1993b). 
Reproductive Effects. No effects on reproduction were observed in mice following acuteduration oral 
exposure to chlorpyrifos during pregnancy (Deacon et al. 1980). However, decreased 
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sperm production was observed in bulls to which an undetermined amount of chlorpyrifos had been dermally 
applied (Everett 1982). 
Developmental Effects. The potential for chlorpyrifos to be developmentally toxic was assessed in mice 
exposed to 0, 1, 10, or 25 mg/kg/day chlorpyrifos on Gd 6-15 (Deacon et al. 1980). On Gd 18, all fetuses were 
weighed, sexed, examined for external malformations and cleft palate, and had their crown-rump length 
determined. One-third of the fetuses of each litter were also examined for evidence of soft-tissue alterations. 
There was no biologically significant effect of treatment on the number of live fetuses per litter, the number of 
dead fetuses per litter, the number of resorptions per litter, the average fetal body weight, or average crown-
rump length. However, significant increases in skeletal variations were observed in litters exposed to 25 
mg/kg/day chlorpyrifos, a level also causing significant maternal toxicity. Increases were seen in the number of 
fetuses with delayed ossification of the skull bones (6.8-fold increase), delayed ossification of the stemebrae 
(2.1-fold increase), and unfused stemebrae (4-fold increase) at the same dosage. In the same study, total fetal 
homogenate cholinesterase levels were decreased by 19, 35, and 65% in the litters of mice given 1, 10, or 25 
mg/kg/day chlorpyrifos, respectively, on Gd 6-15 (Deacon et al. 1980). The decreases in cholinesterase activity 
were significantly different from controls at the 10 and 25 mg/kg/day doses. 
Genotoxic Effects. Results of studies conducted with rodent and insect cell lines suggest that chlorpyrifos 
may be genotoxic (Amer and Fahmy 1982; Patnaik and Tripathy 1992; Sobti et al. 1982; Woodruff et al. 1983). 
A dose-response effect of chlorpyrifos on the induction of micronuclei in bone marrow has been observed 
(Amer and Fahmy 1982). A dose-response relationship for chlorpyrifosinduced cytotoxic cytogenetic effects in 
human lymphoid cells has also been demonstrated.  Chlorpyrifos has been shown to produce significant 
increases in sister chromatid exchanges (Sobti et al. 1982). It has also been reported that chlorpyrifos causes X 
chromosome loss (Woodruff et al.1983). Spindle poisoning and induction of micronuclei and polyploidy have 
also been reported following chlorpyrifos exposure (Rao et al. 1988). Sex-linked recessive lethals have also 
been produced by chlorpyrifos exposure, indicating that chlorpyrifos is genotoxic to both somatic and germ cells 
(Patnaik and Tripathy 1992). Finally, chlorpyrifos at a concentration of 0.05 µg/mL caused induction of 
chromosomal aberrations and sister chromatid exchanges in spleen cells. Chromosomal aberrations included 
chromatic and chromosomal gaps and fragments. Additionally, some polyploid metaphases were observed 
(Amer and Aly 1992). The results of these studies are summarized in Tables 2-4 and 2-5. 
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Cancer Effects. Research in rats and dogs (McCollister et al. 1974) found that chlorpyrifos did not increase 
the incidence of cancer, but the data from this study are not sufficient to assess any human cancer risk to 
chlorpyrifos exposure. The EPA has not classified chlorpyrifos for carcinogenicity (Class D). 
2.6 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biological systems or samples. They have been 
classified as markers of exposure, markers of effect and markers of susceptibility (NAS/NRC 1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers as tools of 
exposure in the general population is very limited. A biomarker of exposure is a xenobiotic substance or its 
metabolitets), or the product of an interaction between a xenobiotic agent and some target molecule(s) or cell(s) that 
is measured within a compartment of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are 
generally the substance itself or substance-specific metabolites in readily obtainable body fluid(s) or excreta. 
However, several factors can confound the use and interpretation of biomarkers of exposure. The body burden of a 
substance may be the result of exposures from more than one source. The substance being measured may be a 
metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from exposure to several 
different aromatic compounds). Depending on the properties of the substance (e.g., biologic half-life) and 
environmental conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left 
the body by the time samples can be taken. It may be difficult to identify individuals exposed to hazardous substances 
that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as copper, zinc, and 
selenium). Biomarkers of exposure to chlorpyrifos are discussed in Section 2.6.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within 
an organism that, depending on magnitude, can be recognized as an established or potential health
 impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals 
of tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital 
epithelial cells), as well as physiologic signs of dysfunction such as increased blood pressure or 
decreased lung capacity. Note that these markers are not often substance specific. They also may not 
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be directly adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers of effects 
caused by chlorpyrifos are discussed in Section 2.6.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism’s ability to 
respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic or other 
characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the biologically 
effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are discussed in Section 2.8, 
Populations That Are Unusually Susceptible. 
2.6.1 Biomarkers Used to Identify or Quantify Exposure to Chlorpyrifos 
Measurement of erythrocyte or plasma cholinesterase activity is usually performed if organophosphate 
poisoning is suspected. Erythrocyte cholinesterase activity may be used as both an index of exposure and as a 
harbinger of potential toxicity.  Butyrylcholinesterase activity may also be used as an indicator of exposure to a 
cholinesterase-inhibiting agent, but due to its lack of substrate specificity, it may not, by itself, be used as a 
reliable index of toxicity. 
Chlorpyrifos is known to inhibit acetylcholinesterase activity, but the degree of inhibition does not correlate well with 
the onset of toxicity or the amount of exposure. Moreover, acetylcholinesterase inhibition may occur after exposure to 
a wide variety of organophosphate and carbamate pesticides.  Thus, acetylcholinesterase activity is not a specific 
marker for chlorpyrifos exposure. However, unlike many pesticides, chlorpyrifos metabolism yields some relatively 
unique compounds. The major metabolite of chlorpyrifos is TCP. TCP can be found in the general circulation and in 
the urine, its principal route of excretion. Moreover, TCP levels correlate well with the degree of exposure to 
chlorpyrifos, and current analytic methods can detect TCP in the nanomolar range. The results of metabolism studies 
conducted in animals indicate that >90% of absorbed chlorpyrifos is eliminated from the body within 48 hours. 
Therefore, urine TCP can be used as a qualitative biomarker for chlorpyrifos exposure, providing the testing is 
performed within 48 hours after exposure, It should be noted that clinical signs of chlorpyrifos-induced toxicity may 
persist for several weeks after exposure, or longer in the case of extremely high exposures. 
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2.6.2 Biomarkers Used to Characterize Effects Caused by Chlorpyrifos 
There are no specific biomarkers that may be used to characterize the effects caused by chlorpyrifos.  All the signs 
and symptoms (weakness, headache, dizziness, visual disturbances, increased salivation, increased lacrimation, 
nausea, vomiting, lack of appetite, stomachache, restlessness or increased excitement, myosis, bronchial spasms, 
diarrhea, miosis, sweating, bradycardia, hypertonia, facial muscle twitching, tremors, gait disturbances, feeling of 
fear, chest pain, difficult respiration, cyanosis of the mucous membrane, generalized convulsions, psychic 
disturbances, edema of lung, coma) of chlorpyrifos exposure relate directly to its inhibition of acetylcholinesterase, 
which may be caused by any organophosphate or carbamate insecticide. 
For more information on biomarkers for renal and hepatic effects of chemicals, see ATSDR/CDC Subcommittee 
Report on Biological Indicators of Organ Damage (1990), and for information on biomarkers for neurological 
effects, see OTA (1990). 
2.7 INTERACTIONS WITH OTHER CHEMICALS 
The primary risk of interaction is with other compounds that also inhibit acetylcholinesterase. In those cases, the dose 
needed to produce chlorpyrifos-induced toxicity would be correspondingly lower.  Additionally, it would be expected 
that concurrent exposure to other central nervous system toxicants such as solvents may exacerbate the chlorpyrifos­
induced neurotoxicity or confound the diagnosis, depending on whether the toxicant has excitatory or depressant 
neurological effects. Additionally, chlorpyrifos toxicity in bovines appears to correlate with high circulating levels of 
testosterone, suggesting that sex steroids may lower the threshold for toxicity. 
2.8 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population may exhibit a different or enhanced response to chlorpyrifos than will most 
persons exposed to the same level of chlorpyrifos in the environment. Reasons may include genetic 
makeup, age, health and nutritional status, and concurrent exposure to some pharmaceuticals or other 
toxic substances. These parameters may result in reduced detoxification or excretion of chlorpyrifos, or 
compromised function of target organs affected by chlorpyrifos. Populations that are at greater risk 
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due to their unusually high exposure to chlorpyrifos are discussed in Section 5.6, Populations With Potentially 
High Exposure. 
There are many populations at potentially greater risk to chlorpyrifos-induced toxicity. Populations at risk include the 
elderly, persons with pre-existing medical conditions, infants and children, and pregnant women. The elderly are 
considered at risk for increased toxicity because of the general decline in health that accompanies aging. Persons with 
chronic respiratory ailments such as asthma, emphysema, and bronchitis would be at greater risk for respiratory 
distress following chlorpyrifos exposure due to the insecticide’s ability to cause bronchochronstriction and increase 
mucous secretions in the airways. Persons suffering from heart disease may also represent a group at particular risk 
due to both direct cardiac effects and restriction in airway diameter. Research using rats indicates that females are 
more susceptible to the toxic effects of chlorpyrifos, possibly because they detoxify chlorpyrifos at a lower rate than 
males. However, in bovines, bulls have been shown to be at increased risk to chlorpyrifos toxicity. It is not known if 
gender differences in chlorpyrifos metabolism or susceptibility exist in humans. Additionally, the doses of 
chlorpyrifos needed to cause death in pregnant mice are approximately six times lower than those need to cause death 
in nonpregnant mice, suggesting that pregnancy may increase the risk of chlorpyrifos-induced toxicity. 
Infants and children may also be at increased risk for toxicity. Results from animal studies suggest that chlorpyrifos 
more easily penetrates the skin of young animals, compared to adults. Children also have a decreased metabolic 
capacity to eliminate toxicants and are more susceptible to central nervous system toxicants, thus lowering the 
exposure levels considered protective against the potential toxicity of chlorpyrifos in that population. Chlorpyrifos 
may also be developmentally toxic. Studies of pregnant rats suggest that low levels of chlorpyrifos exposure during 
gestation have the potential to increase offspring mortality, reduce birth weight, and alter offspring behavior. 
2.9 METHODS FOR REDUCING TOXIC EFFECTS 
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to chlorpyrifos. However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to chlorpyrifos. When specific 
exposures have occurred, poison control centers and medical toxicologists should be 
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consulted for medical advice. The following texts provide specific information about treatment following 
exposures to chlorpyrifos: 
•	 Cholinesterase inhibitor pesticides, in Handbook of Poisoning, 1987, Appleton and Lang, Norwalk; R.H. 
Dreisbach, 110-l 18. 
•	 Organophosphates and other insecticides, in Clinical Management of Poisoning and Drug Overdose, 2nd. 
Edition, 1990, W.B. Saunders, Philadelphia; M. Haddad and J.F. Winchester, eds., 1105-l 119. 
•	 Insecticides: organophosphates and carbamates, in Goldfrank’s Toxicologic Emergencies, 5th edition, 1994, 
Norwalk; C.K. Aaron and M.A. Howland, 1076-1087. 
2.9.1 Reducing Peak Absorption Following Exposure 
Gastric lavage may be used to reduce peak absorption following oral exposure to chlorpyrifos (Aiuto et al. 1993; 
Namba et al. 1971). Additionally, the oral administration of activated charcoal with a saline cathartic given 
repeatedly interrupts the enterohepatic circulation of chlorpyrifos and its metabolites by blocking intestinal 
absorption and reducing residency time in the intestine. For dermal exposure, gently washing the exposed area 
with soap and water would be recommended; however, rough cleansing may damage the skin, leading to 
increased absorption of the pesticide. 
2.9.2 Reducing Body Burden 
Repeated oral administration of activated charcoal interrupts enterohepatic circulation and reduces body burden 
via hepatic excretion into the gastrointestinal tract. 
2.9.3 Interfering with the Mechanism of Action for Toxic Effects 
There are two commonly used procedures (antidotes) to interfere with the mechanism of chlorpyrifos. 
One is to administer pralidoxime (2-PAM) intravenously to displace the chlorpyrifos or its oxon from the 
acetylcholinesterase enzyme and restore its activity (Namba et al. 1971). Since 2-PAM is itself a potent 
inhibitor of acetylcholinesterase, care should be taken not to use it in cases of concurrent exposure to 
carbamate insecticides, since this may exacerbate the toxicity of that group of pesticides.  Additionally, 
2-PAM cannot displace chlorpyrifos or its oxon from the aged form of the cholinesterase enzyme. 
However, 2-PAM may be given if clinical signs of toxicity are still observable. Since the 
   
 
  
 
  
 
 
CHLORPYRIFOS 93 
2. HEALTH EFFECTS 
percentage of aged acetylcholinesterase increases with time after exposure, 2-PAM treatment should be given as 
soon as chlorpyrifos exposure has been determined. Chlorpyrifos toxicosis can also be reduced using muscarinic 
cholinergic receptor blockers such as atropine. Atropine blocks the predominantly parasympathetic effects 
caused by chlorpyrifos (Aiuto et al. 1993; Goodman et al. 1990; Namba et al. 1971). Both atropine and 2-PAM 
are toxic and should be used with care. In addition to the above treatments, diazepam may be used to reduce 
muscle fasciculations and seizure activity (Ballantyne and Marrs 1992). 
2.10 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate 
information on the health effects of chlorpyrifos is available. Where adequate information is not available, 
ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the initiation of a 
program of research designed to determine the health effects (and techniques for developing methods to 
determine such health effects) of chlorpyrifos. 
The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, NTP, 
and EPA. They are defined as substance-specific informational needs that if met would reduce the uncertainties of 
human health assessment. This definition should not be interpreted to mean that all data needs discussed in this 
section must be filled. In the future, the identified data needs will be evaluated and prioritized, and a substance-
specific research agenda will be proposed. 
2.10.1 Existing Information on Health Effects of Chlorpyrifos 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and other animals to 
chlorpyrifos are summarized in Figure 2-5. The purpose of this figure is to illustrate the existing information 
concerning the health effects of chlorpyrifos. Each dot in the figure indicates that one or more studies provide 
information associated with that particular effect. The dot does not necessarily imply anything about the quality of the 
study or studies, nor should missing information in this figure be interpreted as a “data need.” A data need, as defined 
in ATSDR’s Decision Guide for Identifying Substance-Specific Data Needs Related to Toxicological Profiles 
(ATSDR 1989), is substance-specific information necessary to conduct comprehensive public health assessments. 
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Generally, ATSDR defines a data gap more broadly as any substance-specific information missing from the 
scientific literature. 
2.10.2 Identification of Data Needs 
Acute-Duration Exposure. In general, acute-duration toxicity of chlorpyrifos has been well characterized in 
humans and other animals. The most common effect in humans and other animals following acute-duration 
chlorpyrifos exposure is inhibition of cholinesterase activity (Berteau and Deen 1978; Deacon et al. 1980; Hooser 
et al. 1988; Joubert et al. 1984; Kaplan et al. 1993; Long et al. 1986; Selden and Curry 1987). In humans, acute-
duration exposure to chlorpyrifos is associated with a variety of symptoms, including headache, excessive 
salivation and lacrimation, diaphoresis, bradycardia, tachycardia, excessive respiratory tract secretions, 
bronchoconstriction, paresthesia, lightheadedness, memory impairment, stupor (Joubert et al. 1984), seizure-like 
motor activity, and coma (Aiuto et al. 1993; Kaplan et al. 1993; Lotti et al. 1986; Selden and Curry 1987). Motor 
symptoms such as muscle twitching, fasciculations, and coreo-athetotic movements have also been observed 
following acute-duration oral exposure to chlorpyrifos (Aiuto et al. 1993; Joubert et al. 1984; Lotti et al. 1986; 
Selden and Curry 1987). Transient, delayed polyneuropathy has been noted in humans following acute- (Aiuto et 
al. 1993; Lotti et al. 1986) or intermediate-duration (Kaplan et al. 1993) exposure to chlorpyrifos. Neurotoxic 
effects similar to the ones described above have also been observed in laboratory animals following acute-duration 
exposure (Capodicasa et al. 1991; Deacon et al. 1980; Hooser et al. 1988). These data indicate that the database is 
adequate for this exposure duration and sufficient to derive an acute-duration exposure MRL. Although the 
symptoms associated with chlorpyrifos exposure are well characterized, the correlation between cholinesterase 
inhibition and the severity of the symptoms is not. Increased reporting in the biomedical literature of human 
chlorpyrifos exposures, and animal studies designed to examine the correlation between cholinesterase inhibition 
and toxicity are needed. Acute-duration exposure toxicity in bovines appears to be associated with high levels of 
testosterone. The nature of the chlorpyrifos-testosterone interaction needs to be evaluated to determine if gender-
related susceptibility to chlorpyrifos toxicity exists. 
Intermediate-Duration Exposure. The toxic effects of chlorpyrifos following intermediate-
duration exposure are expected to be similar to the cholinergic effects seen after acute-duration 
exposure. For example, blurred vision and skin flushing have been reported following occupational 
exposure to chlorpyrifos by multiple routes (Ames et al. 1989). Sufficient oral exposure data exist to 
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calculate an MRL for this exposure route. However, toxicological data for dermal and inhalation exposure are sparse. 
Since chlorpyrifos is rapidly absorbed through the lungs, inhalation exposure may represent a significant health risk. 
Limited attempts to identify chlorpyrifos-related toxicity in pesticide applicators suggest that intermediate-duration 
exposure to low levels of chlorpyrifos may adversely affect health (Ames et al. 1989); but whether the effects may be 
related to cumulative direct target insult or simply to cholinesterase inhibition is less clear. Low-level inhalation or 
dermal exposures are assumed for the Ames et al. (1989) study because pesticide applicators are usually presumed to 
wear protective clothing and respirators when spraying the pesticide. However, neither the dose nor the length of 
exposure could be estimated. Thus, toxicity-based dose-response information is needed following inhalation and 
dermal exposure to chlorpyrifos. Based on the Ames et al. (1989) study, it would be particularly relevant to assess the 
toxic effects of low-level intermediate-duration exposure on human health. Intermediate-duration exposure 
neurotoxicity studies conducted in animals are recommended. Better quantification of the toxicity caused by 
intermediateduration occupational exposure would help in assessing the health risks posed by chlorpyrifos. 
Chronic-Duration Exposure and Cancer. There is limited information regarding the potential toxic and 
carcinogenic effects of chronic, low-level exposure to chlorpyrifos (Brenner et al. 1984; McCollister et al. 1974; 
Miyazaki and Hodgson 1972). Of particular concern are the potential systemic effects of chronic-exposure to 
low levels of the pesticide by the oral, dermal, and inhalation routes, because of its widespread use in industry, 
the home, and agriculture. 
Genotoxicity. Results of studies conducted with rodent and insect cell lines indicate that chlorpyrifos may be 
genotoxic (Amer and Fahmy 1982; Patnaik and Tripathy 1992; Sobti et al. 1982; Woodruff et al. 1983). A dose 
response effect of chlorpyrifos on the induction of micronuclei in bone marrow has been observed (Amer and 
Fahmy 1982). A dose response relationship of cytotoxic cytogenetic effects to chlorpyrifos exposure has also 
been demonstrated in human lymphoid cells.  Chlorpyrifos has been shown to produce significant increases in 
sister chromatid exchanges, with the percentage of M3 metaphases showing a dose response decrease (Sobti et 
al. 1982). It has also been reported that chlorpyrifos causes X chromosome loss (Woodruff et al. 1983). Spindle 
poisoning and induction of micronuclei have also been reported following chlorpyrifos exposure (Rao et al. 
1988).  In addition, some polyploid metaphases were observed (Amer and Aly 1992). Sex-linked 
recessivelethals have also been produced by chlorpyrifos exposure, indicating that chlorpyrifos is genotoxic in 
both somatic and germ cells (Patnaik and Tripathy 1992). Finally, chlorpyrifos at concentrations of 
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0.05 µg/rnL caused induction of chromosomal aberrations and sister chromatic exchanges in spleen cells. 
Chromosomal aberrations included chromatic and chromosomal gaps, and fragments. Thus, sufficient data exist 
to identify chlorpyrifos as genotoxic. Epidemiological studies are recommended to investigate whether the 
effects observed may also occur in humans. 
Reproductive Toxicity. Chlorpyrifos administered orally at 25 mg/kg/day from Gd 6 to 15 caused severe 
maternal toxicity (Deacon et al. 1980). The toxicity was characterized by symptoms of profound cholinergic 
stimulation and death. Despite the maternal toxicity, the surviving dams gave birth to normal numbers of 
offspring. No effects on reproduction were observed in mice receiving lower doses of chlorpyrifos. Decreased 
sperm production was observed in bulls to which an undetermined amount of chlorpyrifos had been dermally 
applied (Everett 1982). The data are not sufficient to evaluate the reproductive health risk of chlorpyrifos, 
especially in light of its genotoxic potential. Since chlorpyrifos may affect sperm production and viability, and 
because the effects of intermediate or long-term exposure are not known, a two-generation reproductive toxicity 
assessment is recommended. This type of study would be useful because it would address the effects of 
chlorpyrifos on both male and female reproduction. 
Developmental Toxicity. The acute oral administration of 25 mg/kg/day chlorpyrifos from Gd 615 decreased 
average fetal weight and crown-rump length (Deacon et al. 1980). Chlorpyrifos also inhibits fetal cholinesterase 
activity (Deacon et al. 1980). However, the fetal effects in that study occurred in tandem with severe maternal 
toxicity. Thus, it is not certain if the reduction in fetal growth was secondary to maternal toxicity. More 
information is needed in this area, especially as it relates to the effect of chlorpyrifos on the developing nervous 
system, because of the potential for chlorpyrifos to affect cholinergic systems. Developmental toxicity and 
neurotoxicity studies are recommended. Dosing in the neurotoxicity studies should extend from gestation 
through weaning in order to expose brain regions that develop primarily postnatally. 
Immunotoxicity. Work by Brenner et al. (1984) failed to identify immunotoxicity in a comparison 
of 175 employees involved in the production of chlorpyrifos and 335 matched controls with no 
history of exposure to organophosphorus chemicals. Exposure in this study was assumed to be via 
inhalation and dermal routes. A study which assessed a number of pesticides via patch tests in California 
nursery workers observed no positive responses with chlorpyrifos in 38 out of the 39 exposed workers 
who were tested (O’Malley et al. 1995). In contrast, work by Thrasher et al. (1993) raises the 
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possibility that certain aspects of human immune function may be altered by chlorpyrifos exposure. It should be 
noted that while the Thrasher et al. (1993) had several flaws, it nevertheless suggests that certain components of the 
immunological system may be affected by chlorpyrifos. Because of the lack of a definitive immunotoxicity study, 
this area must be considered a data gap. Thus, an assessment of a validated immune functional test battery 
following intermediate- and chronic-duration exposure by inhalation and dermal exposure to low levels (levels not 
causing overt toxicity) of chlorpyrifos is recommended. 
Neurotoxicity. Acute-duration exposure to chlorpyrifos has been shown to cause transient delayed
 
peripheral neuropathy in humans and hens. Limited epidemiological studies in humans failed to reveal motor
 
effects of intermediate-duration chlorpyrifos exposure beyond those seen in acute-exposure scenarios.
 
However, acute-duration oral exposure to chlorpyrifos in humans and other animals has been reported to
 
cause transient memory impairment. Information is lacking regarding the potential for inhaled or dermally
 
absorbed chlorpyrifos to cause similar cognitive deficits. Thus, data are needed regarding the potential
 
development of neuropathies and neurobehavioral toxicity associated with intermediate- or chronic-duration
 
oral, inhalation, and dermal exposure to chlorpyrifos.  Epidemiological research is also needed to identify
 
levels of cholinergic inhibition associated with the onset of cholinergic symptoms in people exposed to
 
chlorpyrifos, and to determine if susceptible or sensitized individuals can be identified.
 
Epidemiological and Human Dosimetry Studies. Epidemiological/occupational studies are needed
 
because of the large population that is potentially at risk to chlorpyrifos exposure, both in the work place and
 
the home.
 
Biomarkers of Exposure and Effect. No additional information is needed in this area.
 
Chlorpyrifos has a unique metabolite, TCP, that has been well characterized and for which sensitive analytic
 
methods exist.
 
Exposure. Although chlorpyrifos inhibits acetylcholinesterase, the degree of inhibition does not
 
correlate well with toxicity or the amount of exposure. Moreover, acetylcholinesterase inhibition
 
may occur after exposure to a wide variety of organophosphate and carbamate pesticides. Thus,
 
acetylcholinesterase activity is not a specific marker for chlorpyrifos exposure, though total blood
 
cholinesterase is a good indicator in animals. However, unlike many pesticides, chlorpyrifos
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metabolism yields some unique compounds. The major and unique metabolite of chlorpyrifos is TCP.  TCP can 
be found in the general circulation and in the urine, its principal route of excretion.  Moreover, TCP levels 
correlate well with the degree of exposure to chlorpyrifos, and analytic methods can detect TCP in the 
nanomolar range. Thus, TCP is a specific and sensitive marker for chlorpyrifos exposure. 
Effect. There are no specific biomarkers that may be used to characterize the effects caused by chlorpyrifos. All 
clinical signs and symptoms of chlorpyrifos exposure relate directly to its inhibition of acetylcholinesterase, 
which may be caused by any organophosphate or carbamate insecticide. 
Absorption, Distribution, Metabolism, and Excretion. In general, the absorption, distribution, 
metabolism, and excretion of chlorpyrifos have been well characterized in humans and other animals.  However, 
female rats and bulls with high circulating testosterone levels appear to more susceptible to chlorpyrifos toxicity. 
Thus, toxicokinetic data is needed in rats and bovines to determine whether there are gender-related differences 
in chlorpyrifos metabolism which could be used to identify a specific population at risk. Additionally, clinical 
signs of chlorpyrifos toxicity may persist long after it has been eliminated form the body. Information is needed 
to determine if this is due to a metabolite or to long-term changes in organ responsiveness resulting from the 
exposure. 
Comparative Toxicokinetics. Adequate data exist for this area. 
Methods for Reducing Toxic Effects. The methods for reducing the toxic effects of chlorpyrifos are well 
established. Any improvements in management of organophosphate poisoning would be expected to be relevant 
to chlorpyrifos. 
2.10.3 Ongoing Studies 
No ongoing studies for chlorpyrifos were found. 
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3. CHEMICAL AND PHYSICAL INFORMATION 
3.1 CHEMICAL IDENTITY 
Information regarding the chemical identity of chlorpyrifos is located in Table 3-l. 
3.2 PHYSICAL AND CHEMICAL PROPERTIES 
Information regarding the physical and chemical properties of chlorpyrifos is located in Table 3-2. 
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4.1 PRODUCTION 
Chlorpyrifos is prepared commercially by several methods (Rigterink 1966). In a preferred method, the final step 
in the synthesis is reacting 3,5,6-trichloro-2-pyridinol (TCP) and O,O-diethylphosphorochloridothioate under basic 
conditions in dimethylformamide (Sittig 1985). Chlorpyrifos was introduced in 1965 by Dow Chemical Company 
under the protection of U.S. Patent 3,244,586. It is produced under many trade names including Brodan®, Detmol 
UA®Dowco 179®, Dursban®, Empire®, Equity®, Eradex®, Lentrek®, Lock-On®, Lorsbanv®, Pageant®, Piridane®, 
and Stipend® Producers of chlorpyrifos in the United States are DowElanco in Midland, Michigan and Lafayette, 
Indiana, and SureCo, Inc. in Fort Valley, Georgia (SRI 1994). Production volumes have not been located. 
No information is available in the Toxics Release Inventory (TRI) database on total environmental releases of 
chlorpyrifos from production facilities, because chlorpyrifos is not included under SARA, Title III, and, 
therefore, is not one of the chemicals that facilities are required to report (EPA 1993c). 
4.2 IMPORT/EXPORT 
Information on import/export volumes was not located. 
4.3 USE 
Chlorpyrifos is a broad spectrum organophosphate insecticide/acaricide which is used to control a variety 
of insects. First introduced into the non-crop specialty market, it was marketed in the late 1960s to control 
pests in turfgrass and omamentals, and to control indoor pests. Chlorpyrifos was first registered for 
termiticide use in the United States in 1980 (Racke 1993). Products are available for both professional pest 
control workers and homeowners. Agricultural commercial products were introduced in the mid-1970s. 
As a foliar pesticide for alfalfa and cotton, it is used to control aphids, armyworms, pillbugs, chinch 
bugs, common stalk borers, corn borers, corn earworm, corn rootworm adults, cutworms, flea 
beetle adults, grasshoppers, and lesser cornstalk borers. It also controls peach tree borer and 
overwinter scale on dormant fruit trees and is used as a slurry seed treatment for seed 
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corn maggot. It has additional uses as a foliar and soil applicant on sorghum, soybeans, sugarbeets, and sunflowers, 
and as a soil applicant for peanuts. Dursban® is used to control fire ants, ornamental plant insects, stored-product 
insects, and turf- and wood-destroying insects. Lorsban® is used as a soil insecticide for pillbugs, corn rootworms, 
cutworms, flea beetle larvae, grubs, lesser cornstalk. borer, seed corn beetle, seed corn maggot, symphylan, and 
wireworm on corn (Farm Chemicals Handbook 1994). At one time, it was used to kill mosquitoes in the immature, 
larval stage of development, a use that involved application of formulated product directly to bodies of water, but 
hlorpyrifos is no longer registered for this purpose (EPA 1986). Other discontinued uses are spray-dip or pour-on 
applications of chlorpyrifos for cattle and sheep (Racke 1993). 
Formulations for chlorpyrifos include emulsifiable concentrate, dust, flowable, granular wettable powder, 
microcapsule, pellet, and spray. Chlorpyrifos acts on pests primarily as a contact poison, with some action as 
a stomach poison. It is a nonsystemic contact chemical, meaning that it acts only where it comes into direct 
contact with plant tissues, and is not transported to other plant parts. It interferes with the activity of 
acetylcholinesterase, an enzyme that is essential for the proper working of the nervous systems of both 
humans and insects. 
There is currently no federal requirement to report sales or use of pesticides; consequently, the only figures 
available are estimates (Felsot 1991). From data collected from usage surveys conducted by USDA, EPA, and the 
Department of Food and Agriculture of the State of California, the usage of chlorpyrifos is estimated to be 
7,023,190 pounds active ingredient per year (Gianessi 1986).  Agricultural uses account for most of its 
applications. In 1982, total agricultural use of chlorpyrifos was estimated at 2.2-3.2 million kg (4.8-7.0 million 
pounds), and industrial uses ranged between 0.68 and 1.04 million kg (1.5-2.3 million pounds) (EPA 1982). The 
State of Ohio Agricultural Extension Service estimates that 36.33 metric tons (80,093 pounds) of chlorpyrifos were 
used in the Lake Erie Basin in 1986 (Baker and Richards 1988). In 1984, about 0.15 million kg (0.33 million 
pounds) of chlorpyrifos was applied to about 600,000 hectares (1.48 million acres) of wetlands in the United States 
for mosquito control (Odenkirchen and Eisler 1988); this use has since been discontinued. 
Chlorpyrifos is used significantly in urban settings, where it has replaced chlordane and other chlorinated 
cyclodiene termiticides. Therefore, its use can be estimated based on former chlordane use; the annual 
application of chlorpyrifos for termite control is estimated at approximately 1.7 million 
  
 
 
CHLORPYRIFOS 107 
4. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
pounds of active ingredient (Cink and Coats 1993). Each year, the pesticides used to control structural pests 
account for about 15% of California’s nonagricultural use of conventional pesticides. Structural pest control 
encompasses treatment of private residences, office buildings, schools, hotels, hospitals, restaurants, and other 
publicly used buildings. In 1990, 604,713 pounds of chlorpyrifos were used as structural pesticides in 
California, and 693,354 pounds were used in 1991 (Robinson et al. 1994). Pesticides for commercial landscape 
maintenance account for about 2% of nonagricultural use in California. The landscaping use figures for 
chlorpyrifos in 1990 and 1991 were 45,267 pounds and 32,118 pounds, respectively. Nationally, chlorpyrifos is 
ranked twelfth in frequency of indoor pesticide applications and fifth in frequency of outdoor pesticide 
applications (Robinson et al. 1994). 
4.4 DISPOSAL 
The recommended treatment and disposal methods for chlorpyrifos are incineration, adsorption, and landfilling 
(IRPTC 1989). For small amounts, the recommended disposal is adsorption onto materials such as sand and burying 
in locations away from domestic water supplies. For the decontamination of containers, the triple rinse and drain 
procedure is recommended. The use of a caustic soda-methanol or caustic soda-detergent rinse solution is also 
effective in decontaminating the container, but the rinse solutions must be disposed of either by incineration or burial 
in an area away from water supplies (IRPTC 1989). 
Small-scale farm operators have a pressing need for methods to dispose of unused concentrated and dilute 
formulated chlorpyrifos suspensions or solutions such as rinsate. The use of solid state fermentation techniques 
to dispose of pesticide waste may be a viable alternative to other disposalmethods that are either too expensive 
or technically too sophisticated. Chlorpyrifos was evaluated in bioreactors by Berry et al. (1993), who reported 
that chlorpyrifos levels were reduced to 0.6% (by solvent extraction) in 290 days in wheat straw/horse manure 
reactors, and that leachability studies showed that of the  28 µg chlorpyrifos in the soil column, only 72 ng 
leached. 
While not strictly a disposal method, it is worth pointing out that NaOH-methanol and sodium hypochlorite can 
be used to degrade (but not necessarily detoxify) chlorpyrifos. For example, on exposed surfaces, the use of 
caustic soda-methanol or caustic soda-detergent rinse solution can also be effective in decontaminating 
containers used to store chlorpyrifos, but these rinse solutions must be 
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disposed of either by incineration or proper burial (Dillon 1981). A full discussion of regulations regarding 
disposal of chlorpyrifos is given in Chapter 7. 
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5.1 OVERVIEW 
Chlorpyrifos enters the environment as the result of its use as a broad spectrum insecticide/acaricide for treatment of 
crops, lawns, ornamental plants, domestic animals, and a variety of building structures.  Unintentional releases to the 
environment include improper indoor application, redeposition of air residues, spills, and the disposal of chlorpyrifos 
wastes. Indoor use by unlicensed or untrained applicators has occasionally resulted in excessive human exposure. 
EPA (1997) reported that most of the more serious chlorpyrifos poisonings appear to involve either the misuse or 
inappropriate use of the pesticide by pest control operators. 
The important physical and chemical characteristics which influence the fate and transport of chlorpyrifos in the 
environment are its low solubility, volatility, and strong affinity for colloidal matter.  Abiotic hydrolysis, 
photodegradation, and biodegradation are all important processes for the transformation and degradation of 
chlorpyrifos. Chlorpyrifos bioconcentrates to only a limited extent, and has little mobility in most soils. 
Chlorpyrifos exists in the atmosphere primarily in the vapor phase, but can partition to particulates. Chlorpyrifos 
is not persistent in water, due to volatilization and strong adsorption to particulate matter. 
Indoor air, food, and soil are the environmental media with the highest degree of chlorpyrifos contamination; 
ambient air, groundwater, and surface water have lesser degrees of contamination.  Although a large amount of 
chlorpyrifos is used in various environments (see Chapter 4), levels of general exposure are mediated by its 
limited mobility and persistence, and by environmental degradation processes. 
Several subpopulations are at higher risk of exposure: workers in industries that manufacture and formulate 
chlorpyrifos, those who apply the insecticide, and farm workers who enter treated fields after the insecticide has 
been applied. Among the general population, people who use the insecticide in homes and gardens and people 
who ingest food exposed to chlorpyrifos are at higher risks of exposure. 
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Chlorpyrifos has been identified in at least 7 of the 1,428 current or former EPA National Priorities List (NPL) 
hazardous waste sites (HazDat 1996). However, the number of sites evaluated for chlorpyrifos is not known. 
The frequency of these sites within the United States can be seen in Figure 5- 1. 
5.2 RELEASES TO THE ENVIRONMENT 
5.2.1 Air 
Chlorpyrifos enters the atmosphere as a result of its use as an insecticide/acaricide. Chlorpyrifos is released to 
the atmosphere by volatilization during foliage or soil application by ground or air broadcast equipment (Racke 
1993). Air emissions from chlorpyrifos production have been reported to be 0.5 kg per 1,000 kg (one metric ton) 
produced (Sittig 1980). The Toxics Release Inventory in 1992 did not require reporting of chlorpyrifos releases 
to air (EPA 1993c). No information was found on detections of chlorpyrifos in air at NPL hazardous waste sites 
(HazDat 199). 
5.2.2 Water 
Chlorpyrifos is released to water during foliage or soil application as an insecticide/acaricide by ground or air 
broadcast equipment and during subsequent runoff or leaching (Racke 1993). Leaching and runoff from treated fields, 
pesticide disposal pits, or hazardous waste sites may inadvertently contaminate both groundwater and surface water 
with chlorpyrifos. Entry into water can also occur from accidental spills, redeposition of atmospheric chlorpyrifos, 
and discharge of waste water from chlorpyrifos manufacturing, formulation, and packaging facilities (HSDB 1996; 
Racke 1993). In the past, chlorpyrifos was aerially applied to water over swamps for mosquito abatement; however, it 
is no longer registered for this use. No other uses are known which result in direct application to water (EPA 1986). 
The Toxics Release Inventory in 1992 did not require reporting of chlorpyrifos releases to water (EPA 1993c). There 
is also a potential for release of chlorpyrifos to water from hazardous waste sites. Chlorpyrifos has been detected in 
surface water samples collected at 4 of the 7 NPL sites and in groundwater samples collected at 1 of the 7 NPL sites 
where chlorpyrifos has been detected in some environmental medium (HazDat 1996). The HazDat information used 
includes data from NPL sites only. 
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5.2.3 Soil 
Chlorpyrifos is released in agricultural, home, and garden soil during direct soil or foliar treatment, and from disposal 
of chlorpyrifos-containing wastes in hazardous waste sites (HSDB 1994). Much of the chlorpyrifos (or its 
metabolites) applied to foliage eventually reaches soil (Racke 1993). Soil in waste disposal sites may include 
manufacturing wastes containing chlorpyrifos. A primary method for disposing of liquid pesticide wastes has been 
the dumping of liquid materials into soil evaporation pits, ditches, and ponds. Topsoil from such discharge areas is 
expected to be contaminated with pesticides; the soil from one discharge pit contained chlorpyrifos at concentrations 
of 1,012-3,193 mg/L in the top 7.5 cm (Winterlin et al. 1989). Soil from tail water pits used for collecting irrigation 
runoff may also be a source of chlorpyrifos if the soil is treated with this insecticide (Kadoum and Mock 1978). 
Chlorpyrifos may also enter soil by redeposition of atmospheric chlorpyrifos (Racke 1992). Entry may also occur 
from spills during storage, transport, or equipment loading and cleaning, although the sophistication of contemporary 
management practices limits this amount. The Toxics Release Inventory in 1992 did not require reporting of 
chlorpyrifos releases to soils (EPA 1993c). Chlorpyrifos also can be released to soils and sediments from hazardous 
waste sites. Chlorpyrifos has been detected in soil samples collected at 3 of the 7 NPL sites and in sediment samples 
collected at 1 of the 7 NPL sites where chlorpyrifos has been detected in some environmental medium (HazDat 
1996). The HazDat information used includes data from NPL sites only. 
5.3 ENVIRONMENTAL FATE 
5.3.1 Transport and Partitioning 
The vapor pressure of chlorpyrifos is 1.9x10-5  mm Hg at 25 °C (2.5x10-8 atm) (Racke 1993). This suggests that 
while chlorpyrifos is in the atmosphere, it will exist primarily in the vapor phase but will also partition to 
available airborne particulate (Eisenreich et al. 1981). Experimental evidence during fog events (Glotfelty et al. 
1990) supports this hypothesis. The removal rate by dry deposition is low for such compounds (Schroeder and 
Lane 1988); therefore, depending on its reactivity characteristics and the amount of available airborne 
particulate, chlorpyrifos may travel long distances in the air. The low solubility of chlorpyrifos at 1.12 mg/L at 
24 °C (Felsot and Dahm 1979) indicates that dry deposition is a more important process than wet deposition. 
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The transport of chlorpyrifos from water to air can occur due to volatilization. Compounds with a Henry’s law 
constant (H) of <10-5 atm-m3/mol may volatilize slowly from water (Lyman et al. 1990).  Therefore, 
chlorpyrifos, with an H value of 6.6x10-6 atm-m3/mol at 25 °C (Downey 1987) may volatilize slowly from 
water. The dimensionless Henry’s law constant (H′) or air/water partition coefficient for chlorpyrifos, as 
calculated from vapor pressure and solubility data, has been reported to be 5x10-4 (Glotfelty et al. 1987), 
7.3x10-4 (Suntio et al. 1987), and 1.7 ±0.3x10-4 (Fendinger and Glotfelty 1990). Using these data, the 
estimated volatilization half-life from a river 1 meter deep flowing 1 m/set with a wind velocity of 3 m/sec is 
estimated to be 9 days (Lyman et al. 1982). 
The amount of chlorpyrifos available to be volatilized from surface water is reduced by sediment adsorption. 
Chlorpyrifos has a strong affinity for soil colloids, as evidenced by its measured range of organic carbon-
adjusted soil sorption coefficient (Koc) of 973-31,000 (Felsot and Dahm 1979; Kenaga 1980; McCall et al. 
1980; Racke 1993). This suggests that chlorpyrifos in natural water ecosystems adsorbs strongly to suspended 
solids and sediments, and that this process may transport considerable amounts of chlorpyrifos from water to 
particulate matter. Several studies have reported very low concentrations of chlorpyrifos in surface waters 
(see Section 5.4.2). 
In macrophyte-dominated freshwater model ecosystems, Elodea nutalli vegetation adsorbed a large proportion 
of the dose of chlorpyrifos applied and hampered mixing of the insecticide in the water column (Brock et al. 
1992). Only a relatively small proportion of the applied dose became incorporated in the sediment. In open-
water model ecosystems, however, mixing was rapid and the sediment compartment, particularly its upper 
layer, was a sink for chlorpyrifos. 
Aquatic bioconcentration factors (BCF) ranging from 1 to 5,100 for chlorpyrifos and metabolites have been 
determined extensively from laboratory and field studies (ASTER 1996; Cid Montafies et al. 1995; Macek et al. 
1972; Mulla et al. 1973; Odenkirchen and Eisler 1988; Racke 1993). These studies suggest that chlorpyrifos 
bioconcentrates to varying degrees in different organisms, and with different doses and durations of exposure. It 
has been suggested that the BCF values determined-during short duration single-dose exposure studies may not be 
indicative of long-term exposure due to nonattainment of equilibrium conditions (Racke 1993). It has been 
observed that 5-9 days are necessary for steady-state conditions (Hedlund 1973; Welling and deVries 1992). 
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The transport processes that may move chlorpyrifos from soil to other media are volatilization, leaching, runoff, 
and biotransfer by plants. Post-application volatilization of chlorpyrifos applied as an agricultural insecticide and 
subsequent atmospheric transport is thought to be a primary means by which chlorpyrifos is dispersed throughout 
the environment. Volatilization is affected by soil cultivation practices. Cumulative losses of chlorpyrifos by 
volatilization from no-till (NT) and from conventionally tilled (CT) plots were measured by Whang et al. (1993). 
The NT/CT flux ratio increased from a factor of about 3 on days 1 and 2 to a factor of 12 by day 26. Soil dryness 
did not often limit volatilization, and differences in soil moisture resulting from different tillage practices were not 
usually a major reason for differences between fluxes. 
Volatilization rates, which result from the complex interplay between chlorpyrifos sorbed to soil, dissolved in the 
soil pore water, and present in the soil air spaces, can be quite variable. Chlorpyrifos (applied to the soil at 11 
µg/cm2) was captured from 3 moist soils (0.3 bar soil moisture tension, 25 °C) by blowing an airstream of 1 
km/hour over the soils. The calculated flux rate ranged from 80-290 g/hectare/day during the first 3 days, with 62­
89% of applied chlorpyrifos remaining after 36 hours (McCall et al. 1985). Racke et al. (1991) observed 
significantly less volatility over a longer exposure period with ranges of 3-39 g/hectare/day, and >90% of the 
applied chlorpyrifos remaining after 30 days. When applied as a foliar spray, chlorpyrifos volatilized from corn 
leaves rapidly. In the laboratory, 80% volatilized within 48 hours at 30 °C with a simulated wind speed of 0.8 
km/hour (McCall et al. 1985). A field study confirmed the fairly rapid rate of volatilization, with an observed half-
life of about 1.5 days on corn and soybean foliage (McCall et al. 1984). 
Leaching studies have shown chlorpyrifos to have little mobility in soil. Laboratory leaching studies revealed that 
all the surface-applied residues of chlorpyrifos were confined to the upper 5 cm of  several soils after elution with 
20 cm of water (Harris et al. 1988; McCall et al. 1985). Field studies have confirmed this lack of mobility, with 
chlorpyrifos residues being confined to the upper 12 inches of soils in several trials (Fontaine and Teeter 1987; 
Oliver et al. 1987). The leaching and dissipation of the applied 14C-chlorpyrifos in sandy soil under simulated field 
precipitation, drainage and temperature was less than 0.2% (Fermanich and Daniel 1991). Amounts of chlorpyrifos 
lethal to termites moved to a depth of at least 30 cm in decomposed granite soil from the Santa Ana River bed in 
Colton, California, after it was applied at 500 ppm to the top 7.62 cm of soil in a long column of 34 mm diameter 
and ≈130 mL of water was dripped through (Smith and Rust 1992). 
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Studies indicate that runoff of chlorpyrifos is of minor environmental significance. In a study conducted in an Iowa 
cornfield, approximately 0.003% of 3 applications of chlorpyrifos was transported via runoff to a pond within the 
watershed (McCall et al. 1984). Information from irrigated environments (e.g., turf) indicates that because of the 
lack of erosion of soil particles, strongly sorbed chlorpyrifos is not transported via runoff (Watschke and Mumma 
1989). Even during a simulated l00-year rainfall event (13.6 cm) occurring less than a week after application, only 
between 0.10 and  0.29% of the applied chlorpyrifos was present in runoff. In another study of runoff from 
turfgrass treated at 1.12 kg/hectare with irrigation applied at 150 mm/hour, no residue of chlorpyrifos was detected 
at 5 µg/L (minimum detection level) (Harrison et al. 1992). The movement of chlorpyrifos was studied from 1985 
to 1987 in a small agricultural Saskatchewan watershed (Waite et al. 1992). In 1985-86, 3-4 million hectares of 
farmland were treated with insecticides at application rates as high as 1 kg/hectare to control grasshopper 
infestations. The frequency of occurrence and concentrations of chlorpyrifos in groundwater, surface water and 
runoff from spring snow melt were measured. No chlorpyrifos was found in any of the samples at detection limits 
of 1 ppb in 1985 and 0.1 ppb in 1986. 
Spills are an important way that chlorpyrifos enters surface waters. A spill of chlorpyrifos into a marine bay 
resulted in initial water concentrations of up to 300 µg/L, but because of sediment sorption, dissipation, and 
dilution, the concentration had dropped to below detectable levels within 17 days (Cowgill et al. 1991). 
Some research has shown that only very small levels of chlorpyrifos are taken up by plant roots, translocated, 
or metabolized by plant tissues (Kenaga et al. 1965; Smith et al. 1967). Cranberry bean plants were 
hydroponically grown in nutrient solutions containing 50 ppm of chlorpyrifos emulsifiable concentration. 
After 72 hours, only 0.07-0.1% of the radioactivity present, composed of TCP and other degradation products, 
had been translocated to the plant tops. In another experiment (Smith et al. 1967), one leaf of the cranberry 
bean plant was treated foliarly with 1 mg of chlorpyrifos. After 7 days, <1% of the chlorpyrifos applied was 
found in nontreated areas of the plant. 
However, other researchers have found that soil-applied doses of chlorpyrifos are transported to 
foliage (Rouchaud et al. 1991). Cauliflower and brussels sprouts were treated with chlorpyrifos by 
pouring it onto soil around the stem of the plant for protection against the root fly. During plant 
growth, chlorpyrifos and its soil metabolites were transported from soil into the plant foliage, where 
it could give a secondary plant protection against the foliage insects. The foliage concentrations of the 
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nonsystemic chlorpyrifos was ≥1 mg/kg fresh weight during a period of about 44 days after soil treatment in 
brussels sprouts crops and a period of 3.5 days in cauliflower crops. 
5.3.2 Transformation and Degradation 
Chlorpyrifos undergoes a number of different transformation and degradation reactions in the environment as 
discussed in the following sections. The resulting environmental transformation products are shown in Figure 
5-2. 
5.3.2. 1 Air 
Both chlorpyrifos and its degradation product, TCP, have ultraviolet (UV) absorbencies above 295 nm, 
indicating their susceptibility to photodegradation by sunlight. The photodegradation half-life of chlorpyrifos 
in the laboratory is approximately 2.6 days (Fontaine and Teeter 1987). While in the atmosphere, chlorpyrifos 
will react with photochemically induced hydroxyl radicals. Its estimated halflife is 6.34 hours (Atkinson 
1987). 
5.3.2.2 Water 
The processes primarily responsible for the transformation and degradation of chlorpyrifos in water are abiotic 
hydrolysis and photosensitized oxidation. Neutral hydrolysis is favored below pH 9, whereas alkaline hydrolysis 
dominates above pH 9 (Macalady and Wolfe 1983). Thus, both the disappearance half-life and the products are 
pH-dependent. Neutral hydrolysis yields O-ethyl-O-3,5,6-trichloro-2-pyridyl phosphorothioate, while alkaline 
hydrolysis occurs by base-catalyzed cleavage at the phosphate ester linkage to produce TCP and phosphorthioic 
acid. Neutral hydrolysis is pseudo-first-order kinetics, while alkaline hydrolysis is second-order kinetics (Wolfe 
1988). Keeping the temperature at 25 °C, the half-life of chlorpyrifos in distilled water was 89.14 days at pH 1, and 
0.01 days at pH 12.9 (Macalady and Wolfe 1983). At 20 °C, it has a half-life of 120 days at pH 6.1 and 53 days at 
pH 7.4 (Freed et al. 1979). The activation energy for the hydrolysis of chlorpyrifos at pH 7.4 is 14 kcal/mol, 
indicating its sensitivity to temperature change. Laboratory studies on the interaction of chlorpyrifos with Cu2+ 
have demonstrated metal-catalyzed hydrolysis and have provided rate constants for this pathway (Blanchet and St. 
George 1982). 
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Photodegradation in water is possible since chlorpyrifos absorbs in the UV region at >295 nm; however, its 
relative importance as a dissipative force in the environment is unclear. Laboratory studies from artificial light 
sources may not be very useful for predicting environmental photodegradation kinetics (Miller and Zepp 1983). 
For example, chlorpyrifos in natural waters is usually very strongly sorbed to suspended particulate and bottom 
sediment, and thus less readily available to photolytic forces than chlorpyrifos in clear distilled water in the 
laboratory. 
Brock et al. (1992) performed experiments using macrophyte-dominated freshwater ecosystems and open-water 
model ecosystems. In both systems, 50% of the chlorpyrifos dose applied had disappeared on day 8 post­
treatment. In the long run, loss of chlorpyrifos was more rapid in the macrophytedominated ecosystems than in 
the open-water ecosystems. 
Under field conditions, chlorpyrifos exhibits very short persistence in the water compartment of aquatic ecosystems, 
and half-lives as short as several hours have been observed. This is due to its considerable volatility from water 
(arising from low solubility and moderate vapor pressure) and its high association with sediment. The rate of 
disappearance of chlorpyrifos from river and well waters in a pH range of 8-8.5 was studied in the laboratory at a 
range of temperatures and under conditions of light and dark (Frank et al. 1991). The half-life for the disappearance 
of chlorpyrifos was 4.8 days at 21 °C and 27 days at 4 °C, indicating that temperature plays a major role in the 
degradation of chlorpyrifos in water. The half-life for disappearance of chlorpyrifos was 56 days in the dark and 46 
days in the light at 21 °C, indicating that sunlight photolysis is not a major route of chlorpyrifos degradation in water. 
The persistence of chlorpyrifos in surface water was studied (Hughes et al. 1980) by application of 10 ppb 
chlorpyrifos to polyethylene-lined ponds and a single natural pond inoculated with leaf litter.  In early post-treatment, 
there was rapid partitioning to adsorption on bottom sediments and polyethylene; 30-60% disappeared from the water 
within 24 hours. The time for the concentration of chlorpyrifos to decline to 0.01 ppb in the polyethylene-lined pond 
was estimated to be 40 to >200 days compared to 18 days for the natural pond. The desorption from sediments was 
considerably slower from organic matter than from polyethylene. Desorption from the polyethylene contributed to 
residual concentrations in the water of artificial ponds for up to 18 months. Similar results were noted in an artificial 
lake treated with chlorpyrifos: lake water concentrations peaked 1 day after treatment at 0.9 µg/L and leveled near 0.2 
µg/L after 3 weeks (Mulla et al. 1973). 
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First-order degradation rate constants of chlorpyrifos were determined in estuarine water and sediment/water 
slurry systems (Walker et al. 1988). Half-lives of chlorpyrifos in sediment/slurry systems calculated from 
these rate constants ranged from 12 to 30 days for the non-sterile system, and 16-51 days for the sterile 
system. Half-lives for the seawater-only systems ranged from 13 to 41 days for the non-sterile systems and 
3.5-24 days for the sterile systems. The half-life of chlorpyrifos in seawater was 24 days in a sediment-
seawater slurry (Schimmel et al. 1983). These data indicate that abiotic processes predominate in estuarine 
systems. 
5.3.2.3 Sediment and Soil 
Chlorpyrifos may undergo degradation on the surface of soils by photo-induced reactions. Laboratory 
photodegradation of chlorpyrifos on soil surfaces with UV light (254 nm from mercury lamps) demonstrated that 
three different photochemical processes (hydrolysis, dechlorination, and oxidation) take place simultaneously 
(Walia et al. 1988). The oxidative and dehalogenated products formed during photo-irradiation of soil undergo 
further photolysis to form chloropyridinols and O,O-diethyl phosphorothioic acid. The oxon is unstable; it tends to 
hydrolyze more rapidly than chlorpyrifos and does not accumulate in the soil. With the passage of time, the 
percentage of chlorinated pyridinols also decreased, suggesting that these products are mineralized in the soil under 
UV-photo-irradiation conditions. Under simulated sunlight conditions, the rate of photodegradation of chlorpyrifos 
on a leaf surface was slow. Chlorpyrifos was stable up to 10 days; then the oxon (1.5%) and the hydrolytic product, 
TCP (2.5%), were detected. Dehalogenated analogs of chlorpyrifos could be detected only after 15 days of constant 
irradiation. Under these conditions, the photo-oxidation process was more predominant than the photohydrolytic or 
dehalogenation process. Formation of such photoproducts on an irradiated soil surface was very fast, but the rates 
in the laboratory will differ from those found under environmental conditions. 
Chlorpyrifos undergoes transformation in soil by the processes of abiotic hydrolysis and microbial 
degradation. A few studies have attempted to separate abiotic chemical hydrolysis from-microbial 
processes and to determine their relative importance (Miles et al. 1979, 1983). The half-lives of 
chlorpyrifos in muck (48% organic matter [OM]) and loam (2.7% OM) were determined in sterilized 
and natural soils at 3 temperatures (3, 15, and 28 °C). The results indicate that in sterile soils, 
chlorpyrifos is progressively more degraded by abiotic hydrolysis as the temperature increases, and 
that it degrades faster in sandy loam than in muck (after 24 weeks, 38 versus 68% remaining at the 
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highest temperature). An explanation for the soil difference may lie in the pH. The sterile loam had a pH of 6.5, 
whereas the sterile muck had a pH of 5.9, indicating that increasing pH increases degradation. The degradation 
study of chlorpyrifos in natural soil gave the same progression for increasing temperature, and it continued to 
degrade faster in the loam than in the muck (half-lives of 16, 6, and 2.5 weeks versus >24, 15, and 6 weeks at 
the respective temperatures). All half-lives were shorter in the natural soils as opposed to the sterile soils, 
however, indicating microbial degradation in addition to abiotic chemical hydrolysis. 
Some researchers have concluded that chlorpyrifos is not catabolized (Racke and Coats 1988, 1990) because it is 
resistant to enhanced degradation by microbes. When chlorpyrifos is applied to fields with a soil history of 
chlorpyrifos use, the breakdown of chlorpyrifos is not enhanced, and is often delayed (Racke and Coats 1988; 
Somasundaram et al. 1989). The biotic process at work is probably co-metabolism. Patterns of persistence were 
observed in a variety of agricultural soils after treatment with 14C-chlorpyrifos and its hydrolysis product, TCP 
(Racke et al. 1988). In soils with no previous history of chlorpyrifos use, significant quantities of TCP and soil-bound 
residues were produced, but little 14CO2. In soils with a history of chlorpyrifos use, neither TCP nor soil-bound 
residues accumulated, but large quantities of 14C02 were produced. Direct treatment of fresh samples of each of these 
soils with 14C-TCP resulted in rapid mineralization of TCP to 14CO2 only in those soils with a history of prior 
chlorpyrifos use. The rapid mineralization of TCP in these soils was microbially mediated. It is unclear if catabolic or 
co-metabolic processes are predominant (Racke and Robbins 1990) in the degradation of TCP. TCP exhibited 
sorption (Kd) coefficients of between 0.3 and 20.3 mL/g (mean of 3.1) and calculated mean Koc coefficients for the 
neutral and anionic forms of 3,344 and 54 mL/g, respectively. 
In a study of persistence of chlorpyrifos in a silt loam soil, the disappearance rate was fast in the first 15 days, 
but slowed after that. The pseudo-first-order rate constants were 0.041 day-1 and 0.044 day-1, for the band 
treatment at seeding, and 0.04 day-1 for the drench at seeding. The calculated half-lives ranged from 15.8 to 17.3 
days (Szeto et al. 1988). 
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT 
Reliable evaluation of the potential for human exposure to chlorpyrifos depends, in part, on the reliability of 
supporting analytical data from environmental samples and biological specimens. In 
  
 
   
 
  
CHLORPYRIFOS 121 
5. POTENTIAL FOR HUMAN EXPOSURE 
reviewing data on chlorpyrifos levels monitored in the environment, it should also be noted that the amount of 
chemical identified analytically is not necessarily equivalent to the amount that is bioavailable. 
5.4.1 Air 
Chlorpyrifos has been detected in both outdoor and indoor air; of special concern are levels in fogwater and 
environments receiving broadcast pesticide application, and in selected indoor environments such as poorly 
ventilated and artificially lit environments and the infant breathing zone (25 cm above the carpet). Selected 
studies documenting chlorpyrifos concentration and persistence in these environments include Anderson and 
Hites (1988); Fenske et al. (1990); Jackson and Lewis (1981); Leidy et al. (1992); Lewis et al. (1988); Moye 
and Malagodi (1987); Vaccarro (1993); and Wright et al. (1991, 1994). Special issues in these environments 
are discussed below. 
Substantially higher chlorpyrifos concentrations were measured in the infant breathing zone than in the adult 
breathing zone, implying a vertical gradient with the treated carpet serving as a source of volatilized chlorpyrifos 
(Fenske et al. 1990). All concentrations in the infant breathing zone exceeded the National Academy of Sciences 
interim guideline of 10 µg/m3. This study also indicated that broadcast applications appear to produce average 
levels 5-10 times higher and peak levels l-2 orders of magnitude greater than other application procedures, with 
peak concentrations occurring 3-7 hours after application. Following treatment in the crawl spaces, significantly 
more chlorpyrifos was present in the air of houses built over sand than in the air of houses built over clay soils. 
However, no differences were found between rooms or construction types (slab, crawl, crawl-slab) (Wright et 
al.1988). The air of storage rooms in commercial pest control buildings was found to have a higher concentration 
(220 ng/m3) of chlorpyrifos than office rooms (126 ng/m3). The same study detected levels of chlorpyrifos from 20 
to 1,488 ng/m3 in the air of 6 food preparation serving areas following application of a 0.5% emulsion spray into 
cracks and crevices, although concentrations dropped considerably over 24 hours in all areas. Chlorpyrifos was 
detected in homes and pest control offices and vehicles, with residues ranging from 0.1 to 5 µg/m3 (Leidy et al. 
1992). Air concentrations in commercial pest control vehicles ranged from 9 to 221 ng/m3 (Wright and Leidy 
1980). 
High fogwater concentrations (320-6,500 ng/L) were reported at Parlier, Corcoran, and Lodi, California, 
relative to air concentrations (0.6-14.7 ng/L), with enrichment factors of 160-260 (Plimmer 
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1992). Other researchers have found similar enrichment factors (Glotfelty et al. 1987, 1990).  Enrichment was 
attributed to the effect of temperature correction, colloidal organic matter, and adsorption. The enrichment factor 
has also been correlated to hydrophobicity, as indicated by Kow (Valsaraj et al. 1993). 
There is less evidence of general contamination of ambient air, although residues have been detected.  Ambient air 
monitoring at 10 U.S. locations in 1980 resulted in 14 detections from 123 samples, with a maximum of 100 ng/m3 
and an arithmetic mean of 2.1 ng/m3 (Carey and Kutz 1985). This same study reported 2 detections of chlorpyrifos 
from 11 air samples in Pekin, Illinois, in 1980. Ambient air and wet-deposition monitoring of chlorpyrifos in 
California indicated that atmospheric transport is occurring from the Central Valley, where chlorpyrifos is used 
agronomically, to the Sierra Nevada Mountains; concentrations decrease with distance from the source area and 
elevation (Zabik and Seiber 1993). A maximum concentration of 6.5 ng/m3 was recorded in the valley; the maximum 
value midslope was 0.083 ng/m3. A loading rate of 0.8 µg/m2 to Sierra National Park was calculated. 
5.4.2 Water 
Chlorpyrifos has been detected in groundwater and surface water, but only rarely, and generally well below levels of 
concern. Hallberg (1989) reported that chlorpyrifos was detected (concentrations unspecified) in 0.2% of 334 samples 
from groundwater used for public drinking water supply in Illinois, but was not detected in 15 Iowa samples. This 
same study detected chlorpyrifos in 45% of the wells in the vicinity of agrochemical dealers, and in 1.4% of farm 
water supply wells. In a survey of surface waters in southern Ontario from 1975-77, chlorpyrifos was detected in 3 of 
949 samples from 11 agricultural watersheds (Braun and Frank 1980). Krill and Sonzogni (1986) reported no 
detections of chlorpyrifos in groundwater sampling of 358 wells in Wisconsin. In a study of 54 wells in California, 
Maddy et al. (1982) found no detectable levels of chlorpyrifos. Pionke et al. (1988) and Pionke and Glotfelty (1989) 
found no detectable levels of chlorpyrifos in a study of 21 wells and 2 springs (detection limit of 4 ng/L) in 
Pennsylvania. Maddy et al. (1982) found no detectable levels of chlorpyrifos in a study of 53 wells in California. In 
an intensive monitoring effort, Richards and Baker (1993) detected chlorpyrifos in  0-l .06% of 750 samples for each 
of 7 tributaries to Lake Erie from 1983 to 1991. A maximum chlorpyrifos concentration of 480 µg/kg in runoff from 
irrigated cropland in California was reported by Leonard (1990). Total seasonal losses as a percentage of application 
were 0.02-0.24, and were attributed to aerial application during irrigation. Chlorpyrifos 
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detections were not reported as part of the national surface water monitoring program for 1976-80 (Carey and 
Kutz 1985). 
5.4.3 Sediment and Soil 
Limited data on chlorpyrifos residues in soils or sediments were located. At a detection limit of 0.01 mg/kg, 
chlorpyrifos was not detected in sediment samples collected from Lakes Superior and Huron, including 
Georgian Bay, in 1974 (Gloschenko et al. 1976). Chlorpyrifos detections were not reported in sediments as part 
of the national surface water monitoring program for 1976-80 (Carey and Kutz 1985). Soil evaporation pits, 
ditches, and ponds have been used to dispose of liquid pesticide wastes in California (Winterlin et al. 1989). A 
core soil sample taken from one such pit in northern California contained detectable levels of chlorpyrifos to a 
depth of 67.5 cm (Winterlin et al.1989). 
5.4.4 Other Environmental Media 
The Food and Drug Administration (FDA) identified chlorpyrifos in four grain samples and in four samples of animal 
feed in 1975 (Duggan et al. 1983). The FDA’s pesticide residue monitoring program for domestic and imported food 
commodities detected chlorpyrifos 33 times in 1,044 samples in unspecified foods at unspecified concentrations 
during fiscal years 1978-82 and 295 times from 3,744 samples during fiscal years 1982-86 (Yess et al. 1991a, 1991b). 
From October 1, 1981, to September 30, 1986, the FDA Los Angeles District Laboratory detected chlorpyrifos in 
1,969 of 19,851 samples of domestic and imported food and feed commodities (Luke et al. 1988). Chlorpyrifos was 
detected in 440 of 4,916 samples analyzed as part of the FDA Total Diet Study between 1986 and 1991. As part of 
the FDA’s Pesticide Monitoring Program for domestic and imported foods, chlorpyrifos residues have been detected 
during 1988-89, 1989-90, 1990-91, and 1991-92 (FDA 1990, 1991, 1992, 1993). Chlorpyrifos was detected in 
domestic feed, lavender, lettuce, cantaloupe, peanuts, bell peppers, summer squash, and cherry tomatoes; and in 
imported apples, green beans, cabbage, coriander, cucumbers, eggplant, feijoa, kiwi, green leaf lettuce, cantaloupe, 
honeydew, nectarine, Chinese peas, peaches, peppers, spinach, squash, tomatillos, and tomatoes (Hundley et al. 
1988). In the FDA’s Revised Market Basket Study (FDA 1995), ready-to-eat foods were analyzed for pesticides 
and industrial chemicals repetitively for 10 years (1982-91). During that period, 37 market baskets, each 
containing 234 food items, were collected. Chlorpyrifos was detected in 121 of the food 
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items a total of 718 times; the average concentration found was 0.0036 µg/g (ppm). Gartrell et al.(1986) found 
chlorpyrifos in meat, fish and poultry, grain and cereal products, garden fruits, oils and fats, and sugar. Chlorpyrifos 
was detected in 121 different domestic foods (0.9% of samples) in 1988 and 128 domestic foods (1% of samples) in 
1989 by state regulatory monitoring (Minyard et al. 1991). In a study of processed foods imported into Hawaii from 
western Pacific rim countries, chlorpyrifos was detected in oriental-style noodle soup and roasted peas at 
concentrations of 4.7 ppb and 10.95 ppb, respectively (Gans et al. 1994). In a pesticide residue screening program 
conducted in 1989-91 in San Antonio, Texas, on 6,970 produce samples, chlorpyrifos was detected in 41 produce 
samples (lemons, oranges, peppers, turnips), with a detection limit of 0.25 ppm (Schattenburg and Hsu 1992).  In a 
study of pesticide residue contamination of processed milk-based and soy-based infant formula, chlorpyrifos was not 
detected (Gelardi and Mountford 1993). However, in a study of pesticide residues in cornposited milk, chlorpyrifos 
was found in 23 of  806 composite samples (Trotter and Dickerson 1992). 
The EPA Office of Water has recommended that chlorpyrifos residues be monitored by states in their fish and 
shellfish contaminant monitoring programs in watersheds where this pesticide has been or is currently used 
extensively in agriculture (EPA 1993c. While no fish or shellfish consumption advisories are currently in effect for 
chlorpyrifos, this contaminant has not been widely monitored in state fish contaminant monitoring programs or the 
U.S. Fish and Wildlife Service National Contaminant Biomonitoring Program (EPA 1993c). In a national study, EPA 
(1992a) did detect chlorpyrifos in fish in 26% of 362 sites, with mean and maximum concentrations of 4.09 ng/g and 
344 ng/g, respectively. 
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 
The general population is exposed to chlorpyrifos primarily by inhaling indoor air and ingesting food containing 
chlorpyrifos, and through skin contact during or after pesticide application. Chlorpyrifos has been very 
infrequently detected in ambient air, and only at very low concentrations (see Section 5.4.1). It is not anticipated 
that the general population would experience substantial levels of exposure by inhaling ambient air. 
Chlorpyrifos has rarely been detected in drinking water (see Section 5.4.2), and consumption of chlorpyrifos­
contaminated drinking water is not considered a significant exposure route for the general population. 
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Chlorpyrifos has been detected in some foods (see Section 5.4.4), so ingestion may be a route of exposure for the 
general population. The FDA has estimated daily food intakes of chlorpyrifos for different age/sex groups in the 
United States. The FDA estimated the dietary intake of chlorpyrifos for a 14-16-year-old male in the United States to 
be 3.4 ng/kg body weight/day, which is much lower than the Food and Agricultural Organization of the United 
Nations/World Health Organization’s (FAO/WHO) acceptable daily intake (ADI) of 10 µg/kg body weight/day and 
ATSDR’s intermediate oral MRL and EPA’s RfD of 3 µg/kg body weight/day (FDA 1992; IRIS 1994). 
Other than during home and garden insecticide application, exposure of the general public to chlorpyrifos 
through skin contact is not anticipated. 
The Non-Occupational Exposure Survey (NOES) conducted by NIOSH from 1981 to 1983 on the number of workers 
and the number of facilities where workers could be potentially exposed to chlorpyrifos in the United States estimated 
that 911 janitors and cleaners in meat packing plants, and bread, cake, and related product industries; 10,452 pest 
control workers; and 41 groundskeepers and gardeners in the medical industry were potentially exposed (NOES 
1994). The American Conference of Governmental Industrial Hygienists (ACGIH) (1993-94) recommends that 
workplace air levels of chlorpyrifos not exceed 0.2 mg/m3 as a time-weighted average (TWA) for an 8-hour workday, 
40-hour workweek and not exceed a 0.6 mg/m3 short-term exposure limit (STEL). The STEL is a 15-minute TWA 
exposure which should not be exceeded during a workday, even if the 8-hour TWA is within the threshold limit value 
(TLV)-TWA; also exposure should not be >15 minutes and should occur not more than 4 times per day. 
Workers involved in the manufacture, formulation, handling, or application of chlorpyrifos, or those involved in 
the disposal of chlorpyrifos-contaminated wastes are likely to be exposed to higher concentrations by dermal 
contact and inhalation than the general population. Persons working with plants that have been previously 
treated with these compounds also can be exposed by absorption through the respiratory system or skin (Aprea 
et al. 1994). A study of pet handlers responsible for flea control in California in 1987 indicated that chlorpyrifos 
was associated with increased frequency of blurred vision, flushing of skin, and a decrease in urination (Ames et 
al. 1989). In a study of airborne and surface concentrations of chlorpyrifos after application in offices, Currie et 
al. (1990) found airborne concentrations peaked 4 hours after application at 27 µg/m3, and surface residue 
concentrations peaked at 5.9 ng/cm2 48 hours after application. Airborne levels were found to be 
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lower in furnished offices than unfurnished offices. When granular chlorpyrifos at 0.75 active ingredient per 
acre was applied to a field by air, the estimated inhalation exposure to chlorpyrifos was 0.02 mg per 8-hour 
day for the pilot and 0.03 mg per 8-hour day for the ground staff (Myram and Forrest 1969). The estimated 
inhalation exposure to chlorpyrifos for workers using ground machines was 0.33 mg per 8-hour day (Myram 
and Forrest 1969). 
Hodgson et al. (1986) reported symptoms of organophosphate intoxication among five office workers after 
chlorpyrifos treatment for termites. The duration of symptoms and erythrocyte cholinesterase levels over time 
suggested redistribution of the active ingredient after absorption to a second body compartment, with 
subsequent slow release into the bloodstream. Estimated potential dermal exposure (i.e., unprotected by 
clothing) of three greenhouse workers in Florida ranged from 17,500 to 24,000 µg/hour (Stamper et al. 1989), 
with highest exposure to applicators’ legs. Tyvek® protective clothing afforded 89%, ±5% protection. 
In a study of termiticide applicator exposure in eight North Carolina homes, exposures of 
0.1-98 µg/m3 were reported. Exposure levels were higher in houses constructed over a crawl-space (Wright et al. 
1988). The NOES reported detectable levels of chlorpyrifos in indoor, outdoor, and personal air in Jacksonville, 
Florida, and in Springfield/Chicopee, Massachusetts (Whitmore et al.1994). Concentrations tended to be highest in 
summer, lower in spring, and lowest in winter. Indoor and personal air concentrations were generally higher than 
outdoor concentrations. Of 11 carpets sampled in the study, all had detectable levels of chlorpyrifos in carpet dust, 
(mean concentration of 5.8 µg/g), suggesting that infants and toddlers may be at higher risk of exposure. 
NAS/NRC (1982) recommends that air levels in houses not exceed 10 µg chlorpyrifos/m3. Measurements of 
pesticides or their metabolites in human biological specimens, such as urine, are considered an appropriate way of 
approximating total pesticide exposure through all routes of entry into the body. As part of the National Health and 
Nutrition Examination Survey III (NHANES III), urine samples were collected from approximately 1,000 adults 
ranging in age from 20 to 59 years. These individuals represented a relatively board spectrum of the U. S. 
population, including individuals from both sexes-and different age groups, races/ethnicities, urban/rural 
residences, and regions of the country (Needham et al. 1995).  Hill et al. (1995) examined the ranges of pesticide 
residues found in the urine of approximately 1,000 U.S. adults and found that 3,5,6-trichloro-2-pyridinol (TCP), 
considered a fairly specific metabolite and indicator of exposure to chlorpyrifos or chlorpyrifos-methyl, was 
present at detectable levels in 82% of the (993) individuals examined. Further, 31% of those subjects had urinary 
TCP concentrations of 
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5 µg/L or greater. This was consistent with the report of Bartele and Kastl (1992) that TCP was present in the pooled 
urine of unexposed control subjects at a concentration of 5 µg/L. 
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
Workers in industries that manufacture and formulate chlorpyrifos and applicators of the insecticide are at higher risk 
than the general population for chlorpyrifos exposure. Farm workers who enter treated fields after insecticide 
application may also be exposed to chlorpyrifos at higher levels than the general population. Those who use the 
insecticide for homes and gardens are also at higher risk of exposure to chlorpyiifos. Although no investigative 
evidence from the hazardous waste sites was located, it is likely that people who live near hazardous waste sites 
containing chlorpyrifos wastes are at higher risk of exposure to chlorpyrifos. 
5.7 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate 
information on the health effects of chlorpyrifos is available. Where adequate information is not available, ATSDR, 
in conjunction with the NTP, is required to assure the initiation of a program of research designed to determine the 
health effects (and techniques for developing methods to determine such health effects) of chlorpyrifos. 
The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, 
NTP, and EPA. They are defined as substance-specific informational needs that if met would reduce the 
uncertainties of human health assessment. This definition should not be interpreted to mean that all data needs 
discussed in this section must be filled. In the future, the identified data needs will be evaluated and prioritized, 
and a substance-specific research agenda will be proposed. 
5.7.1 Identification of Data Needs 
Physidal and Chemical Properties. As seen in Table 3-2, the relevant physical and chemical properties of 
chlorpyrifos are known (HSDB 1994; Sanbom et al. 1977), and it is possible to predict 
  
 
 
  
CHLORPYRIFOS 128 
5. POTENTIAL FOR HUMAN EXPOSURE 
the environmental fate and transport of chlorpyrifos based on Kow Koc and H. Therefore, further data 
acquisition and research are not recommended as a high-priority activity. 
Production, Import/Export, Use, Release, and Disposal.  Knowledge of production and use data for 
a chemical is important in predicting its potential for environmental contamination and human exposure. 
Since chlorpyrifos is produced by two manufacturers (SRI 1994), to maintain confidentiality, its recent 
production volume is not known. Similarly, data concerning the import and export volumes for chlorpyrifos 
in recent years have not been located. There is currently no federal requirement to report the use of 
chlorpyrifos. The most recent estimates of its yearly use in the United States were published in 1986 (Gianessi 
1986). Therefore, more current estimates of use and projected trends are needed. No information in the 
available literature was located that indicates the use of chlorpyrifos in any consumer products other than 
edible crops and vegetables during and after their planting. Although some information regarding the disposal 
of wastes containing chlorpyrifos is available, more detailed and recent information would be helpful. The 
standards promulgated by the EPA for the disposal of wastes containing chlorpyrifos are available (Berlow 
and Cunningham 1989). 
According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, 
industries are required to submit chemical release and off-site transfer information to the EPA.  The Toxics Release 
Inventory (TRI), which contains this information for 1992, became available in May of 1994. This database will be 
updated yearly and should provide a list of industrial facilities and emissions. However, no TRI data were located 
for chlorpyrifos because this chemical is not required to be reported. As with most pesticide agents, it is virtually 
impossible to make decent quantitative estimates of the amounts of chlorpyrifos produced, used, disposed, 
imported and exported.  This presents some fundamental problems in making more than the most general sorts of 
risk assessments. Improved information for any of these categories is considered a major data need. 
Environmental Fate. Information regarding the fate of chlorpyrifos in air was limited in the literature. 
Although the available data indicate that the concentration of chlorpyrifos in air will be low (Carey 
and Kutz 1985), more information would help predict the residence time and distance of its aerial 
transport. Knowledge about the fate of chlorpyrifos in water is also limited. Although it has been 
estimated that sorption onto particulates and settling into the sediment are important for 
chlorpyrifos in water, more information regarding the relative importance of sorption for removal of 
chlorpyrifos from water to sediment would be helpful. There is some evidence in the literature 
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regarding the mobility of chlorpyrifos in soil. Additional information on the degradation of chlorpyrifos in water 
and air and the fate of the degradation products in soil would be helpful. 
Bioavailability from Environmental Media. Available information regarding the rate of 
chlorpyrifos absorption following inhalation, oral, or dermal contact has been discussed in Section 2.3, 
Toxicokinetics. Although no data on the bioavailability of chlorpyrifos from contaminated air are available, the 
bioavailability from inhalation exposure is expected to be high because chlorpyrifos is likely to be present in the 
vapor phase and not in the particulate phase in the adsorbed state. Similarly, no data on the bioavailability of 
chlorpyrifos from water, soil, or plant material are available; however, chlorpyrifos is adsorbed rather strongly 
to soil. Since the part that remains adsorbed to soil or sediments may be, at most, partially bioavailable, 
chlorpyrifos is expected to have reduced bioavailability from soil and water. Data on the bioavailability of 
chlorpyrifos from actual environmental media and the difference in bioavailability for different media need 
further development. 
Food Chain Bioaccumulation. Measured BCF values for chlorpyrifos are available for a large number of 
aquatic invertebrate and fish species (Odenkirchen and Eisler 1988; Racke 1993). Research on accumulation of 
chlorpyrifos applied to soils in the roots, stems, and leaves of plants has also been undertaken (Rouchaud et al. 
1991). 
Exposure Levels in Environmental Media. A number of studies have been conducted dealing with 
chlorpyrifos concentrations in indoor air. Although some data on the levels of chlorpyrifos in ambient air are 
available (Carey and Kutz 1985), these data are neither current nor general enough to estimate inhalation 
exposure to chlorpyrifos for the general population in the United States. Limited data on the level of 
chlorpyrifos in drinking water were located in the literature. More recent data regarding the levels of 
chlorpyrifos in ambient air, drinking water, and soil are needed. Data on chlorpyrifos levels in food and recent 
estimates of the human intake of chlorpyrifos from foods are available (Duggan et al. 1983; FDA 1990, 1991, 
1992, 1993; Gelardi and Mountford 1993; Gunderson 1988; Luke et al. 1988; Schattenburg and Hsu 1992; Yess 
et al. 1991a, 1991b). 
Reliable monitoring data for the levels of chlorpyrifos in contaminated media at hazardous waste sites are 
needed so that the information obtained on levels of chlorpyrifos in the environment can be used 
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in combination with the known body burden of chlorpyrifos to assess the potential risk of adverse health effects 
in populations living in the vicinity of hazardous waste sites. 
Exposure Levels in Humans. Aside from the NHANES III and Hill et al. (1995) data, no other quantitative 
information on chlorpyrifos levels in human tissues and body fluids for a control population, populations near 
hazardous waste sites, or occupationally exposed groups were located.  Additionally, data on the levels of 
chlorpyrifos and its metabolites in body tissues and fluids in symptomatic, exposed individuals, as well as RBC 
and plasma ChE activity levels in these persons, are needed to correlate exposure levels with adverse symptoms 
and to identify levels of ChE inhibition associated with the onset of toxic manifestations. One potential source of 
this information is the American Association of National Poison Control Centers. 
Exposure Registries. No exposure registries for chlorpyrifos were located. This substance is not currently 
one of the compounds for which a subregistry has been established in the National Exposure Registry. The 
substance will be considered in the future when chemical selection is made for subregistries establishment. The 
information that is amassed in the National Exposure Registry facilitates the epidemiological research needed to 
assess adverse health outcomes that may be related to exposure to a substance. 
5.7.2 Ongoing Studies 
As part of the National Pesticide Impact Assessment Program, research is in progress at North Carolina State 
University (Leidy) to study the movement of herbicides into poorly drained soils of the Tidewater region of 
North Carolina and to determine the dislodgeable residue of chlorpyrifos from carpet samples. 
Research is in progress at the University of Florida, Belle Glade (Snyder) to quantify organophosphate losses in 
percolate, retention in soil and thatch, and removal in grass clippings. 
Research is in progress at the University of Florida, Gainesville (Moye and Wheeler), Texas A&M (Plapp), and 
Clemson (Camper) to determine the metabolic fate of chlorpyrifos in different media. 
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Researchers at the University of Puerto Rico (Singmaster and Acin-Diaz) are determining the dissipation and 
persistence of chlorpyrifos in surface and vadose-zone soils and water. 
The USDA Agricultural Research Service (ARS) (Wauchope) is determining chlorpyrifos residues for 22 minor 
food crops at Tifton, Georgia, 7 crops at Yakima, Washington (Toba), and chlorpyrifos residues in coffee in 
Puerto Rico (Acin-Diaz, Liu, Armstrong). 
The USDA-ARS in Riverside, California (Spencer and Yates) is studying water and pesticide management 
systems for minimizing groundwater and air contamination, as well as the persistence (fate and transport) of 
chlorpyrifos (Gaston). 
The USDA-ARS in Beltsville, Maryland (Wright and Hapeman) are quantifying chlorpyrifos volatilization, 
transport, partitioning, and deposition. 
The University of Nevada at Reno (Seiber), with funding from the U.S. Department of Agriculture, is studying 
the aerial transport and deposition of organophosphate pesticides, including chlorpyrifos, in Sierra Nevada 
forests. 
The National Taiwan University (Hsu and Epstein), with funding from the USDA, is investigating the effects of 
different processing/cooking variables on chlorpyrifos residues in meat and poultry products. 
Research is in progress at the University of Nebraska (Shea) to determine the mobility and bioavailability of 
chlorpyrifos in soil and at Iowa State University to compare degradation kinetics at high as opposed to low 
concentrations, persistence of TCP, and effect of temperature and moisture on degradation of chlorpyrifos 
(coats). 
The U.S. Department of Energy (DOE) is funding a cooperative research and development agreement (CRADA) 
between Argonne National Laboratory (Kakar), the University of Notre Dame, and COGNIS, Inc., to study the 
biodegradability of pesticides by direct enzyme treatment. 
The University of California at Davis (Kilgore), with funding from the U.S. Department of Agriculture, is 
developing methods to measure exposure, ab,sorption, and toxicity of pesticides to 
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workers and is preparing guidelines for best management practices to reduce worker exposure to pesticides. 
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The purpose of this chapter is to describe the analytical methods that are available for detecting, measuring, and/or 
monitoring chlorpyrifos, its metabolites, and other biomarkers of exposure and effect to chlorpyrifos. The intent is not 
to provide an exhaustive list of analytical methods. Rather, the intention is to identify well-established methods that 
are used as the standard methods of analysis. Many of the analytical methods used for environmental samples are the 
methods approved by federal agencies and organizations such as EPA and the National Institute for Occupational 
Safety and Health (NIOSH). Other methods presented in this chapter are those that are approved by groups such as 
the Association of Official Analytical Chemists (AOAC) and the American Public Health Association (APHA). 
Additionally, analytical methods are included that modify previously used methods to obtain lower detection limits, 
and/or to improve accuracy and precision. 
6.1 BIOLOGICAL SAMPLES 
Methods for the determination of chlorpyrifos and its metabolites are shown in Table 6- 1.  Chlorpyrifos has 
been measured in human whole blood, plasma, and urine at concentrations as low as 10 ppb (Drevenkar et al. 
1994; Jitsunari et al. 1989; Nolan et al. 1984). The chlorpyrifos oxygen analog (oxon) has been reported to be 
recoverable from serum and urine by hexane extraction, but no limit of detection (LOD) or recovery was 
reported (Drevenkar et al. 1993). The chlorpyrifos metabolite TCP has been measured at concentrations as low 
as 0.5 ng/mL weight per volume (0.5 ppb, w/v) in human blood and urine (Bartels and Kastl 1992; Jitsunari et 
al. 1.989; Nolan et al. 1984). The hydrolysis product diethyl phosphate (DEP) has been measured in urine and 
plasma (Drevenkar et al.1994; Takamiya 1994) and the hydrolysis product diethylthiophosphate (DETP) has 
been measured in plasma (Drevenkar et al. 1994) with LODs of approximately 50 ppb. Chlorpyrifos and its 
oxon can be extracted directly into organic solvent while TCP, DEP, and DETP can be isolated after acid 
hydrolysis of the conjugated forms. Chlorpyrifos and its oxon can be determined directly using gas 
chromatography (GC) and selective detection methods (see below). The metabolites TCP, DEP, and DETP are 
typically derivatized to improve the chromatography and, hence, detectability. No methods were found for 
chlorpyrifos and its metabolites in human tissue, but methods have been reported for animal tissue (see Table 6­
2) (Brown et al. 1987; Clabom et al. 1968; Dishburger et al. 1977; Ivey and Clabom 1968; Lino and Noronha da 
Silveira 1994) and could most likely be applied to human tissues. 
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6.2 ENVIRONMENTAL SAMPLES 
Methods for the determination of chlorpyrifos and environmental transformation products are shown in Table 
6-2. 
The analytical methods for chlorpyrifos in air are based on GC with some form of selective detection.  For air 
matrices, collection methods rely on the entrapment of chlorpyrifos onto a polymeric material, such as XAD or 
polyurethane foam, as the air is pulled through the sorbent (EPA 1988c; Fenske et al.1990; OSHA 1986). The 
analyte is subsequently recovered from the sorbent through solvent extraction. Losses of chlorpyrifos can occur 
during Soxhlet extraction or extract concentration using Kudema-Danish devices as a result of the boiling chips 
used (Hsu et al. 1988). Thus, it is very important that the performance of any method be verified prior to its 
application in a study. The proper use of field control samples is also very important. Reported LODs were as low 
as sub parts per trillion (EPA 1988c). Although chlorpyrifos can be converted to its oxygen analog (thiophosphate 
to phosphate) under normal environmental conditions (see Chapter 5), none of the methods surveyed indicated that 
this conversion was problematic for the determination of chlorpyrifos in air. 
In the case of water, soils, and wastes, sample preparation is based on liquid/liquid extractions (EPA 1986c, 1986d, 
1992b, 1992c; Sherma and Slobodien 1984), solid phase extraction (SPE) (Bogus et al.1991; Johnson et al. 1991; 
Lacorte et al. 1993; Mattem et al. 1991), or Soxhlet extractions (EPA 1986c, 1986d). Humic material in natural 
waters can reduce recoveries of chlorpyrifos in SPE-based sample preparation (Johnson et al. 1991). The decreased 
recovery is hypothesized to be the result of inefficient trapping of the chlorpyrifos/humic material complex. EPA 
Method 507 for the determination of nitrogen- and phosphorus-containing pesticides in drinking water (EPA 1991) 
should be applicable to chlorpyrifos but has not been validated for this compound. Soxhlet extractions are 
commonly employed in methods used to study chlorpyrifos residues in carpet dust and on surfaces sampled using 
wiping approaches (Fenske et al. 1990; Lewis et al. 1994). Supercritical fluid extraction (SFE) has shown promise 
for the recovery of chlorpyrifos from environmental solids (Lopez-Avila et al. 1991; Miles and Randall 1992). 
Chlorpyrifos in sample extracts is typically determined using GC, although thin-layer chromatography (TLC) and 
high-performance liquid chromatography (HPLC) have also been employed (Bogus et al. 1990; Sherma and 
Slobodien 1984).  Sherma and Slobodien (1984) also used TLC to quantify the chlorpyrifos transformation product 
TCP in drinking water. Gerhart and Cortes (1990) have reported a method for chlorpyrifos that used direct 
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injection of well water into a GC retention gap. Reported lower LODs for chlorpyrifos ranged from 5 ppt (w/v) 
for surface water (Mattem et al. 1991) to 3 ppm (w/w) for soils and sludges (EPA 1986c). 
The determination of chlorpyrifos and its transformation products, especially chlorpyrifos oxygen analog and TCP in 
foods has received considerable attention. Foods are generally divided into fatty (animal products, oils) and non-fatty 
types (produce). Chlorpyrifos is fairly non-polar and thus tends to partition into fat. This dictates that slightly 
different methods be used for the extraction of fatty and non-fatty samples. In general, chlorpyrifos, chlorpyrifos 
oxygen analog, and TCP are extracted from fatty foods using petroleum ether (Hunt et al. 1969), methylene 
chloride/acetone (Leoni et al. 1992), methanol/methylene chloride (Holstege et al. 1991) acetonitrile (Clabom et al. 
1968), or methanol (Dishburger et al. 1977). The sample or initial extracts are usually acidified followed by 
additional extraction steps to recover TCP (Dishburger et al. 1977; Inman et al. 1981). Non-fatty samples are most 
often extracted with acetone (FDA 1994a; Helrich 1990b; Thier and Zeumer 1987a, 1987b), although the use of 
benzene has also been reported (Mansour 1985). Supercritical fluid extraction has been successfully used to recover 
chlorpyrifos from potatoes and butter fat (Hopper and King 1991) and grass (Cortes et al. 1991). 
The determinative step for chlorpyrifos, chlorpyrifos oxygen analog, and TCP is usually GC in conjunction with 
selective detection such as flame photometric detection (FPD), nitrogen phosphorus thermionic detection (NPD), or 
electron capture detection (ECD). Depending on the original sample matrix, additional clean-up can be required to 
remove fats or other material that can interfere with the chromatography (Walters 1990) or with detection (FDA 
1994a). In addition, natural sample constituents, such as large amounts of sulfur-containing compounds in 
cauliflower, onions and broccoli, can increase the FPD background detector signal and make the method less 
sensitive (Lee and Wylie 1991). Common approaches to further extract purification include SPE (Gillespie and 
Walters 1991; Leoni et al. 1992; Thier and Zeumer 1987a, 1987b), gel permeation chromatography (GPC) (FDA 
1994a; Holstege et al. 1991; Thier and Zeumer 1987b), Florisil column chromatography (Brown et al. 1987; Clabom 
et al. 1968; FDA 1994a; Hopper and King 1991; Leoni et al. 1992), sweep co-distillation (Luke and Richards 1984) 
and HPLC (Gillespie and Walters 1986, 1989). The adequate recovery of the desired compound must be validated for 
the fractionation technique to be used. For example, SPE cartridges from different vendors or production lots have 
been shown to affect retention and recovery (Gillespie and Walters 1991). Chlorpyrifos oxygen analog has been 
found to be hydrolyzed by activated silica (Braun 1974). Florisil can also give rise to poor recoveries 
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of chlorpyrifos oxygen analog (FDA 1994a, 1994b; Leoni et al. 1992). The FDA method for fatty foods or 
cornposited food (Method 304) can be applied with limited success to chlorpyrifos (variable recovery) but not at 
all to the oxygen analog (FDA 1994b). 
TLC has been used to separate chlorpyrifos and TCP (Judge et al. 1993) and to screen for 170 commonly used 
pesticides, including chlorpyrifos (Erdmann et al. 1990). Additional analytical techniques that have been applied 
to chlorpyrifos include GC with atomic emission detection (Lee and Wylie 1991), GC with pulsed positive 
ion/negative ion chemical ionization mass spectrometry (Stan and Kellner 1989), simultaneous analysis on two 
GC columns with both ECD and electrolytic conductivity detectors (Hopper 1991), and two-dimensional GC 
with simultaneous detection by ECD, NPD, and FPD (Stan and Heil 1991). 
6.3 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate 
information on the health effects of chlorpyrifos is available. Where adequate information is not available, ATSDR, 
in conjunction with the NTP, is required to assure the initiation of a program of research designed to determine the 
health effects (and techniques for developing methods to determine such health effects) of chlorpyrifos. 
The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, NTP, 
and EPA. They are defined as substance-specific informational needs that if met would reduce the uncertainties of 
human health assessment. This definition should not be interpreted to mean that all data needs discussed in this 
section must be filled. In the future, the identified data needs will be evaluated and prioritized, and a substance-
specific research agenda will be proposed. 
6.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect. Chlorpyrifos and TCP can serve 
as biomarkers of exposure. TCP will be present at much greater concentrations relative to chlorpyrifos, so 
it is a better and more sensitive marker of exposure (He 1993; WHO 1975). The method for TCP in urine 
published by Bartels and Kastl (1992) should be adequately sensitive to study 
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background concentrations in the general population because they measured low concentrations in control urine from 
presumably unexposed individuals. A LOD of  0.5 ng/mL (0.5 ppb, w/v) for TCP in urine was stated. The methods of 
Nolan et al. (1989) and Jitsunari et al. (1989) for TCP in blood and urine claim an LOD of 10 ppb with a 
reproducibility of 4% at 100 ppb. Chlorpyrifos oxon was not detected in serum and urine of poisoned persons, 
presumably because of the rapid rate of hydrolysis of the oxon relative to its rate of formation from chlorpyrifos 
(Drevenkar et al. 1993). The metabolites DEP and DETP can serve as markers of exposure to chlorpyrifos but can 
also be present as a result of exposure to organophosphorus compounds that have the same phosphate moiety. Thus, 
they are not specific. Exposure to organophosphorus pesticides also results in decreases in whole blood and 
erythrocyte acetylcholinesterase activities (Drevenkar et al. 1993; He 1993) and are not specific to exposure to 
chlorpyrifos. The best marker of exposure to chlorpyrifos appears to be TCP, for which there are adequate methods; 
therefore, no new methods for TCP are needed. 
Methods for Determining Parent Compounds and Degradation Products in 
Environmental Media. Methods are available for the determination of chlorpyrifos in air at sub-ppb 
concentrations (EPA 1988c; Fenske et al. 1990; OSHA 1986) and are adequate to estimate potential exposures 
of the general population. No methods were found for chlorpyrifos oxon in air. It has been reported that the 
oxon is more toxic than the parent compound (Drevenkar et al. 1993), but it does not persist (Walia et al. 1988). 
No additional methods are needed. 
The predominant route of exposure to chlorpyrifos is through contact with contaminated environmental 
matrices such as food and water. Methods for the determination of chlorpyrifos in water, wastes, soils, and foods 
are available that have LODs in the ppb and sub-ppb range (e.g., EPA 1992c; FDA 1994a; Gerhart and Cortes 
1990; Gillespie and Walters 1991; Mansour 1985; Mattem et al. 1991). Assuming an oral MRL of  0.003 
mg/kg/day (Chapter 2), 2 L/day water consumption and a 70-kg person, this converts to a needed method LOD 
of 0.105 ppm (w/v) in drinking water. Reported LODs in water are 2 ppb (Sherma and Slobodien 1984), 0.9 ppb 
(Gerhart and Cortes 1990), 0.1 ppb (Lacorte et al. 1993), 0.005 ppb (Mattem et al. 1991), and 5 ppb (Bogus et 
al. 1990). These methods are sufficiently sensitive to detect concentrations at or below the MRL. Method 
reproducibilities range from 4 to 16% and will be adequate for most measurements. If 2 kg/day food 
consumption is assumed, method LODs of 0.105 ppm or 105 ppb (w/w) are needed. The methods of Hunt et al. 
(1969), Leoni et al. (1992), Lino and Noronha da Silveira (1994), Clabom et al. (1968), Ivey and Clabom 
(1968), Dishburger et al. (1977), Hopper and King (1991), Thier and Zeumer (1987a), FDA (1994a), and 
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Mansour (1985) claim method LODs that range from 2 to 100 ppb and are sufficiently sensitive to detect 
concentrations at or below the MRL. No reproducibility information was available. No additional methods for 
chlorpyrifos in foods are needed. 
Methods are also available for the determination of the oxon in some foods (tissue and produce) (FDA 1994a; 
Ivey and Claborn 1968; Mansour 1985) at the sub-ppm level. Chlorpyrifos and its oxon are quickly hydrolyzed 
to TCP; some methods exist for the determination of TCP in drinking water (Sherma and Slobodien 1984), 
peppermint oil (Gillespie and Walters 1991), and bovine tissue (Dishburger et al. 1977). 
6.3.2 Ongoing Studies 
Researchers at North Dakota State University (Fargo) and at the University of Maine, Department of Food 
Science, have been working on immunochemical-based methods for the determination of chlorpyrifos. 
Researchers at the U.S. Department of Agriculture in Beltsville, Maryland; at the University of Florida 
(Gainesville) Department of Food Science and Nutrition; and at the University of Puerto Rico (Mayaguez), Crop 
Protection, are working on fate and transport of chlorpyrifos in the environment and will be developing methods 
as needed to define the processes and to develop models to predict fate and transport. 
Researchers at National Taiwan University (Taipei) are studying the degradation of chlorpyrifos residues in 
meat and poultry as a function of cooking methods for modeling purposes and might need to develop some 
methods. 
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The international, national, and state regulations and guidelines regarding chlorpyrifos in air, water, and other 
media are summarized in Table 7-l. 
ATSDR has derived a Minimal Risk Level (MRL) of 0.003 mg/kg/day for both acute (14 days or less) and 
intermediate (15-364 days) duration oral exposure to chlorpyrifos, based on a NOAEL of 0.03 mg/kg/day 
observed in human adult males exposed orally to chlorpyrifos (Coulston et al. 1972).  An uncertainty factor of 
10 was used in the calculation of the MRL to account for variability in susceptibility within the human 
population. 
ATSDR has derived a chronic-duration oral MRL of 0.001 mg/kg/day, based on a NOAEL for 
acetylcholinesterase inhibition in rats exposed to 0.1 mg/kg/day chlorpyrifos in feed for 2 years (McCollister et 
al. 1974). An uncertainty factor of 100 was used in the calculation of the MRL: 10 for extrapolation from 
animals to humans and 10 for variability within the human population. 
The U.S. EPA oral reference dose for chlorpyrifos is 3x10-3 mg/kg/day (IRIS 1994). No inhalation reference 
concentration exists for this compound. 
Chlorpyrifos is one of the chemicals regulated under “The Emergency Planning and Community Rightto-Know 
Act of 1986” (EPCRA) (EPA 1988a). Section 313 of Title III of EPCRA requires owners and operators of 
certain facilities that manufacture, import, process, or otherwise use the chemicals on this list to report annually 
their release of those chemicals to any environmental media. 
An Occupational Safety and Health Administration (OSHA) permissible exposure limit (PEL) for chlorpyrifos 
has not been set. 
Chlorpyrifos is designated a hazardous substance and subject to regulations implementing Section 311 of the 
Federal Water Pollution Act (EPA 1978b) and Section 311 of the Clean Water Act (EPA 1986b). A maximum 
contaminant level in (MCL) drinking water does not exist. 
Tolerances for chlorpyrifos in raw agricultural commodities, foods, and animal feeds have been established by 
EPA (EPA 1987, 1982, 1979) ranging from 0.05 to 25 ppm. 
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Acute Exposure-Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Adsorption Coefficient (Koc)-The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)-The amount of a chemical adsorbed by a sediment or soil (i.e., the solid 
phase) divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at 
a fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
Bioconcentration Factor (BCF)-The quotient of the concentration of a chemical in aquatic 
organisms at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
Cancer Effect Level (CEL)-The lowest dose of chemical in a study, or group of studies, that 
produces significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control. 
Carcinogen-A chemical capable of inducing cancer. 
Ceiling Value-A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure-Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Developmental Toxicity-The occurrence of adverse effects on the developing organism that may 
result from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point in the 
life span of the organism. 
Embryotoxicity and Fetotoxicity-Any toxic effect on the conceptus as a result of prenatal exposure to a 
chemical; the distinguishing feature between the two terms is the stage of development during which the insult 
occurred. The terms, as used here, include malformations and variations, altered growth, and in utero death. 
EPA Health Advisory-An estimate of acceptable drinking water levels for a chemical substance 
based on health effects information. A health advisory is not a legally enforceable federal standard, but serves as 
technical guidance to assist federal, state, and local officials. 
Immediately Dangerous to Life or Health (IDLH)-The maximum environmental concentration of a 
contaminant from which one could escape within 30 min without any escape-impairing symptoms or irreversible 
health effects. 
Intermediate Exposure-Exposure to a chemical for a duration of 15-364 days, as specified in the 
Toxicological Profiles. 
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Immunologic Toxicity-The occurrence of adverse effects on the immune system that may result
 
from exposure to environmental agents such as chemicals.
 
In Vitro-Isolated from the living organism and artificially maintained, as in a test tube.
 
In Vivo-Occurring within the living organism.
 
Lethal Concentration(LO) (LCLO)-The lowest concentration of a chemical in air which has been
 
reported to have caused death in humans or animals.
 
Lethal Concentration (50) (LC50)-A calculated concentration of a chemical in air to which exposure for a 
specific length of time is expected to cause death in 50% of a defined experimental animal population. 
Lethal Dose (50) (LD50) -The lowest dose of a chemical introduced by a route other than inhalation that is 
expected to have caused death in humans or animals. 
Lethal Dose (50) (LD50)-The dose of a chemical which has been calculated to cause death in 50% of a defined 
experimental animal population.
 
Lethal Time (50) (LT50)-A calculated period of time within which a specific concentration of a
 
chemical is expected to cause death in 50% of a defined experimental animal population.
 
Lowest-Observed-Adverse-Effect Level (LOAEL)-The lowest dose of chemical in a study, or 
group of studies, that produces statistically or biologically significant increases in frequency or severity of 
adverse effects between the exposed population and its appropriate control. 
Malformations-Permanent structural changes that may adversely affect survival, development, or function. 
Minimal Risk Level-An estimate of daily human exposure to a dose of a chemical that is likely to be without an 
appreciable risk of adverse noncancerous effects over a specified duration of exposure. 
Mutagen-A substance that causes mutations. A mutation is a change in the genetic material in a 
body cell. Mutations can lead to birth defects, miscarriages, or cancer. 
Neurotoxicity-The occurrence of adverse effects on the nervous system following exposure to 
chemical. 
No-Observed-Adverse-Effect Level (NOAEL) -The dose of chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen 
between the exposed population and its appropriate control. Effects may be produced af this dose, but they are 
not considered to be adverse. 
Octanol-Water Partition Coefficient (Kow)-The equilibrium ratio of the concentrations of a 
chemical in n-octanol and water, in dilute solution. 
Permissible Exposure Limit (PEL) -An allowable exposure level in workplace air averaged over an 8-hour 
shift. 
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q1*- The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure. The ql* can be used to calculate an estimate of carcinogenic potency, the incremental 
excess cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and µg/m3 for air). 
Reference Dose (RfD)-An estimate (with uncertainty spanning perhaps an order of magnitude) of the daily 
exposure of the human population to a potential hazard that is likely to be without risk of deleterious effects 
during a lifetime. The RfD is operationally derived from the NOAEL (from animal and human studies) by a 
consistent application of uncertainty factors that reflect various types of data used to estimate RfDs and an 
additional modifying factor, which is based on a professional judgment of the entire database on the chemical. 
The RfDs are not applicable to nonthreshold effects such as cancer. 
Reportable Quantity (RQ)-The quantity of a hazardous substance that is considered reportable 
under CERCLA. Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an amount 
established by regulation either under CERCLA or under Sect. 311 of the Clean Water Act. Quantities are 
measured over a 24-hour period. 
Reproductive Toxicity-The occurrence of adverse effects on the reproductive system that may result from 
exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related endocrine 
system. The manifestation of such toxicity may be noted as alterations in sexual behavior, fertility, pregnancy 
outcomes, or modifications in other functions that are dependent on the integrity of this system. 
Short-Term Exposure Limit (STEL)-The maximum concentration to which workers can be exposed for up to 
1.5 min continually. No more than four excursions are allowed per day, and there must be at least 60 min 
between exposure periods. The daily TLV-TWA may not be exceeded. 
Target Organ Toxicity-This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Teratogen-A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV)-A concentration of a substance to which most workers can be 
exposed without adverse effect. The TLV may be expressed as a TWA, as a STEL, or as a CL. 
Time-Weighted Average (TWA)-An allowable exposure concentration averaged over a normal 
8-hour workday or 40-hour workweek. 
Toxic Dose (TD50)-A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
Uncertainty Factor (UF)-A factor used in operationally deriving the RfD from experimental data. UFs are 
intended to account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from data 
obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using LOAEL data rather 
than NOAEL data. Usually each of these factors is set equal to 10. 
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ATSDR MINIMAL RISK LEVEL 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 9601 et 
seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 994991, requires 
that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with the U.S. 
Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most commonly 
found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological profiles for each 
substance included on the priority list of hazardous substances; and assure the initiation of a research program to 
fill identified data needs associated with the substances. 
The toxicological profiles include an examination, summary, and interpretation of available toxicological information 
and epidemiologic evaluations of a hazardous substance. During the development of toxicological profiles, Minimal 
Risk Levels (MRLs) are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the 
most sensitive health effect(s) for a specific duration for a given route of exposure. An MRL is an estimate of the 
daily human exposure to a hazardous substance that is likely to be without appreciable risk of adverse noncancer 
health effects over a specified duration of exposure. MRLs are based on noncancer health effects only and are not 
based on a consideration of cancer effects. These substance-specific estimates, which are intended to serve as 
screening levels, are used by ATSDR health assessors to identify contaminants and potential health effects that may 
be of concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or action 
levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to such 
chemical-induced effects. MRLs are derived for acute (1-14 days), intermediate (15-364 days), and chronic (365 
days and longer) durations and for the oral and inhalation routes of exposure. Currently, MRLs for the dermal 
route of exposure are not derived because ATSDR has not yet identified a method suitable for this route of 
exposure. MRLs are generally based on the most sensitive chemical-induced end point considered to be of 
relevance to humans. Serious health effects (such as irreparable damage to the liver or kidneys, or birth defects) 
are not used as a basis for 
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establishing MRLs. Exposure to a level above the MRL does not mean that adverse health effects will occur. 
MRLs are intended only to serve as a screening tool to help public health professionals decide where to look more 
closely. They may also be viewed as a mechanism to identify those hazardous waste sites that are not expected to 
cause adverse health effects. Most MRLs contain a degree of uncertainty because of the lack of precise toxicological 
information on the people who might be most sensitive (e.g., infants, elderly, nutritionally or immunologically 
compromised) to the effects of hazardous substances. ATSDR uses a conservative (i.e., protective) approach to 
address this uncertainty consistent with the public health principle of prevention. Although human data are preferred, 
MRLs often must be based on animal studies because relevant human studies are lacking. In the absence of evidence 
to the contrary, ATSDR assumes that humans are more sensitive to the effects of hazardous substance than animals 
and that certain persons may be particularly sensitive. Thus, the resulting MRL may be as much as a hundredfold 
below levels that have been shown to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the Division of 
Toxicology, expert panel peer reviews, and agencywide MRL Workgroup reviews, with participation from other 
federal agencies and comments from the public. They are subject to change as new information becomes available 
concomitant with updating the toxicological profiles.  Thus, MRLs in the most recent toxicological profiles supersede 
previously published levels. For additional information regarding MRLs, please contact the Division of Toxicology, 
Agency for Toxic Substances and Disease Registry, 1600 Clifton Road, Mailstop E-29, Atlanta, Georgia 30333. 
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MINIMAL RISK LEVEL WORKSHEET 
Chemical name: Chlorpyrifos 
CAS number: 508 15-00-4 
Date: August 1997 
Profile status: Final Post-public Draft 
Route: [ ] Inhalation [X] Oral 
Duration: [X] Acute [ ] Intermediate [ ] Chronic 
Key to figure: 5 
Species: Human 
MRL: 0.003 [X] mg/kg/day [ ] ppm [ ] mg/m3 
Reference: Coulston et al. (1972) 
Exnerimental design: 16 adult human male volunteers (4 per dose group) were treated with 0,0.014,0.03, or 
0.10 mg/kg/day chlorpyrifos by capsule. Those subjects receiving 0.014 and 0.03 mg/kg/day were exposed for 
20 days; those receiving 0.10 mg/kg/day were exposed for only 9 days. 
Effects noted in study and corresnonding doses: Those subjects receiving 0.10 mg/kg/day were exposed for 
only 9 days because of blurred vision and a runny nose in one of the subjects. Plasma cholinesterase was 
decreased approximately 65% compared to controls in that group. No effect on plasma cholinesterase was 
seen at the lower doses and erythrocyte cholinesterase was unaffected by any of the chlorpyrifos doses. Thus, 
the NOAEL for chlorpyrifos plasma cholinesterase inhibition was 0.03 mg/kg/day. Based on this NOAEL, an 
MRL of 0.003 mg/kg was calculated: 0.03 mg/kg divided by an uncertainty factor of 10 for human variability. 
Please note that the combination of length of exposure period and the critical effect in this study enable it to 
be used for the derivation of both acute- and intermediate-duration oral exposure MRLs. 
MRL = Human dose t Uncertainty factor 
= 0.03 mg/kg ÷ 10 
= 0.003 mg/kg 
Dose endpoint used for MRL derivation: Plasma cholinesterase inhibition 
[X] NOAEL [ ] LOAEL 
Uncertainty factors used in MRL derivation: 
[] 1 [ ] 3 [ ] 10(for use of a LOAEL) 
[ ] 1 [ ] 3 [ ] 10 (for extrapolation from animals to humans) 
[ ] 1 [ ] 3 [X] 10 (for human variability) 
Was a conversion factor used from num in food or water to a mg/bodv weight dose? No. 
If so, explain: 
If an inhalation studv in animals. list conversion factors used in determining human eauivalent dose: 
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If an inhalation study in animals, list conversion factors used in determining human equivalent dose: 
Was a conversion used from intermittent to continuous exposure? No. 
If so, explain: 
Other additional studies or pertinent information that lend support to this MRL: 
Deacon et al. (1980) Embryotoxicity and Fetotoxicity of Orally Administered Chlorpyrifos in Mice.Toxicology 
and Applied Pharmacology. 54, 31-40. 
The MRL study is further supported by a study by Deacon et al. (1980). Female CF-1 mice were 
exposed by gavage to 1, 10, or 2 mg/kg/day Dursban F (96.8% chlorpyrifos) as a solution in 
cottonseed oil on gestation day (Gd) 6, Gds 610, or Gds 6-15. Controls received cottonseed oil 
alone. Five hours after the final dosing (Gds 6, 10, or 15) blood was obtained via cardiac puncture 
and plasma and erythrocyte cholinesterase activities determined. Plasma and erythrocyte cholinesterase levels 
were significantly decreased from control values among mice given 10 or 25 mg/kg chlorpyrifos on day 6 
(plasma, 95 and 97%, respectively; erythrocyte, 40 and 20%, respectively) and, days 6-10 (plasma, 97 and 99%, 
respectively; erythrocyte, 43 and 71%, respectively), or Gds 6-15 (plasma, 96 and 98%, respectively; 
erythrocyte, 43 and 57%, respectively). Plasma cholinesterase levels were significantly reduced among mice 
given 1 mg/kg chlorpyrifos during the same time intervals (69, 78, and 85%, respectively). Erythrocyte 
cholinesterase levels were also reduced (43%) after 1 mg/kg chlorpyrifos, but only after exposure on Gds 6-10. 
In a concurrent study, no effects on plasma or erythrocyte cholinesterase activity were observed at 0.1 mg/kg 
chlorpyrifos. 
Agency Contact (Chemical Manager): John F. Risher, Ph.D. 
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MINIMAL RISK LEVEL WORKSHEET 
Chemical name: Chlorpyrifos 
CAS number: 50815-00-4 
Date: July 1997 
Profile status: Final Post-public Draft 
Route: [ ] Inhalation [X] Oral 
Duration: [ ] Acute [X] Intermediate [ ] Chronic 
Key to figure: 15 
Species: Human 
MRL: 0.003 [X] mg/kg/day [ ] ppm [ ] mg/m3 
Reference: Coulston et al. 1972. 
Experimental design: 16 adult human male volunteers (4 per dose group) were treated with 0, 0.014, 0.03, or 
0.10 mg/kg/day chlorpyrifos by capsule. Those subjects receiving 0.014 and 0.03 mg/kg/day were exposed for 
20 days; those receiving 0.10 mg/kg/day were exposed for only 9 days. 
Effects noted in study and corresnonding doses: Those subjects receiving 0.10 mg/kg/day were 
exposed for only 9 days because of blurred vision and a runny nose in one of the subjects. Plasma 
cholinesterase was decreased approximately 65% compared to controls in that group. No effect on plasma 
cholinesterase was seen at the lower doses and erythrocyte cholinesterase was unaffected by any of the 
chlorpyrifos doses. Thus, the NOAEL for chlorpyrifos plasma cholinesterase inhibition was 0.03 mg/kg/day. 
Based on this NOAEL, an MRL of 0.003 mg/kg was calculated: 0.03 mg/kg divided by an uncertainty factor of 
10 for human variability. Please note that the combination of length of exposure period and the critical effect in 
this study enable it to be used for the derivation of both acute- and intermediate-duration oral exposure MRLs. 
MRL = Human dose ÷ Uncertainty factor 
= 0.03 mg/kg x 1

 10

     = 0.003 mg/kg/day
 
Dose endpoint used for MRL derivation: Plasma cholinesterase inhibition 
[X] NOAEL [ ] LOAEL
 
Uncertainty factors used in MRL derivation:
 
[ ] 1 [ ] 3 [ ] 10 (for use of a LOAEL)
 
[ ] 1 [ ] 3 [ ] 10 (for extrapolation from animals to humans)
 
[ ] 1 [ ] 3 [X] 10 (for human variability)
 
Was a conversion factor used from ppm in food or water to a ma/body weight dose? No. 
If so, explain: 
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If an inhalation study in animals, list conversion factors used in determining. human equivalent dose: 
Was a conversion used from intermittent to continuous exposure? No. 
If so, explain: 
Other additional studies or pertinent information that lend support to this MRL: 
Deacon et al. (1980) Embryotoxicity and Fetotoxicity of Orally Administered Chlorpyrifos in Mice. 
Toxicology and Applied Pharmacology. 54, 31-40. 
The MRL study is further supported by a study by Deacon et al. (1980). Female CF-1 mice were 
exposed by gavage to 1, 10, or 2 mg/kg/day Dursban F (96.8% chlorpyrifos) as a solution in 
cottonseed oil on Gds 6, 6-10, or 6-15. Controls received cottonseed oil alone. Five hours after the final 
dosing (Gds 6, 10, or 15), blood was obtained via cardiac puncture and plasma and erythrocyte cholinesterase 
activities determined. Plasma and erythrocyte cholinesterase levels were significantly decreased from control 
values among mice given 10 or 25 mg/kg chlorpyrifos on day 6 (plasma, 95 and 97%, respectively; 
erythrocyte, 40 and 20%, respectively) and, days 6-10 (plasma, 97 and 99%, respectively; erythrocyte, 43 and 
71%, respectively), or Gds 6-15 (plasma, 96 and 98%, respectively; erythrocyte, 43 and 57%, respectively). 
Plasma cholinesterase levels were significantly reduced among mice given 1 mg/kg chlorpyrifos during the 
same time intervals (69, 78, and 85%, respectively). Erythrocyte cholinesterase levels were also reduced 
(43%) after 1 mg/kg chlorpyrifos, but only after exposure on Gds 6-10. In a concurrent study, no effects on 
plasma or erythrocyte cholinesterase activity were observed at 0.1 mg/kg chlorpyrifos. 
Agency Contact (Chemical Manager): John F. Risher, Ph.D. 
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MINIMAL RISK LEVEL WORKSHEET 
Chemical name: Chlorpyrifos 
CAS number: 50815-00-4 
Date: July 1997 
Profile status: Final Post-public Draft 
Route: [ ] Inhalation [X] Oral 
Duration: [ ] Acute [] Intermediate [X] Chronic 
Key to figure: 42 
Species: Rat 
MRL: 0.001 [X] mg/kg/day [ ] ppm [ ] mg/m3 
Reference: McCollister et al. 1974 
Experimental design: Sherman rats (25 males and 25 females) were dose fed chlorpyrifos at 0, 0.01, 0.03, 0.1, 1, 
or 3 mg/kg/day for 2 years beginning at 7-weeks of age. Additional groups of 5-7 rats of each sex at each dose 
level were set up to provide interim pathological examination and cholinesterase (ChE) determinations. Clinical 
observations, body weights, food consumption and mortality were monitored. At 6-month intervals, blood and 
urine samples were collected from selected rats receiving 0, 1, or 3 mg/kg/day. The packed cell volume, 
hemoglobin, erythrocyte count and total and differential leucocyte counts were determined in the blood. Urine 
was analyzed for total solids, pH, albumin, sugar, occult blood and ketones. The ChE activity of the plasma and 
red blood cells (RBC) was determined for all rats in the groups that were killed after receiving the test diets for 1 
week, and 1, 3, 6, 9, 12, and 18 months, as well as for selected rats from those given each dose for 2 years. Brain 
ChE was measured in rats killed at 6, 12, 18, and 24 months. To characterize the recovery of the ChE activity in 
plasma, red cells and brain, some rats were maintained on the various diets containing chlorpyrifos for 12 
months, and subsequently on the control diet for 7-8 weeks prior to sacrifice. Blood urea nitrogen (BUN), serum 
alkaline phosphatase (AP) and serum glutamic-pyruvic transaminase (SGPT) were determined on blood samples 
collected from rats killed at 12, 18, and 24 months. Necropsies were conducted on all rats killed at 12, 18, and 
24 months and on those that received control feed for 7-8 weeks after having received chlorpyrifos diets for 12 
months. These rats were fasted for 16 hours, decapitated, and weighed. The brain, heart, liver, kidney, spleen, 
and testes were removed and weighed. Portions of these tissues were preserved in 10% formalin, and 
histopathological examinations were performed on these tissues, as well as eye, pituitary, thyroid, and 
parathyroid glands, trachea, esophagus, lungs, aorta, stomach, pancreas, small intestine, colon, 
mesenteric lymph nodes, urinary bladder, accessory sex glands, ovaries, uterus, skeletal muscle, sciatic nerve, 
spinal cord, sternum, sternal bone marrow, adrenal gland, and any nodules or masses suggestive of tumor 
development or other pathological processes. Histopathological examinations were also conducted on the tissues 
of all rats exhibiting grossly visible nodules or masses, and on those killed in a moribund state or that died 
spontaneously, unless this was precluded by autolysis. 
Effects noted in study and corresponding doses: Clinical observations did not detect evidence of a 
cholinergic overstimulation or any other compound-related effect. Brain cholinesterase (ChE) activity in both 
male and female rats displayed an overall reduction of 56% in rats fed 3 mg/kg/day chlorpyrifos during the 2­
year study. No overall effect on brain ChE was observed at the lower doses. Plasma and RBC ChE activity were 
depressed for both male and female rats dosed with diets containing 1 or 3 mg/kg/day chlorpyrifos. At 1 
mg/kg/day chlorpyrifos, plasma ChE was depressed 
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20-53%; RBC ChE activity was decreased 65-70% at that dose. Doses of 0.1 mg/kg/day and below had no effect 
on either plasma or RBC activity. Cholinesterase activities in plasma, RBC, and brain of rats fed chlorpyrifos­
containing diets for 1 year returned to normal levels after switching to a control diet for 7-8 weeks. There was 
no effect of treatment on organ weights, histopathology, or number and types of tumors. It was concluded that 
0.1 mg chlorpyrifos/kg/day fed in the diet for 2 years produced no significant toxicological effect in rats. 
MRL = Human dose + Uncertainty factor (UF = 10 for extrapolation from animal data; UF = 10 for human 
variability) 
= 0.1 mg/kg/day x 1 x 1 
10 10 
= 0.00 1 mg/kg/day 
Dose endpoint used for MRL derivation: Acetylcholinesterase inhibition 
[X] NOAEL [ ] LOAEL
 
Uncertainty factors used in MRL derivation:
 
[ ] 1 [ ] 3 [ ] 10 (for use of a LOAEL)
 
[ ] 1 [ ] 3 [X] 10 (for extrapolation from animals to humans) 
[ ] 1 [ ] 3 [X] 10 (for human variability)
 
Was a conversion factor used from ppm in food or water to a mg/bodv weight dose? No.
 
If so, explain:
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:
 
Was a conversion used from intermittent to continuous exposure? No.
 
If so, explain:
 
Other additional studies or pertinent information that lend support to this MRL: No.
 
Agency Contact (Chemical Manager): John F. Risher, Ph.D.
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USER’S GUIDE 
Chapter 1 
Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language. Its intended audience 
is the general public especially people living in the vicinity of a hazardous waste site or chemical release. If the 
Public Health Statement were removed from the rest of the document, it would still communicate to the lay 
public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern. The topics are 
written in a question and answer format. The answer to each question includes a sentence that will direct the 
reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Tables and Figures for Levels of Significant Exposure (LSE) 
Tables (2-1, 2-2, and 2-3) and figures (2-l and 2-2) are used to summarize health effects and illustrate 
graphically levels of exposure associated with those effects. These levels cover health effects observed at 
increasing dose concentrations and durations, differences in response by species, minimal risk levels (MRLs) to 
humans for noncancer endpoints, and EPA’s estimated range associated with an upperbound individual lifetime 
cancer risk of 1 in 10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health 
effects and to locate data for a specific exposure scenario. The LSE tables and figures should always be used in 
conjunction with the text. All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of No-Observed-Adverse- Effect Levels (NOAELs), Lowest-Observed- Adverse-Effect 
Levels (LOAELs), or Cancer Effect Levels (CELs). 
The legends presented below demonstrate the application of these tables and figures. Representative examples 
of LSE Table 2-l and Figure 2-l are shown. The numbers in the left column of the legends correspond to the 
numbers in the example table and figure. 
LEGEND 
See LSE Table 2-1 
(1) 	 Route of Exposure One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. When sufficient 
data exists, three LSE tables and two LSE figures are presented in the document. The three LSE tables 
present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE Table 2-1, 
2-2, and 2-3, respectively). LSE figures are limited to the inhalation (LSE Figure 2-l) and oral (LSE 
Figure 2-2) routes. Not all substances will have data on each route of exposure and will not therefore 
have all five of the tables and figures. 
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(2)	 Exposure Period Three exposure periods - acute (less than 15 days), intermediate (15-364 days), and 
chronic (365 days or more) are presented within each relevant route of exposure. In this example, an 
inhalation study of intermediate exposure duration is reported. For quick reference to health effects 
occurring from a known length of exposure, locate the applicable exposure period within the LSE table 
and figure. 
(3)	 Health Effect The major categories of health effects included in LSE tables and figures aredeath, 
systemic, immunological, neurological, developmental, reproductive, and cancer. NOAELs and 
LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are further 
defined in the “System” column of the LSE table (see key number 18). 
(4)	 Key to Figure Each key number in the LSE table links study information to one or more datapoints 
using the same key number in the corresponding LSE figure. In this example, the study represented by 
key number 18 has been used to derive a NOAEL and a Less Serious LOAEL (also see the 2 “18r” data 
points in Figure 2-l). 
(5)	 Species The test species, whether animal or human, are identified in this column. Section 2.4, 
“Relevance to Public Health,” covers the relevance of animal data to human toxicity and Section 2.3, 
“Toxicokinetics,” contains any available information on comparative toxicokinetics.  Although 
NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent human doses to 
derive an MRL. 
(6)	 Exposure Freouencv/Duration The duration of the study and the weekly and daily exposure regimen are 
provided in this column. This permits comparison of NOAELs and LOAELs from different studies. In 
this case (key number 18), rats were exposed to toxaphene via inhalation for 6 hours per day, 5 days per 
week, for 3 weeks. For a more complete review of the dosing regimen refer to the appropriate sections 
of the text or the original reference paper, i.e., Nitschke et al. 1981. 
(7)	 System This column further defines the systemic effects. These systems include: respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. 
“Other” refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. In 
the example of key number 18, 1 systemic effect (respiratory) was investigated. 
(8)	 NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at which no 
harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 3 ppm for 
the respiratory system which was used to derive an intermediate exposure, inhalation MRL of 0.005 
ppm (see footnote “b”). 
(9)	 LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest dose used in the study that 
caused a harmful health effect. LOAELs have been classified into “Less Serious” and “Serious” effects. 
These distinctions help readers identify the levels of exposure at which 
adverse health effects first appear and the gradation of effects with increasing dose. A brief description 
of the specific endpoint used to quantify the adverse effect accompanies the LOAEL.  The respiratory 
effect reported in key number 18 (hyperplasia) is a Less serious LOAEL of 10 ppm. MRLs are not 
derived from Serious LOAELs. 
(10)	 Reference The complete reference citation is given in chapter 8 of the profile. 
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(11) 	 CEL A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset 
ofcarcinogenesis in experimental or epidemiologic studies. CELs are always considered serious effects. 
The LSE tables and figures do not contain NOAELs for cancer, but the text may report doses not 
causing measurable cancer increases. 
(12) 	 Footnotes Explanations of abbreviations or reference notes for data in the LSE tables are found in the 
footnotes. Footnote “b” indicates the NOAEL of 3 ppm in key number 18 was used to derive an MRL of 
0.005 ppm. 
LEGEND 
See Figure 2-1 
LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the reader 
quickly compare health effects according to exposure concentrations for particular exposure periods. 
(13) 	 Exposure Period The same exposure periods appear as in the LSE table. In this example, health effects 
observed within the intermediate and chronic exposure periods are illustrated. 
(14)	 Health Effect These are the categories of health effects for which reliable quantitative data exists. The 
same health effects appear in the LSE table. 
(15) 	 Levels of Exposure concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log scale 
“y” axis. Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in mg /kg/day. 
(16) 	 NOAEL In this example, 18r NOAEL is the critical endpoint for which an intermediate 
inhalation exposure MRL is based. As you can see from the LSE figure key, the open-circle symbol 
indicates to a NOAEL for the test species-rat. The key number 18 corresponds to the entry in the LSE 
table. The dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see 
entry 18 in the Table) to the MRL of 0.005 ppm (see footnote “b” in the LSE table). 
(17) 	 CEL Key number 38r is 1 of 3 studies for which Cancer Effect Levels were derived. The 
diamond symbol refers to a Cancer Effect Level for the test species-mouse. The number 38 corresponds 
to the entry in the LSE table. 
(18) 	 Estimated Upper-Bound Human Cancer Risk Levels This is the range associated with the 
upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived 
from the EPA’s Human Health Assessment Group’s upper-bound estimates-of the slope of the cancer 
dose response curve at low dose levels (ql*). 
(19) 	 Key to LSE Figure The Key explains the abbreviations and symbols used in the figure. 
. 
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Chapter 2 (Section 2.5) 
Relevance to Public Health 
The Relevance to Public Health section provides a health effects summary based on evaluations of existing 
toxicologic, epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, 
weight-of-evidence discussions for human health endpoints by addressing the following questions. 
1. What effects are known to occur in humans? 
2. What effects observed in animals are likely to be of concern to humans? 
3. What exposure conditions are likely to be of concern to humans, especially around
 
hazardous waste sites?
 
The section covers endpoints in the same order they appear within the Discussion of Health Effects by Route of 
Exposure section, by route (inhalation, oral, dermal) and within route by effect. Human data are presented first, 
then animal data. Both are organized by duration (acute, intermediate, chronic). In vitro data and data from 
parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in this section. If data are 
located in the scientific literature, a table of genotoxicity information is included. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using existing 
toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer potency or perform 
cancer risk assessments. Minimal risk levels (MRLs) for noncancer endpoints (if derived) and the endpoints 
from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public health 
are identified in the Data Needs section. 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information is available, we have derived minimal risk levels (MRLs) for
 
inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs
 
are not meant to support regulatory action; but to acquaint health professionals with exposure levels at which
 
adverse health effects are not expected to occur in humans. They should help physicians and public health
 
officials determine the safety of a community living near a chemical emission, given the concentration of a
 
contaminant in air or the estimated daily dose in water. MRLs are based largely on toxicological studies in
 
animals and on reports of human occupational exposure.
 
MRL users should be familiar with the toxicologic information on which the number is based.
 
Chapter 2.4, “Relevance to Public Health,” contains basic information known about the substance. Other
 
sections such as 2.6, “Interactions with Other Substances,” and 2.7, “Populations that are Unusually
 
Susceptible” provide important supplemental information.
 
MRL users should also understand the MRL derivation methodology. MRLs are derived using a
 
modified version of the risk assessment methodology the Environmental Protection Agency (EPA) provides
 
(Barnes and Dourson 1988) to determine reference doses for lifetime exposure (RfDs).
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To derive an MRL, ATSDR generally selects the most sensitive endpoint which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration. ATSDR cannot make 
this judgement or derive an MRL unless information (quantitative or qualitative) is available for all potential 
systemic, neurological, and developmental effects. If this information and reliable quantitative data on the 
chosen endpoint are available, ATSDR derives an MRL using the most sensitive species (when information 
from multiple species is available) with the highest NOAEL that does not exceed any adverse effect levels. 
When a NOAEL is not available, a lowest-observed-adverse-effect level (LOAEL) can be used to derive an 
MRL, and an uncertainty factor (UF) of 10 must be employed. Additional uncertainty factors of 10 must be used 
both for human variability to protect sensitive subpopulations (people who are most susceptible to the health 
effects caused by the substance) and for interspecies variability (extrapolation from animals to humans). In 
deriving an MRL, these individual uncertainty factors are multiplied together. The product is then divided into 
the inhalation concentration or oral dosage selected from the study.  Uncertainty factors used in developing a 
substance-specific MRL are provided in the footnotes of the LSE Tables. 





